Quarterlytics / Healthcare / Medical - Care Facilities / Addus HomeCare Corporation

Addus HomeCare Corporation

adus · NASDAQ Healthcare
Claim this profile
Ticker adus
Exchange NASDAQ
Sector Healthcare
Industry Medical - Care Facilities
Employees 6165
← All annual reports
FY2023 Annual Report · Addus HomeCare Corporation
Sign in to download
Loading PDF…
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

☒

☐

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-34504

ADDUS HOMECARE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

6303 Cowboys Way, Suite 600 Frisco, TX
(Address of principal executive offices)

20-5340172
(I.R.S. Employer
Identification No.)

75034
(Zip Code)

469-535-8200
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common Stock, $0.001 par value

Trading Symbol(s)

Name of each exchange on which registered

ADUS

The Nasdaq Global Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     

   Yes  ☒     No  ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.      Yes  ☐     No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter 
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the 
preceding 12 months (or for such shorter period that the registrant was required to submit such files).       

           Yes  ☒    No ☐ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large 
accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer
Non-Accelerated Filer

☒   
☐  

Accelerated Filer
Smaller Reporting Company
Emerging Growth Company

☐
☐
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided 
pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the 
Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☒    

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously 
issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during 
the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act)     

   Yes  ☐     No  ☒

The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, based on the last sale price on The Nasdaq Global Market on June 30, 2023 (the last business 
day of the registrant’s most recently completed second fiscal quarter) was approximately $1,473,419,000.

As of February 16, 2024, there were 16,227,251 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the registrant’s Definitive Proxy Statement for its 2024 Annual Meeting of Stockholders (which is expected to be filed with the Commission within 120 days after the end of the registrant’s 
2023 fiscal year) are incorporated by reference into Part III of this Annual Report on Form 10-K.

Auditor Firm PCAOB Id:

238

Auditor Name:

PricewaterhouseCoopers LLP

Auditor Location:

Dallas, Texas

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

TABLE OF CONTENTS

PART I

Item 1.
Item 1A.
Item 1B.
Item 1C.
Item 2.
Item 3.
Item 4.

PART II

Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.

PART III

Item 10.
Item 11.
Item 12.
Item 13.
Item 14.

PART IV

Item 15.
Item 16.

  Business
  Risk Factors
  Unresolved Staff Comments
  Cybersecurity
  Properties
  Legal Proceedings
  Mine Safety Disclosures

  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  [Reserved]
  Management’s Discussion and Analysis of Financial Condition and Results of Operations
  Quantitative and Qualitative Disclosures about Market Risk
  Financial Statements and Supplementary Data
  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
  Controls and Procedures
  Other Information
  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

  Directors, Executive Officers and Corporate Governance
  Executive Compensation
  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
  Certain Relationships and Related Transactions, and Director Independence
  Principal Accounting Fees and Services

  Exhibits and Financial Statement Schedules
  Form 10-K Summary

3
3
17
33
33
33
34
34

35
35
35
36
56
56
56
56
57
57

58
58
58
58
58
58

59
59
62

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

When included in this Annual Report on Form 10-K, or in other documents that we file with the Securities and Exchange Commission (“SEC”) or in 

statements made by or on behalf of the Company, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” 
“may,” “might,” “would,” “should,” and similar expressions are intended to be forward-looking statements as defined by the Private Securities Litigation 
Reform Act of 1995. These statements are based on the beliefs and assumptions of our management based on information currently available to 
management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing 
of certain events to differ materially from future results expressed or implied by such forward-looking statements. These risks and uncertainties include, but 
are not limited to: 

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

The impact of macroeconomic conditions, including significant global inflation and elevated interest rates, legislative developments, trade 
disruptions and the potential adverse effects of current geopolitical conditions;

business disruptions due to natural disasters, acts of terrorism, pandemics, riots, civil insurrection or social unrest, looting, protests, strikes or 
street demonstrations;

changes in operational and reimbursement processes and payment structures at the state or federal levels; 

changes in Medicaid, Medicare, other government program and managed care organizations policies and payment rates, and the timeliness of 
reimbursements received under government programs;  

changes in, or our failure to comply with, existing federal and state laws or regulations, or our failure to comply with new government laws or 
regulations on a timely basis;

competition in the healthcare industry;

the geographical concentration of our operations; 

changes in the case mix of consumers and payment methodologies;

operational changes resulting from the assumption by managed care organizations of responsibility for managing and paying for our services to 
consumers;

the nature and success of future financial and/or delivery system reforms;

changes in estimates and judgments associated with critical accounting policies;

our ability to maintain or establish new referral sources;

our ability to renew significant agreements or groups of agreements;

our ability to attract and retain qualified personnel;

federal, state and city minimum wage pressure, including any failure of any governmental entity to enact a minimum wage offset and/or the 
timing of any such enactment;

changes in payments and covered services due to the overall economic conditions and deficit reduction measures by federal and state 
governments, and our expectations regarding these changes;

cost containment initiatives undertaken by federal and state governmental and other third-party payors;

our ability to access financing through the capital and credit markets;

1

 
Table of Contents

•

•

•

•

•

•

•

•

•

•

•

•

•

our ability to meet debt service requirements and comply with covenants in debt agreements;

our ability to integrate and manage our information systems;

the potential impact of security breaches, cyber-attacks, loss of data, or cybersecurity threats or incidents, and any actual or perceived failures 
to comply with legal requirements related to the privacy of confidential consumer data and other sensitive information;

the size and growth of the markets for our services, including our expectations regarding the markets for our services;

eligibility standards and limits on services imposed by state governmental agencies;

the potential for litigation, audits and investigations;

discretionary determinations by government officials;

our ability to successfully implement our business model to grow our business;

our ability to continue identifying, pursuing, consummating and integrating acquisition opportunities and expand into new geographic markets;

the impact of acquisitions and dispositions on our business, including the potential inability to realize the benefits of potential acquisitions;

the effectiveness, quality and cost of our services;

changes in tax rates; and

various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should 
not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to 
release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or 
circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above 
as well as additional factors, see Part I, Item 1A—“Risk Factors” and Part II, Item 7—”Management’s Discussion and Analysis of Financial Condition and 
Results of Operations—Critical Accounting Policies and Estimates.”

Unless otherwise provided, “Addus,” “we,” “us,” “our,” and the “Company” refer to Addus HomeCare Corporation and our consolidated 

subsidiaries and “Holdings” refers to Addus HomeCare Corporation. When we refer to 2023, 2022 and 2021, we mean the twelve-month period then ended 
December 31, unless otherwise provided. 

A copy of this Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC, including all exhibits, is available on our 
internet website at http://www.addus.com on the “Investors” page link. Information contained on, or accessible through, our website is not a part of, and is 
not incorporated by reference into, this Annual Report on Form 10-K.

2

 
Table of Contents

ITEM 1. BUSINESS

Overview

PART I

Addus has been providing home care services since 1979. We operate three segments: personal care, hospice, and home health. Our services are 

principally provided in-home under agreements with federal, state and local government agencies, managed care organizations, commercial insurers and 
private individuals. Our consumers are predominantly “dual eligible,” meaning they are eligible to receive both Medicare and Medicaid benefits.

As of December 31, 2023, we provided services in 22 states through approximately 219 offices. For the year ended December 31, 2023, we served 

approximately 91,000 discrete consumers.

We continue to drive organic growth while also growing through acquisitions, focusing on growth in the states in which we have a presence while 

adding clinical care services to our offerings. As of December 31, 2023, we provide all three levels of care, personal care, home health and hospice 
services, in Ohio, Tennessee, Illinois and New Mexico and strategically continue to pursue other markets.

A summary of our financial results is provided in the table below.

Personal care
Hospice
Home health
Total net service revenue by segment

Net income
Total assets

For the Years Ended December 31,
2022
2023

(Amounts in Thousands)
794,718  
  $
207,155  
56,778  
1,058,651  

  $

62,516  
1,024,426  

  $

706,507    
201,772    
42,841    
951,120    

46,025    
937,994    

  $

  $

  $

Our services and operating model address a number of crucial needs across the healthcare continuum. Care provided in the home generally costs less 

than facility-based care and is typically preferred by consumers and their families. By providing services in the home to the elderly and others who require 
long-term care and support with the activities of daily living, we lower the cost of chronic and acute care treatment by delaying or eliminating the need for 
care in more expensive settings. In addition, our caregivers observe and report changes in the condition of our consumers for the purpose of facilitating 
early intervention in the disease process, which often reduces the cost of medical services by preventing unnecessary emergency room visits and/or hospital 
admissions and re-admissions. We coordinate the services provided by our team with those of other healthcare providers and payors, as appropriate. 
Changes in a consumer’s conditions are evaluated by appropriately trained managers, which may result in a report to the consumer’s case manager at a 
managed care organization or other payor. By providing care in the preferred setting of the home and by providing opportunities to improve the consumer’s 
conditions and allow early intervention as indicated, our model also is designed to improve consumer outcomes and satisfaction.

We believe our model provides significant value to managed care organizations. States continue to implement managed care programs for Medicaid 

enrollees, and, as a result, managed care organizations have been increasingly responsible for the healthcare needs and the related healthcare costs of our 
consumers. Managed care organizations have an economic incentive to better manage the healthcare expenditures of their members, lower costs and 
improve outcomes. We believe that our model is well positioned to assist in meeting those goals while also improving consumer satisfaction, and, as a 
result, we expect increased referrals from managed care organizations.

3

 
 
 
 
   
 
 
 
 
 
 
 
 
   
   
   
   
 
   
 
   
   
   
   
 
 
Table of Contents

Our Market and Opportunity

We provide home care services that primarily include personal care services to assist with activities of daily living, as well as hospice and home 
health services. These services allow the elderly and other infirm adults who require long-term care and assistance with activities of daily living to maintain 
their independence at home with their families. Personal care services are a significant component of home and community-based services (“HCBS”), 
which have grown in significance and demand in recent years. In particular, the demand for personal care services is growing from managed care delivery 
models, including Medicaid Long-Term Services and Supports (“LTSS”) programs and Medicare Advantage plans. Managed care plans aim to manage 
cost, utilization and quality through collaboration of health insurance plans and healthcare providers. We also offer personal care services to private pay 
consumers. We expect demand for HCBS to continue to grow due to the aging of the U.S. population and improved opportunities for individuals to receive 
home-based care as an alternative to institutional care.

Because our model serves an aging population in a home setting at a lower cost, we believe that we have favorable opportunities for growth. The 

personal care, hospice and home health service industries have developed in a fragmented manner, with many small participants and a few larger 
participants that have a significant market share across multiple regions or states. The historic lack of licensure or certification requirements in some states 
makes it difficult to estimate the number of home-based services agencies, although these requirements and other barriers to entry are now increasing. We 
expect ongoing consolidation within our industry, driven by the desire of healthcare systems and managed care organizations to narrow their networks of 
service providers, and also by the industry’s increasingly complex regulatory, operating and technology requirements. We believe we are well positioned to 
capitalize on these trends, given our reputation in the market, strong payor relationships and integration of technology into our business model.

The personal care services industry is subject to increasing regulation. At the federal level, efforts have focused on improved coordination of 
regulation across the various types of Medicaid programs through which personal care services are offered. For example, federal standards require states to 
mandate that providers use an electronic visit verification (“EVV”) system to collect certain data from Medicaid-funded home visits. States have flexibility 
in the model they use to implement the mandate, which means EVV systems, vendors and contracting processes can vary significantly by state. States 
increasingly require providers to register with regulatory authorities or obtain licenses. Providers must dedicate substantial resources to ensure continuing 
compliance with all applicable laws and regulations, and significant expenditures may be necessary to offer new services or to expand into new markets. 
We believe licensing and other operational requirements and regulations, the increasing focus on improving health outcomes, the rising cost and complexity 
of operations and technology and pressure on reimbursement rates may discourage new providers and may encourage industry consolidation.

The Medicare-Medicaid Coordination Office (“MMCO”) was established within the Centers for Medicare & Medicaid Services (“CMS”) to 
improve services for consumers who are eligible for both Medicare and Medicaid, also known as “dual eligibles,” and improve coordination between the 
federal government and states to enhance access to quality services to which they are entitled. The MMCO works with state Medicaid agencies, other 
federal and state agencies, physicians and others, to make available technical assistance and educational tools to improve care coordination between 
Medicare and Medicaid and to reduce costs and improve beneficiary experience while reducing administrative and regulatory barriers between the 
programs. In addition, the MMCO and the CMS Innovation Center are considering or have implemented demonstration projects affecting reimbursement 
for services provided to dual eligibles.

We believe that our personal care program and our technology make us well-suited to partner with managed care organizations to address the needs 

of the “dual eligible” population, and we believe that our ability to identify changes in our consumers’ health and condition before acute intervention is 
required will lower the overall cost of care. We believe this approach to care delivery and the integration of our services into the broader healthcare 
continuum are particularly attractive to managed care organizations and others who are ultimately responsible for the healthcare needs of our consumers 
and over time will increase our business with them.

4

 
 
Table of Contents

Our Growth Strategy

The growth of our revenues is closely correlated with the number of consumers to whom we provide our services. Our continued growth depends on 

our ability to provide consistent high-quality care, maintain our existing payor relationships, establish relationships with new payors, increase our referral 
sources and attract and retain caregivers. Our continued growth is also dependent upon the authorization by state agencies of new consumers to receive our 
services. We believe there are several market opportunities for growth as the population ages. Moreover, individuals generally prefer to receive care in their 
homes, and we believe the COVID-19 pandemic heightened this preference due to health concerns that may be associated with institutional settings for 
long-term care, along with concerns about the re-imposition of visitor restrictions that were imposed in many long-term care facilities in response to the 
pandemic. Finally, we believe the provision of home-based services is more cost-effective than the provision of similar services in institutional settings for 
long-term care. We plan to continue our revenue growth and enhance our competitive positioning by executing on the following growth strategies:

Consistently Provide High-Quality Care

We schedule and require our caregivers to perform their services as defined within the individual plan of care. We monitor the performance of our 

caregivers through regular supervisory visits in the homes of consumers. Our caregivers are provided with pre-service training and orientation and an 
evaluation of their skills. In many cases, caregivers are also required to attend ongoing in-service education. In certain states, our caregivers are required to 
complete certified training programs and maintain a state certification. The training assists our caregivers with identifying changes in our consumers’ health 
and condition before acute intervention is required, which we believe lowers the overall cost of care.

Drive Organic Growth in Existing Markets

We intend to drive organic growth through several initiatives, including continuing to build and enhance our sales and marketing capabilities, 

enhancing our business intelligence analytic capabilities, recruiting and retaining employees and investing in technology and operations to drive 
efficiencies. We also expect our organic growth will benefit from an increase in demand for our services by an aging population and our increased 
alignment with referral sources and payors. We continue to selectively open new offices in existing markets when an opportunity is identified and 
appropriate.

Market to Managed Care Organizations

As a large-scale provider of home-based care, we are partnering with managed care organizations, taking advantage of an industry shift from 
traditional fee-for-service Medicare and Medicaid and toward managed care models which aim to better coordinate care, among other goals. We expect this 
shift to lead to narrower provider networks where we can be competitive by offering a larger, more experienced partner to these organizations, as well as by 
providing more sophisticated technology, electronic visit records and an outcomes-driven approach to service. We believe our coordinated care model and 
integration of services into the broader healthcare industry are particularly attractive to managed care organizations. In particular, our expansion from 
primarily personal care services into hospice and home health has increased our value to our managed care partners by diversifying our home-based care 
offerings.

Grow Through Acquisitions

In addition to our organic growth, we have been growing through acquisitions that have expanded our presence in current markets or facilitated our 
entry into new markets. We completed two acquisitions in 2023: Coastal Nursecare of Florida, Inc. (“CareStaff”) on January 1, 2023 and American Home 
Care, LLC, a Tennessee limited liability company (“AHC”), and its subsidiaries, Homecare, LLC, a Tennessee limited liability company (“Homecare”), 
Tennessee Valley Home Care, LLC (d/b/a Tennessee Quality Care – Home Health), a Tennessee limited liability company (“TQC – Home Health”), and 
Tri-County Home Health and Hospice, LLC (d/b/a Tennessee Quality Care - Hospice), a Tennessee limited liability company (“TQC – Hospice”, and 
collectively with AHC, Homecare and TQC – Home Health, “Tennessee Quality Care”) on August 1, 2023. Acquisitions completed in 2023 accounted for 
$18.8 million in net service revenues for the year ended December 31, 2023. We also completed two acquisitions in 2022: JourneyCare Inc. 
(“JourneyCare”) on February 1, 2022 and Apple Home Healthcare, LTD (“Apple Home”) on October 1, 2022.

Our active pipeline and strong financial position support additional acquisitions. With rising consolidation pressures in the industry, our focus is on 
identifying growing markets with favorable demographics in states that are fiscally well managed and have a reasonable minimum wage environment and 
where we have the potential to become one of the leading providers in the state in order to support our managed care organization strategy. We believe our 
experience identifying and executing on opportunities generated by our acquisition pipeline, as well as our history of integrating acquisitions, will lead to 
additional growth.

5

 
Table of Contents

Our Services

We operate three business segments:  personal care, hospice and home health. Without our services, many of our consumers would be at increased 

risk of placement in a long-term care institution.

Personal Care

Our personal care segment provides non-medical assistance with activities of daily living, primarily to persons who are at increased risk of 
hospitalization or institutionalization, such as the elderly, chronically ill or disabled. The services we provide include assistance with bathing, grooming, 
oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping and transportation services. Many consumers need 
such services on a long-term basis to address chronic or acute conditions. Our personal care segment also includes staffing services, with clients including 
assisted living facilities, nursing homes and hospice facilities. Each payor client establishes its own eligibility standards, determines the type, amount, 
duration and scope of services, and establishes the applicable reimbursement rate in accordance with applicable laws, regulations or contracts.

Hospice

Our hospice segment provides physical, emotional and spiritual care for people who are terminally ill as well as related services for their families. 

The hospice services we provide include palliative nursing care, social work, spiritual counseling, homemaker services and bereavement counseling. 
Generally, patients receiving hospice services have a life expectancy of six months or less.

Home Health

Our home health segment provides services that are primarily medical in nature to individuals who may require assistance during an illness or after 

hospitalization and include skilled nursing and physical, occupational and speech therapy. We generally provide home health services on a short-term, 
intermittent or episodic basis to individuals, typically to assist patients recovering from an illness or injury.

We measure the performance of each segment using a number of different metrics. See “Management’s Discussion and Analysis of Financial 

Condition and Results of Operations—Results of Operations” for information regarding the Company’s segment metrics.

Our Payors

Our payor clients are principally federal, state and local governmental agencies and managed care organizations. The federal, state and local 
programs under which the agencies operate are subject to legislative and budgetary restrictions, changes and other risks that can influence reimbursement 
rates. Managed care organizations that operate as an extension of government payors are subject to similar economic pressures. Our commercial insurance 
payor clients are typically for-profit companies and are continuously seeking opportunities to control costs.

Most of our services are provided pursuant to agreements with state and local governmental social and aging service agencies. These agreements 

generally have an initial term of one to two years and may be terminated with 60 days' notice. They are typically renewed for one to five-year terms, 
provided that we have complied with licensing, certification and program standards, and other regulatory requirements. Reimbursement rates and methods 
vary by state and service type, but are typically based on an hourly or unit-of-service basis. Managed care organizations are becoming an increasing portion 
of our personal care segment payor mix as states shift from administering fee-for-service programs to utilizing managed care models. See “Management’s 
Discussion and Analysis of Financial Condition and Results of Operations—Overview” for our revenue mix by payor type.

6

 
 
Table of Contents

Competition

We believe our industry is highly competitive, fragmented and market specific. Each local market has its own competitive profile and no single 
competitor has significant market share across all of our markets. Our competition consists of personal care service providers, home health providers, 
hospice providers, private caregivers, publicly held companies, privately held companies, privately held single-site agencies, hospital-based agencies, not-
for-profit organizations, community-based organizations, managed care organizations and self-directed care programs. In addition, payors, including 
governmental agencies, contract with other providers for services we offer. We have experienced, and expect to continue to experience, competition from 
new entrants into our markets. Increased competition may result in pricing pressures, loss of or failure to gain market share or loss of consumers or payors, 
any of which could harm our business. In addition, some of our competitors and/or competitive care models may have greater financial, technical, political 
and marketing resources, as well as name recognition with consumers and payors.

Sales and Marketing

We focus on initiating and maintaining working relationships with state and local governmental agencies responsible for the provision of the 
services we offer. We target these agencies in our current markets and in geographical areas that we have identified as potential markets for expansion. We 
also seek to identify service needs or changes in the service delivery or reimbursement systems of governmental entities and attempt to work with and 
provide input to the responsible government personnel, provider associations and consumer advocacy groups.

We establish new referral relationships with various managed care organizations that contract with the states to service the Medicaid programs. We 

have met with many contracted managed care organizations in markets we serve and believe we are building the relationships necessary to generate 
continued referrals of new clients.

We receive substantially all of our personal care consumers through third-party referrals, including state departments on aging, rehabilitation, mental 
health and children’s services, county departments of social services, managed care organizations, the Veterans Health Administration and city departments 
on aging. Generally, family members of potential consumers are made aware of available in-home or alternative living arrangements through state or local 
case management systems. These systems are operated by governmental or private agencies.

We provide ongoing education and outreach in our target communities in order to inform the community about state and locally-subsidized care 

options and to communicate our role in providing quality personal care services. We also utilize consumer-directed sales, marketing and advertising 
programs designed to attract consumers.

With respect to our hospice and home health patients, we receive substantially all of our referrals through other healthcare providers, such as 
hospitals, physicians, nursing homes and assisted living facilities. We have a team of community liaisons in our hospice and home health operations that 
educate and develop relationships with other healthcare providers and the community at large.

Payment for Services

We are reimbursed for substantially all of our services by federal, state and local government programs, such as Medicare and Medicaid state 
programs, managed care organizations, other state agencies and the Veterans Health Administration. In addition, we are reimbursed by commercial 
insurance and private pay consumers. Depending on the type of service, coverage for services may be predicated on a case manager, physician or nurse 
determination that the care is necessary or on the development of a plan for care in the home.

Medicare

Medicare is a federal program that provides certain medical insurance benefits to persons aged 65 or older and other qualified persons. Each of our 

hospice and home care agencies must comply with the extensive conditions of participation in the Medicare program in order to continue receiving 
Medicare reimbursement.

7

 
 
 
Table of Contents

Hospice

Medicare beneficiaries who have a terminal illness and a life expectancy of six months or less may elect to receive hospice benefits (i.e., palliative 
services for management of a terminal illness) in lieu of standard Medicare coverage for treatment. Hospice services are paid under the Medicare Hospice 
Prospective Payment System (“HPPS”), under which CMS sets a daily rate for each day a patient is enrolled in the hospice benefit. CMS requires hospice 
providers to submit quality reporting data each year and updates hospice payment rates annually using a market basket index. Hospices that do not satisfy 
quality reporting requirements are subject to a 2 percentage point reduction to the market basket percentage update. Beginning in federal fiscal year 2024, 
the reduction to the market basket update for failure to satisfy quality reporting requirements will increase to 4 percentage points. Additionally, hospice 
providers are subject to two specific payment limit caps under the Medicare program each federal fiscal year: the inpatient cap and the aggregate cap, as 
discussed further in Note 1 to the Notes to Consolidated Financial Statements.

Home Health

CMS reimburses home health agencies under a prospective payment system, paying a national, standardized 30-day period payment rate if a period 

of care meets a threshold of home health visits. The daily home health payment rate is adjusted for case-mix and area wage levels. CMS uses the Patient-
Driven Groupings Model (“PDGM”) as the case-mix classification model to place periods of care into payment categories, classifying patients based on 
clinical characteristics. An outlier adjustment may be paid for periods of care in which costs exceed a specific threshold amount. CMS updates home health 
payment rates annually using a market basket index. Home health agencies that do not submit required quality data are subject to a 2 percentage point 
reduction to the market basket update. CMS began implementing a nationwide expansion of the Home Health Value-Based Purchasing (“HHVBP”) Model 
in 2022. Under the HHVBP Model, home health agencies receive increases or reductions to their Medicare fee-for-service payments of up to 5% based on 
performance against specific quality measures relative to the performance of other home health providers. Data collected in each performance year impacts 
Medicare payments two years later. Calendar year 2023 was the first performance year under the expanded HHVBP Model, which will affect payments in 
calendar year 2025.

Medicare requires home health agencies to submit a one-time Notice of Admission (“NOA”) for each patient that establishes that the beneficiary is 

under a Medicare home health period of care. Failure to submit the NOA within five calendar days from the start of care date will result in a reduction to 
the 30-day period payment amount for each day from the start of care date until the date the NOA is submitted.

Medicaid Programs

Medicaid is a state-administered program that provides certain social and medical services to qualified low-income individuals and is jointly funded 

by the federal government and individual states. Reimbursement rates and methods vary by state and service type, but are typically based on an hourly or 
unit-of-service basis. Rates are subject to adjustment based on statutory and regulatory changes, administrative rulings, government funding limitations and 
interpretations of policy by individual state agencies. Within guidelines established by federal statutes and regulations, and subject to federal oversight, 
each state establishes its own eligibility standards, determines the type, amount, duration and scope of services, sets the rate of payment for services and 
administers its own program. States typically cover intermittent home health services for Medicaid beneficiaries, but cover continuous services for children 
and young adults with complicated medical conditions and home and community-based services for seniors and people with disabilities.

Payment models vary by state. Currently, home health services are often reimbursed by state Medicaid programs on a fee-for-service basis. For 
hospice services, the state pays an amount for each day that a beneficiary is under the care of a hospice provider based on the type and intensity of services 
furnished. Many states are moving the administration of their Medicaid hospice and home healthcare programs to managed care organizations in order to 
effectively manage costs.

Currently, personal care services and other HCBS are largely reimbursed on a fee-for-service basis. Some states have received permission from 

CMS to provide HCBS under waivers of traditional Medicaid requirements. In an effort to control escalating Medicaid costs, states are increasingly 
requiring Medicaid beneficiaries to enroll in managed care plans for better coordination of HCBS and healthcare services. For example, over three-quarters 
of Medicaid beneficiaries in Illinois are a part of the Health Choice Illinois statewide managed care program, which is serviced by various managed care 
organizations. Reimbursement from the managed care organizations for personal care services is generally on an hourly, fee-for-service basis with rates 
consistent with or as a percentage of the individual state funded rates, where applicable.

8

 
Table of Contents

Illinois Department on Aging

A significant amount of our net service revenues from our personal care segment are derived from once specific payor client, the Illinois Department 

on Aging, which accounted for 20.9% and 20.7% of our net service revenues for 2023 and 2022, respectively. The Illinois Department on Aging 
coordinates programs and community-based services intended to improve quality of life and preserve the independence of older individuals. The Illinois 
Department on Aging is funded by Medicaid, Illinois’s Commitment to Human Services Fund, and general revenue funds of the state of Illinois, and also 
receives funding available under the federal Older Americans Act (“OAA”). The Department on Aging’s Community Care Program (“CCP”) provides 
adult day services, emergency home response, automated medication dispenser services, and in-home services, which consist of personal care services, to 
individuals who are age 60 and over and meet other eligibility requirements. Some of these services are provided through Medicaid waivers granted by 
CMS.

Consumers are identified by “care coordinators” contracted independently with the Illinois Department on Aging. Once a consumer has been 

evaluated and determined to be eligible for a program, an assigned care coordinator refers the consumer to a list of authorized providers, from which the 
consumer selects the provider. We provide our services in accordance with a care plan developed by the care coordinator and under administrative 
directives from the Illinois Department on Aging. We are reimbursed on an hourly fee-for-service basis.

Veterans Health Administration

The Veterans Health Administration operates the nation’s largest integrated healthcare system, with more than 1,300 healthcare facilities, and 
provides healthcare benefits, including personal care, hospice and home health services, to eligible military veterans. The Veterans Health Administration 
provides funding to regional and local offices and facilities that support the in-home care needs of eligible aged and disabled veterans. Services are funded 
by local Veterans Medical Centers and the aid and attendance pension, which reimburses veterans for their otherwise unreimbursed health and long-term 
care expenses. We currently have relationships and agreements with the Veterans Health Administration to provide personal care services in several states, 
principally in New Mexico, Illinois and California.

Other

Other sources of funding are available to support personal care, hospice and home health services in different states and localities. For example, 

many states appropriate general funds or special use funds through targeted taxes or lotteries to finance personal care services for senior citizens and 
individuals with disabilities. Depending on the state, these funds may be used to supplement existing Medicaid programs or for distinct programs that serve 
non-Medicaid eligible consumers.

Commercial Insurance

Most long-term care insurance policies contain benefits for in-home services. Policies are generally subject to dollar limitations on the amount of 

daily, weekly or monthly coverage provided.

Private Pay

Our private pay services are provided on an hourly or type of services basis. Our rates are established to achieve a pre-determined gross margin, and 

are competitive with those of other local providers. We bill our private pay consumers for services rendered weekly, bi-monthly or monthly. Other private 
payors include workers’ compensation programs/insurance, preferred provider organizations and employers.

9

 
 
Table of Contents

Insurance Programs and Costs

We maintain workers’ compensation, general and professional liability, cyber, automobile, directors’ and officers’ liability, fiduciary liability and 
excess liability insurance. We offer various health insurance plans to eligible full-time and part-time employees. We believe our insurance coverage and 
self-insurance reserves are adequate for our current operations. However, we cannot be certain that any potential losses or asserted claims will not exceed 
such insurance coverage and self-insurance reserves.

Human Capital Management

The following is a breakdown of our part- and full-time employees, including the employees in our corporate support center, as of December 31, 

2023:

Caregivers and agency staff
Corporate support centers

Full-time

Part-time

Total

5,528    
531    
6,059    

28,776    
11    
28,787    

34,304  
542  
34,846  

At Addus, our people are crucial to our mission. Our Addus CARES commitment to human capital excellence inspires a culture that attracts, retains, 

and engages our employees to serve our important mission, and it is fundamental to our corporate philosophy. 

Workforce Composition:

Our workforce is a dynamic and diverse assembly of talent. At the core of our operations is a dedicated team of 5,528 full-time caregivers, clinical 
staff, and administrative employees. Complementing their efforts are 28,776 part-time caregivers and administrative employees. We offer flexibility in the 
form of adaptable work options, which may not be as readily available in other industries. In our most recent annual employee engagement survey, our 
workforce scored work-life balance at an 80% satisfaction rating.

 Two corporate support centers house a total of 542 administrative and professional employees. 

Approximately 17,859 or 51.3% of our total employees are represented by labor unions. We maintain strong working relationships with these labor 

unions. We have numerous collective bargaining agreements with local affiliates of the Service Employees International Union (“SEIU”), which are 
renegotiated from time to time.

People Development and Experience:

We believe in a strong workplace culture focused on people development. We have named this initiative “Addus CARES”, which represents our 

commitment to creating a culture that attracts, retains, and engages people to serve our important mission.We aspire to create a workplace that values and 
listens to its employees, provides ample opportunities for their skills development, and effectively recognizes their achievements. By leveraging our People 
Development and Experience Department, we aspire to create a workplace that values and listens to its employees, provides ample opportunities for their 
skills development, and effectively recognizes their achievements throughout the employee life cycle.

Addus prioritizes a robust listening strategy that allows for regular opportunities for feedback throughout an employee’s tenure. People experience 

surveys serve as a foundation of this strategy. In the most recent such survey, company management received an 82% satisfaction rating among all 
employee respondents, and 80% of our caregiver respondents indicated they would recommend Addus as a great place to work. 

10

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

Our dedication to workforce experience is also reflected in the breadth of our training programs and our ongoing commitment to employee 
development. Addus has recently introduced new innovative initiatives such as our Ignite and Emerge employee development programs. Ignite equips new 
leaders with the necessary skills, tools, and resources to lead within our organizational culture and values. Emerge cultivates future leaders, strengthening 
our future with a diverse internal leadership pipeline for potential future promotions. Additionally, Addus deploys ongoing learning opportunities 
throughout the employee life cycle via the Addus Learning Academy and clinical learning management systems. The Addus Learning Academy allows 
employees to access online resources needed to build and enhance the important skills related to their respective roles at Addus and to provide beneficial 
soft-skills training for personal growth. With recent investments in new learning management platforms and additional investments in existing platforms, 
Addus’ clinical learning management systems provide a growing catalog of continuing learning opportunities for patient-facing employees to improve their 
clinical skills and promote consistent, quality care.

We believe it is important to acknowledge our employees and managers who are carrying our mission and values forward every day, and we are 

committed to fostering employee engagement through effective recognition programs and communications. The Addus Elite employee recognition 
program consists of three levels of employee recognition: real-time peer-to-peer, quarterly company-wide, and annual Addus Elite Hall of Fame. All three 
components are designed to recognize and celebrate the work our employees do daily. Additionally, we have focused our organizational communication 
tools to disseminate vital company information more efficiently and effectively through the Addus Resource Center, AddusConnect, and Addus Ink. The 
Addus Resource Center is a company information portal for on-demand company information. AddusConnect is a biweekly e-newsletter that succinctly 
features important company updates, information, and resources. Addus Ink is a semi-annual publication that highlights local stories and news from around 
the country that celebrate our mission and values. 

Employee Welfare

As part of our commitment to providing high quality care and service to our clients and patients, while also promoting the health and well-being of 

our employees, Addus takes a multifaceted approach to employee wellness and safety.

Through strategically designed benefit offerings, Addus provides access to healthcare coverage that balances the medical needs of our workforce 
with affordability for our diverse employment populations. In addition, the company aims to assist in the financial well-being of our workforce through 
company benefits such as early wage access programs, an employee discount marketplace, and educational resources for employees on financial well-
being. Addus offers a non-profit employee disaster relief fund program, Addus ACTS, that provides emergency financial grants for employees in need.

In addition, Addus maintains a structured workplace safety program throughout the employee life cycle that provides job-relevant education, 
training, and skills focused on both the prevention of workplace injuries and improving awareness of mitigation efforts, should risks materialize on the job.  
Through these comprehensive safety efforts, the Addus safety program enhances our ability to provide consistent and quality client care and service.

Talent Acquisition

Talent acquisition is a strategic imperative of the company, and our Addus CARES culture is committed to attracting, retaining, and engaging 
talent. Our commitment to talent acquisition is evident in both our internal mobility efforts and our external recruitment. Internally, the company provides a 
tuition reimbursement program designed to encourage the continued educational pursuit of academic degrees that prepare employees for their next logical 
internal career progression, or that improve their ability to perform their current role. Clinical ladder initiatives focus on clinical certification advancement 
of existing employees. External recruitment has been bolstered by new investments in job search efforts, programmatic job advertising, and new 
recruitment technologies, most recently with the introduction of a new mobile-optimized Applicant Tracking System. Recruitment strategies, including 
company-wide hiring events, local partnerships with colleges and nursing schools, sponsored clinical rotations, and student scholarships have better 
positioned the company to attract top talent. 

11

 
Table of Contents

Technology

We currently utilize multiple applications to support our various lines of business and locations for patient accounting. Each application supports its 
respective line of business and locations with administrative, office, clinical and operating information system needs, including compliance of our operating 
systems with federal and state privacy, security and interoperability requirements. Each assists our staff in gathering information to improve the quality of 
consumer care, optimize financial performance, promote regulatory compliance and enhance staff efficiency. Each application is hosted by the vendor in a 
secure data center, which provides multiple redundancies for storage, power, bandwidth and security.

In order to comply with federal and state laws and regulations around EVV use, we utilize several different vendors and have built interfaces 
between the EVV vendor and the patient accounting system utilized in the respective branch location. Our caregivers use a mix of Interactive Voice 
Response (“IVR”) and mobile applications for EVV. In addition, we use these technologies to record basic information about each visit, record start and 
end times for a scheduled shift, track mileage reimbursement, send text messages to the caregivers and communicate basic payroll information.

We license the Qlik Business Intelligence (“Qlik”) platform to provide historical, current, and forward-looking operational performance analysis. We

currently have our personal care and hospice segments integrated into Qlik. Qlik provides high-level historical and current analytical views to measure 
performance against budget and deliver insight into the various factors driving our execution against our financial, operational, and compliance goals. This 
analysis is available in summary and detailed views to accommodate user needs at all levels, from senior management to operators in the field.

We utilize the ADP Vantage Suite as our base human resources and payroll processing system and use their services and products to manage our 

leave of absence processes, benefits, 401(k) and flexible spending account administration, garnishment services, payroll tax filings, ACA compliance and 
filings, and time and attendance. For financial management, we utilize Oracle’s Planning Budgeting Cloud Service as our solution for budgeting, 
forecasting, and financial reporting and Oracle Fusion for the general ledger, accounts payable and fixed assets.

Government Regulation

Overview

Our business is subject to extensive federal, state and local regulation. Changes in the laws and regulations, or new interpretations of existing laws 
and regulations, may have a material impact on the scope of services offered (including the definition of permissible activities), the relative cost of doing 
business, and the methods and amounts of payment for care by both governmental and other payors. In addition, differences among state laws may impede 
our ability to expand into certain markets. If we fail to comply with applicable laws and regulations, we could suffer administrative civil or criminal 
penalties, including substantial fines, the loss of our licenses to operate and our ability to participate in federal or state programs. In addition, the healthcare 
industry has experienced, and is expected to continue to experience, extensive and dynamic change. It is difficult to predict the effect of these changes on 
budgetary allocations for our services. See further discussion at “Management’s Discussion and Analysis of Financial Condition and Results of Operations
—“Liquidity and Capital Resources.”

Medicare and Medicaid Participation

To participate in and qualify for reimbursement under Medicare, our home health agencies and hospices must comply with extensive conditions of 

participation. Likewise, to participate in Medicaid programs, our personal care services, hospices and home health agencies are subject to various 
requirements imposed by federal and state authorities. If we were to violate the applicable federal and state regulations governing Medicare or Medicaid 
participation, we could be excluded from participation in federal and state healthcare programs and be subject to substantial administrative, civil and 
criminal penalties.

Healthcare Reform

The healthcare industry is subject to changing political, regulatory, and economic influences at the federal and state level, along with scientific and 
technological initiatives and innovations that may affect our business. In recent years, the healthcare industry has undergone significant changes, many of 
which have been aimed at reducing costs and government spending and increasing access to health insurance. The most prominent of these efforts, the 
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”), affects 
how healthcare services are covered, delivered and reimbursed. The ACA increased health insurance coverage through a combination of public program 
expansion, private sector health insurance requirements and other reforms. However, the law has been, and continues to be, subject to legislative and 
regulatory changes and court challenges.

12

 
Table of Contents

States continue to explore payment and delivery reform initiatives, including quality of care incentives. Some states use or have applied to use 
Medicaid waivers granted by CMS to implement the ACA’s Medicaid expansion provisions, impose different eligibility or enrollment restrictions, or 
otherwise implement programs that vary from federal standards. Some of these program changes may reduce the number of current and/or future Medicaid 
enrollees in certain states. For example, Georgia imposes work and community engagement requirements under a Medicaid demonstration program for new 
enrollees that launched in mid-2023 with the permission of a federal court, while the current presidential administration and several courts have rejected 
similar initiatives in other states, making it difficult to predict the nature and success of potential changes. In addition, enrollment in managed Medicaid 
plans has increased in recent years, as state governments seek to control the cost of Medicaid programs. Managed Medicaid programs enable states to 
contract with one or more entities for patient enrollment, care management and claims adjudication. The states usually do not relinquish program 
responsibilities for financing, eligibility criteria and core benefit plan design.

The CMS Innovation Center tests innovative payment and service delivery systems to reduce Medicare and Medicaid program expenditures while 

maintaining or enhancing quality. For example, the CMS Innovation Center has supported testing of new models of care for “dual eligibles,” funding of 
home health providers that offer chronic care management services, and establishment of pilot programs that bundle acute care hospital services with 
physician services and post-acute care services, which may include home health services for certain patients. In addition, the Improving Medicare Post-
Acute Care Transformation Act of 2014 (the “IMPACT Act”) required HHS, in conjunction with the Medicare Payment Advisory Commission, to consider 
and propose a unified post-acute care payment model for post-acute care services. Currently, home health agencies, skilled nursing facilities, inpatient 
rehabilitation facilities, and long-term care hospitals are reimbursed under four distinct Medicare payment systems. In contrast, a unified post-acute care 
payment model would pay these post-acute care providers under a single framework according to a patient’s characteristics, rather than the post-acute care 
setting where the patient receives treatment. As required by the IMPACT Act, CMS and the HHS Office of the Assistant Secretary for Planning and 
Evaluation issued a report in July 2022 that presented an initial prototype, and MedPAC issued a report in June 2023 evaluating a prototype design. 
Although both CMS and MedPAC determined that designing a unified prospective payment system for post-acute care providers is feasible, MedPAC 
concluded that implementation would require significant policy changes and considerable agency resources and noted that CMS may consider smaller-scale 
site-neutral policies to address some of the overlap in patients treated in different settings. Other recent reform initiatives and proposals at the federal and 
state levels include those focused on price transparency, which may impact prices and the relationships between providers, patients, and payors. For 
example, among other consumer protections, the No Surprises Act imposes various requirements on providers and health plans intended to prevent 
“surprise” medical bills. It requires providers to send an insured patient’s health plan a good faith estimate of expected charges, including billing and 
diagnostic codes, prior to when the patient is scheduled to receive the item or service. HHS is deferring enforcement of the good faith estimate requirement 
for insured patients until it issues additional regulations. The No Surprises Act also generally requires providers to provide a good faith estimate of 
expected charges to uninsured or self-pay individuals in advance of the scheduled services or upon request. HHS is delaying enforcement with regard to 
good faith estimates that do not include expected charges for co-providers or co-facilities until the agency issues additional regulations. A number of states 
have adopted their own healthcare price transparency requirements. In addition, trends toward transparency and value-based pricing may impact our 
competitive position and patient volumes. For example, the CMS Care Compare website makes publicly available certain data on home health agency and 
hospice performance on quality measures and patient satisfaction. Further, Medicare reimbursement is tied to reporting of quality measures.

In May 2023, CMS published a proposed rule, intended to improve access to services for Medicaid beneficiaries, that includes provisions related to 

HCBS payments. Specifically, in an effort to address workforce shortages, the proposed rule would (if finalized in its proposed form) require that a 
minimum of 80% of Medicaid payments in a state for home health aide, personal care services and some similar services be spent on compensation to 
direct care workers, in addition to related payment transparency requirements. CMS has proposed allowing states four years to implement changes required 
by a final rule. The ultimate impact of the 80% requirement, if finalized as proposed, could be adverse for periods after implementation, but other aspects 
of the rule could also benefit our business by improving access to services, depending on the policies ultimately set forth in any final rule. The comment 
period for the proposed rule ended July 1, 2023. The Company filed a comment letter on the proposed rule before this deadline, as did many other 
organizations, states and stakeholders. On January 26, 2024, CMS sent a final rule to the Office of Management and Budget (OMB) for review and 
clearance. The contents of the final rule are unknown at this time, and the final rule may be significantly different than the proposed rule. OMB review is 
the last step in the process prior to release of the regulation in the Federal Register. The final rule’s timetable on the OMB website projects a release by 
April 2024.

13

 
 
Table of Contents

There is uncertainty regarding the potential impact of health reform efforts at the federal and state levels. For example, some members of Congress 

have proposed measures that would expand government-sponsored coverage, including single-payor models. Some states have implemented or are 
considering measures such as individual health insurance mandates and public health insurance options. Other industry participants, such as private payors 
and large employer groups and their affiliates, may also introduce financial or delivery system reforms. Health reform initiatives and proposals from the 
government or the private sector may impact prices, our relationships with patients, payors or ancillary providers, and our competitive position, among 
other effects.

Permits, Licensure and Certificate of Need

Our hospice, home health and personal care services are authorized and/or licensed in accordance with various state and county requirements, which 

also address a variety of operational issues including standards for the provision of medical or care services, clinical records, personnel, infection control 
and care plans. Additionally, healthcare professionals at our agencies are required to be individually licensed or certified under state law. Although our 
personal care service caregivers are generally not subject to licensure requirements, certain states require them to complete pre- and post-employment 
training programs, background checks, and, in certain instances, maintain state certification. We believe we are currently licensed appropriately as required 
by the laws of the states in which we operate in all material respects, but additional licensing requirements may be imposed upon us in existing markets or 
markets that we enter in the future.

Some states also require a provider to obtain a certificate of need or permit of approval (“CON”) before establishing, constructing, acquiring or 
expanding certain health services, operations or facilities or making certain capital expenditures. These requirements are intended to avoid unnecessary 
duplication of services. In order to obtain a CON, a state health planning agency must determine that a need exists for the project.

Fraud and Abuse Laws

The laws and regulations governing our operations, including the terms of participation in Medicare, Medicaid and other government programs, 

impose certain requirements and limitations on our operations, business arrangements and our interactions with providers and consumers. These laws 
include, but are not limited to, the federal Anti-Kickback Statute, the federal Stark Law, the federal False Claims Act (“FCA”), the federal Civil Monetary 
Penalties Law, other federal and state fraud and abuse, insurance fraud, and fee-splitting laws, which may extend to services reimbursable by any payor, 
including private insurers.

The fraud and abuse laws and regulations to which we are subject include but are not limited to:

•

•

•

The federal Anti-Kickback Statute, which prohibits providers and others from directly or indirectly soliciting, receiving, offering or paying any 
remuneration with the intent of generating referrals or orders for services or items covered by a federal healthcare program. Courts have 
interpreted this statute broadly and held that there is a violation of the Anti-Kickback Statute if just one purpose of the remuneration is to 
generate referrals.

The federal physician self-referral law, commonly known as the Stark Law, which prohibits physicians from referring Medicare and Medicaid 
patients to healthcare entities in which they or any of their immediate family members have ownership interests or other financial arrangements, 
if these entities provide certain “designated health services” (including home health services) reimbursable by Medicare or Medicaid, unless an 
exception applies. The Stark Law also prohibits entities that provide designated health services reimbursable by Medicare and Medicaid from 
billing the Medicare and Medicaid programs for any items or services that result from a prohibited referral and requires the entities to refund 
amounts received for items or services provided pursuant to the prohibited referral on a timely basis.

The federal FCA and similar state laws that govern the submission of claims for reimbursement and prohibit the making of false claims or 
statements. The government may use the FCA to prosecute Medicare and other government program fraud in areas such as coding errors and 
billing for services not provided. Among the many other potential bases for liability is the knowing and improper failure to report and refund 
amounts owed to the government within 60 days of identifying an overpayment. Submission of claims for services or items generated in 
violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. The federal government has taken the position, and 
some courts have held, that providers who allegedly have violated other statutes, such as the Stark Law, have thereby submitted false claims 
under the FCA. The FCA may be enforced directly by the federal government or by a whistleblower on the government’s behalf.

14

 
Table of Contents

•

•

The federal Civil Monetary Penalties Law, which prohibits, among other conduct, offering remuneration to influence a Medicare or Medicaid 
beneficiary’s selection of a healthcare provider, contracting with an individual or entity known to be excluded from a federal healthcare program, 
billing for services not rendered or for medically unnecessary services, misrepresenting actual services rendered in order to obtain higher 
reimbursement, and the failure to return overpayments in a timely manner.

State anti-kickback and self-referral provisions, false claims laws, insurance fraud laws, and fee-splitting laws. The scope and interpretation of 
these state laws vary, and in some cases apply to items or services reimbursed by any payor, including patients and commercial insurers. For 
instance, the Illinois Insurance Claims Fraud Prevention Act penalizes the knowing offer or payment of remuneration to induce a person to 
procure client or patients under a contract of insurance, including commercial insurance plans. 

Penalties for violation of various fraud and abuse laws or other failure to substantially comply with the numerous conditions of participation in the 

Medicare or Medicaid programs may result in criminal penalties, civil sanctions, including substantial civil monetary penalties, and exclusion from 
participation in federal healthcare programs, including Medicare and Medicaid.

Payment Integrity

We are subject to routine and periodic surveys and audits by various governmental agencies and other payors. From time to time, we receive and 

respond to survey reports containing statements of deficiencies. Periodic and random audits conducted or directed by these agencies could result in a delay 
in receipt or an adjustment to the amount of reimbursements due or received under federal or state programs and could result in referrals to other agencies 
to investigate and/or prosecute potential fraud or abuse.

CMS and state Medicaid agencies contract with third parties to promote the integrity of the Medicaid and Medicare programs through reviews of 

quality concerns and detections and corrections of improper payments. For example, CMS and state Medicaid agencies contract with recovery audit 
contractors (“RACs”) on a contingency fee basis to conduct post-payment reviews to detect and correct improper payments in the Medicare and Medicaid 
programs. RACs review claims submitted to Medicare for billing compliance, including correct coding and medical necessity. The RAC program’s scope 
also includes Medicaid claims. States may coordinate with Medicaid RACs regarding recoupment of overpayments and refer suspected fraud and abuse to 
appropriate law enforcement agencies. In addition, CMS engages unified program integrity contractors (“UPICS”) to perform proactive analysis, audits, 
investigations and other program integrity functions across the Medicare and Medicaid programs, with the goal of identifying and deterring fraud and abuse 
to avoid improper payments. Working across five geographic jurisdictions, UPICs collaborate with states and coordinate provider investigations across the 
Medicare and Medicaid programs.

From time to time, various federal and state agencies, such as HHS, issue pronouncements that identify practices and provider types that may be 
subject to heightened scrutiny, as well as practices that may violate fraud and abuse laws. We believe, but cannot assure you, that our operations comply 
with the principles expressed by HHS in these reports, advisories and guidance.

HIPAA and Other Privacy and Security and Data Exchange Requirements

The Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”) and its implementing regulations require the use of 
uniform electronic data transmission standards and code sets for certain healthcare claims and reimbursement payment transactions submitted or received 
electronically. HIPAA extensively regulates the use, disclosure, confidentiality, availability and integrity of individually identifiable health information, 
known as “protected health information,” and provides for a number of individual rights with respect to such information. As a “covered entity” subject to 
HIPAA, we are required to maintain privacy and security policies, train workforce members, maintain physical, administrative, and technical safeguards, 
enter into confidentiality agreements with vendors that handle protected health information (“business associates”), and permit individuals to access and 
amend their protected health information. In addition, we must report any breaches of unsecured protected health information. HIPAA violations may result 
in criminal penalties and significant civil penalties. 

15

 
 
Table of Contents

Other federal and state laws and regulations that apply to the collection, use, retention, protection, security, disclosure, transfer and other processing 

of personal data, such as the California Consumer Protection Act, which was recently significantly modified by the California Privacy Rights Act, may also 
impose additional or inconsistent obligations and/or result in additional penalties. Virginia and certain other states have also passed comprehensive privacy 
legislation, and several privacy bills have been proposed both at the federal and state level that may result in additional legal requirements that impact our 
business. The potential effects of these laws are far-reaching and may require us to modify our data processing practices and policies and to incur 
substantial costs and expenses in order to comply. Healthcare providers and industry participants are also subject to a growing number of requirements 
intended to promote the interoperability and exchange of patient health information, including prohibitions on information blocking. For example, certain 
healthcare providers and other entities are subject to information blocking restrictions pursuant to the 21st Century Cures Act that prohibit practices that are 
likely to interfere with the access, exchange or use of electronic health information, except as required by law or specified by HHS as a reasonable and 
necessary activity. Violations may result in penalties or other negative financial impacts.

Environmental, Health and Safety Laws

We are subject to federal, state and local regulations governing the storage, transport, use and disposal of hazardous materials and waste products. In 
the event of an accident involving such hazardous materials, we could be held liable for any damages that result, and any liability could exceed the limits or 
fall outside the coverage of our insurance. We may not be able to maintain insurance on acceptable terms, or at all.

In addition, we could be affected by climate change to the extent that climate change results in severe weather conditions or other disruptions 

impacting the communities in which we conduct operations or adversely impacts general economic conditions, including in communities in which we 
conduct operations.  Moreover, legal requirements regulating greenhouse gas emissions or otherwise associated with the transition to a lower carbon 
economy may increase in the future, which could increase our costs associated with compliance and otherwise disrupt and adversely affect our operations.  
At the current time, our compliance with environmental legal requirements, including legal requirements relating to climate change, do not have a material 
effect on our capital expenditures, financial results or operations, and we did not incur material capital expenditures for environmental matters during the 
year ended December 31, 2023. However, it is possible that future environmental-related developments may impact us, including as a result of climate 
change and/or new legal requirements associated with the transition to a lower carbon economy, in a manner that we are currently unable to predict.

Access to Public Filings

Through our website, www.addus.com, we make available, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, 

Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 
1934, as amended (the “Exchange Act”) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In 
addition to our website, the SEC maintains an internet site that contains our reports, proxy and information statements, and other information that we file 
electronically with the SEC at www.sec.gov. The references to our website address in this Form 10-K do not constitute incorporation by reference of the 
information contained on the website and should not be considered part of this document.

16

 
Table of Contents

ITEM 1A. RISK FACTORS

Any of the risks described below, and the risks described elsewhere in this Form 10-K, could have a material adverse effect on our business and 

consolidated financial condition, results of operations and cash flows, cause the trading price of our common stock to decline and cause the actual 
outcome of matters to differ materially from our current expectations as reflected in forward-looking statements made in this Form 10-K. The 
considerations and risks that follow are organized within relevant headings but may be relevant to other headings as well. The risk factors described below 
and elsewhere in this Form 10-K are not the only risks we face. Our business and consolidated financial condition, results of operations and cash flows 
may also be materially adversely affected by factors that are not currently known to us, by factors that we currently consider immaterial or by factors that 
are not specific to us, such as general economic conditions.

You should refer to the explanation of the qualifications and limitations on forward-looking statements under “Special Caution Concerning 

Forward-Looking Statements.” All forward-looking statements made by us are qualified by the risk factors described below.

Risks Related to our Growth Strategy

Our growth strategy depends on our ability to manage growing and effectively integrating operations and we may not be successful in managing 
this growth.

Our business plan calls for significant growth in business over the next several years through the expansion of our services in existing markets and 

the potential establishment of a presence in new markets. This growth has placed and continues to place significant demands on our management team, 
systems, internal controls and financial and professional resources. In addition, we will need to further develop our financial controls and reporting systems 
to accommodate our growth. This could require us to incur expenses for hiring additional qualified personnel, retaining professionals to assist in developing 
the appropriate control systems and expanding our information technology infrastructure. Our inability to effectively manage growth could have a material 
adverse effect on our financial results.

Previously completed or future acquisitions, or growth initiatives, may be unsuccessful and could expose us to unforeseen liabilities.

Our growth strategy includes potential geographical expansion into new markets and the addition of new services in existing markets through the 
acquisition of local service providers. These acquisitions involve significant risks and uncertainties, including difficulties assimilating acquired personnel 
and other corporate cultures into our business, the potential loss of key employees or consumers of acquired providers, regulatory risks, the assumption of 
liabilities, exposure to unforeseen liabilities of acquired providers, and the diversion of the management team’s attention. In addition, our due diligence 
review of acquired businesses may not successfully identify all potential issues. Further, following completion of an acquisition, we may not be able to 
maintain the growth rate, levels of revenue, earnings or operating efficiency that we and the acquired business have achieved or might achieve separately. 
The failure to effectively integrate future acquisitions could have a material adverse impact on our operations.

We have grown our business opportunistically through de novo offices and we may in the future selectively open new offices in existing and new 

states. De novo offices involve risks, including those relating to licensing, accreditation, and payor program enrollment, hiring new personnel, establishing 
relationships with referral sources and delays or difficulty in installing our operating and information systems. We may not be successful in generating 
sufficient business activity to sustain the operating costs of such de novo operations.

We may be unable to pursue acquisitions or expand into new geographic regions without obtaining additional capital or consent from our lenders.

At December 31, 2023 and 2022, we had cash balances of $64.8 million and $80.0 million, respectively, and $126.4 million and $134.9 million, 

respectively, of outstanding debt on our credit facility. After giving effect to the amount drawn on our credit facility, approximately $8.0 million and $8.2 
million of outstanding letters of credit at December 31, 2023 and 2022, respectively, and borrowing limits based on an advanced multiple of Adjusted 
EBITDA (as defined in the Credit Agreement), we had $335.6 million and $237.2 million available for borrowing under our credit facility as of December 
31, 2023 and 2022, respectively. Since our credit facility provides for borrowings based on a multiple of an Adjusted EBITDA ratio, any declines in our 
Adjusted EBITDA would result in a decrease in our available borrowings under our credit facility.

17

 
 
Table of Contents

We cannot predict the timing, size and success of our acquisition efforts, our efforts to expand into new geographic regions or the associated capital 

commitments. If we do not have sufficient cash resources or availability under our credit facility, our growth could be limited unless we obtain additional 
equity or debt financing. In the future, we may elect to issue additional equity securities in conjunction with raising capital, completing an acquisition or 
expanding into a new geographic region. Such issuances could be dilutive to existing shareholders. In addition, our ability under our credit facility to 
consummate acquisitions is restricted if we exceed certain Total Net Leverage Ratio (as defined in the Credit Agreement, and subject to adjustments as 
provided therein) thresholds, without the consent of the lenders; provided, however, in certain circumstances, in connection with a Material Acquisition (as 
defined in the Credit Agreement), we can elect to increase our Total Net Leverage Ratio compliance covenant for the then current fiscal quarter and the 
three succeeding fiscal quarters. Further, our credit facility requires, among other things, that we are in pro forma compliance with the financial covenants 
set forth therein and that no event of default exists before and after giving effect to any proposed acquisition. Our ability to expand in a manner consistent 
with historic practices may be limited if we are unable to obtain such consent from our lenders.

Business Risks

Our financial results have been, and may continue to be, adversely impacted by negative macroeconomic conditions.

Economic conditions in the United States continue to be challenging in various respects, and the United States economy continues to experience 

significant inflationary pressures, elevated interest rates, challenging labor market conditions, potential adverse effects associated with current geopolitical 
conditions. Taking into account these factors, we have incurred, and may continue to incur, increased competition for new caregivers and skilled healthcare 
staff, which will continue to impact our ability to attract and retain new employees. Further, the inflationary conditions have resulted in, and may continue 
to result in, increased operating costs, particularly as the result of increased wages we have paid and may continue to pay our caregivers and other 
personnel and our ability to attract and retain personnel. Our ability to realize rate increases from government programs and private payors, which represent 
most of our revenue, might be limited despite inflation. Higher interest rates also raise our financing costs. These factors had an unfavorable impact on our 
financial results during the year ended December 31, 2023, and may have an unfavorable impact on our financial results in future periods which could be 
material.

Moreover, we anticipate that the federal deficit, the growing magnitude of Medicare and Medicaid expenditures and the aging of the U.S. population 

will continue to place pressure on government healthcare programs, and it is possible that future deficit reduction legislation will mandate additional 
Medicare spending reductions. In addition, if economic conditions in the United States significantly deteriorate, any such developments could materially 
and adversely affect our results of operations, financial position, and/or our cash flows, even if interest rates fall. For example, states could face significant 
fiscal challenges and revise their revenue forecasts and adjust their budgets, and sales tax collections and income tax receipts could be depressed. Negative 
macroeconomic conditions could also disrupt financial markets and capital markets and the businesses of financial institutions, potentially causing a 
slowdown in the decision-making of these institutions. This may affect the timing on which we may obtain any additional funding and there can be no 
assurance that we will be able to raise additional funds on terms acceptable to us, if at all.

Timing differences in reimbursement may cause liquidity problems.

We fund operations primarily through the collection of accounts receivable, but there is a delay between the time that we provide services and the 

time that we receive reimbursement or payment for these services. These delays may result from such factors as changes by payors to data submission 
requirements, requests by fiscal intermediaries for additional data or documentation, other Medicare or Medicaid issues, or information system problems. 
Further, many of the states in which we operate are operating with budget deficits for the 2023 fiscal year and fiscal year 2024 state budgets could be 
impacted to the extent economic conditions in the United States are challenging in 2024. Various states may in the future delay reimbursement, which 
would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit claims before payment is remitted, which 
contributes to our aged receivables. Additionally, we may experience unanticipated delays in receiving reimbursement from state programs due to changes 
in their policies or billing or audit procedures. Delays in receiving reimbursement or payments from Medicare, Medicaid and other payors may adversely 
impact our working capital. As a result, working capital management, including prompt and diligent billing and collection, is an important factor in our 
results of operations and liquidity. Our working capital management procedures may not successfully negate this risk.

18

 
 
Table of Contents

We face routine and periodic surveys, audits and investigations by governmental agencies and private payors, which could have adverse findings 
that may negatively impact our business.

We are and have been subject to routine and periodic surveys, audits and investigations by various governmental agencies. In addition to surveys to 

determine compliance with the conditions of participation, CMS has engaged a number of contractors (including Medicare Administrative Contractors 
(“MACs”), RACs and UPICs) to conduct audits and investigations to evaluate billing practices and identify overpayments. In addition, individual states 
have similar integrity programs, including Medicaid RAC Programs. In certain states, payment of home health claims may be impacted by the Review 
Choice Demonstration for Home Health Services, a program intended to identify and prevent fraud, reduce the number of Medicare appeals, and improve 
provider compliance with Medicare program requirements. The program is currently limited to home health agencies in in certain states, including Illinois, 
Ohio, Oklahoma, North Carolina, Florida and Texas. Providers in these states may initially select from the following claims review and approval processes: 
pre-claim review, post-payment review, or a minimal post-payment review with a 25% payment reduction. Home health agencies that maintain high 
compliance levels will be eligible for additional, less burdensome options. 

Private third-party payors may also conduct audits and investigations, and we also perform internal audits and monitoring. 

These audits and investigations can result and have resulted in recoupments by Medicare, state programs and other payors of amounts previously 

paid to us if we fail to comply with applicable laws or program requirements. Depending on the nature of the conduct found in such audits and 
investigations and whether the underlying conduct could be considered systemic, the resolution of these audits and investigations could have a material, 
adverse effect on our financial position, results of operations and liquidity.

Private third-party payors may also conduct audits and investigations, and we also perform internal audits and monitoring. Depending on the nature 
of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material, 
adverse effect on our financial position, results of operations and liquidity.

Our revenues are concentrated in a small number of states, which makes us particularly sensitive to regulatory and economic changes in those 
states.

Our revenues are particularly sensitive to regulatory and economic changes in states in which we generate a significant portion of our revenues 

including Illinois, New Mexico and New York. Accordingly, any change in the current demographic, economic, competitive or regulatory conditions in 
these states could have an adverse effect on our business, financial condition or results of operations. Changes to the Medicaid programs in these states 
could also have a disproportionately adverse effect on our business, financial condition, results of operations or cash flows.

Future efforts to reduce the costs of the Illinois Department on Aging programs could adversely affect our service revenues and profitability.

For the years ended December 31, 2023 and 2022, we derived approximately 20.9% and 20.7%, respectively, of our revenue from the Illinois 

Department on Aging programs. State government officials have in the past attempted, and in the future may attempt, to reduce government spending by 
proposing changes aimed at reducing expenditures by this department. The nature and extent of any proposed future cost reduction initiatives is unknown. 
If future reforms impact the eligibility of consumers for services, the number of hours authorized or otherwise restrict services provided to existing 
consumers, our service revenues, results of operations, financial position and growth may be adversely affected.

Failure to renew a significant payor agreement or group of related payor agreements may materially impact our revenue.

Each of our agreements is generally in effect for a specific term, but they are also generally terminable with 60 days' notice. Our ability to renew or 

retain our agreements depends on our quality of service and reputation, as well as other factors over which we have little or no control, such as state 
appropriations and changes in provider eligibility requirements. Additionally, failure to satisfy any of the numerous technical renewal requirements in 
connection with our proposals for agreements could result in a proposal being rejected even if it contains favorable pricing terms. Failure to obtain, renew 
or retain agreements with major payors may negatively impact our results of operations and revenue. We can give no assurance these agreements will be 
renewed on commercially reasonable terms or at all.

19

 
 
Table of Contents

Negative publicity or changes in public perception of our services may adversely affect our ability to receive referrals, obtain new agreements and 
renew existing agreements.

Our success in receiving referrals, obtaining new agreements and renewing our existing agreements depends upon maintaining our reputation as a 

quality service provider among governmental authorities, physicians, hospitals, discharge planning departments, case managers, nursing homes, 
rehabilitation centers, advocacy groups, consumers and their families, other referral sources and the public. The HCBS Quality Measure Set, published by 
CMS, is intended to promote more common and consistent use of nationally standardized quality measures within and across state HCBS programs. Use of 
these HCBS measures by states, managed care organizations and other entities involved in HCBS is voluntary. In addition, the CMS Care Compare website 
makes publicly available certain data on home health agency and hospice performance on quality measures and patient satisfaction. Medicare 
reimbursement for these provider types is tied to reporting of quality measures.

While we believe that the services that we provide are of high quality, if our quality measures, some of which are published online by CMS, are 

deemed to be unsatisfactory or not of the highest value in relation to those of our competitors, our reputation could be negatively affected. Negative 
publicity, changes in public perceptions of our services or government investigations of our operations could damage our reputation and hinder our ability 
to receive referrals, retain agreements or obtain new agreements. Increased government scrutiny may also contribute to an increase in compliance costs and 
could discourage consumers from using our services. Any of these events could have a negative effect on our business, financial condition and operating 
results.

Our business may be harmed by labor relations matters.

We are subject to a risk of work stoppages and other labor relations matters because our hourly workforce is highly unionized. As of December 31, 

2023, 51.3% of our workforce was represented by labor unions. We have numerous agreements with local SEIU affiliates which are renegotiated from time 
to time. These negotiations are often initiated when we receive increases in our hourly rates from various state agencies. Upon expiration of these collective 
bargaining agreements, we may not be able to negotiate labor agreements on satisfactory terms with these labor unions. A strike, work stoppage or other 
slowdown could result in a disruption of our operations and/or higher ongoing labor costs, which could adversely affect our business. Moreover, potential 
changes to federal labor laws and regulations, including those supported by the current presidential administration, could increase the likelihood of 
employee unionization activity and the ability of employees to unionize. Labor costs are the most significant component of our total expenditures and, 
therefore, an increase in the cost of labor could significantly harm our business.

If we were required to write down all or part of our goodwill and/or our intangible assets, our net earnings and net worth could be materially 
adversely affected.

Goodwill and intangible assets with finite lives represent a significant portion of our assets. Goodwill represents the excess of cost over the fair 

market value of net assets acquired in business combinations. For example, if our market capitalization drops significantly below the amount of net equity 
recorded on our balance sheet, it might indicate a decline in our fair value and would require us to further evaluate whether our goodwill has been impaired. 
If as part of our annual review of goodwill and intangibles, we were required to write down all or a significant part of our goodwill and/or intangible assets, 
our net earnings and net worth could be materially adversely affected, which could affect our flexibility to obtain additional financing. In addition, if our 
assumptions used in preparing our valuations for purposes of impairment testing differ materially from actual future results, we may record impairment 
charges in the future and our financial results may be materially adversely affected. We had $663.0 million and $582.8 million of goodwill and $92.0 
million and $72.2 million of intangible assets recorded on our Consolidated Balance Sheets at December 31, 2023 and 2022, respectively.

It is not possible at this time to determine if there will be any future impairment charge, or if there is, whether such charges would be material. We 
will continue to review our goodwill and other intangible assets for possible impairment. We cannot be certain that a downturn in our business or changes 
in market conditions will not result in an impairment of goodwill or other intangible assets and the recognition of resulting expenses in future periods, 
which could adversely affect our results of operations for those periods.

If we fail to maintain an effective system of internal control over financial reporting, such failure could adversely impact our business and stock 
price.

Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires our management to report on, and requires our independent 

registered public accounting firm to attest to, the effectiveness of our internal control over financial reporting. Compliance with SEC regulations adopted 
pursuant to Section 404 of the Sarbanes Oxley Act requires annual management assessments of the effectiveness of our internal control over financial 
reporting. Compliance with Section 404(b) of the Sarbanes-Oxley Act has increased our legal and financial compliance costs making some activities more 
difficult, time-consuming or costly and may also place strain on our personnel, systems and resources.

20

 
 
Table of Contents

To the extent that we now or in the future have deficiencies in our internal control over financial reporting that are not remediated, our ability to 
accurately and timely report our financial position, results of operations, cash flows or key operating metrics could be impaired, which could result in a 
material misstatement in our financial statements, late filings of our annual and quarterly reports under the Exchange Act, restatements of our consolidated 
financial statements or other corrective disclosures, or other material adverse effects on our business, reputation, results of operations, financial condition or 
liquidity and could create a perception that our financial results do not fairly state our financial condition or results of operations, any of which could have 
an adverse effect on the value of our stock.

Regulatory Risks

Compliance with changing laws and regulations including specific program compliance may result in additional expenses and pose challenges for 
our management team.

Our industry is subject to extensive government regulation. For example, the state agencies that contract for our services require us to comply with 
various laws and regulations affecting the services we provide. We have a compliance department, headed by our chief compliance officer, that monitors 
and reports on our compliance efforts. The laws and regulations governing our operations are subject to change. The implementation of these changes may 
require us to modify our operations or increase our efforts to remain compliant, may reduce the authorizations for services to be provided, and may result in 
certain consumers no longer being eligible for our services, any of which may result in lower revenues and increased costs, reducing our operating 
performance and profitability. If we continue to serve our consumers without addressing changes in laws and regulations, we are at risk for non-compliance 
with program requirements and potential penalties, which may be significant.

Our hospice operations are subject to annual Medicare caps. If we exceed the caps, our business and consolidated financial condition, results of 
operations and cash flows could be materially adversely affected.

Overall payments made by Medicare to each hospice provider number (generally corresponding to each of our hospice agencies) are subject to an 

inpatient cap and an aggregate cap, which are set each federal fiscal year. The inpatient cap limits the number of days of inpatient care to no more than 20% 
of total patient care days. The aggregate cap limits the amount of Medicare reimbursement a hospice may receive, based on the number of Medicare 
patients served. If a hospice’s Medicare payments exceed its inpatient or aggregate caps, it must repay Medicare for the excess amount. If payments 
received under any of our hospice provider numbers exceed these caps, we may be required to reimburse Medicare such excess amounts, which could have 
a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Reductions in reimbursement and other changes to Medicare, Medicaid, and other federal, state and local medical and social programs could 
adversely affect our consumer caseload, units of service, revenues, gross profit and profitability.

A significant portion of our caseload and revenues are derived from government healthcare programs, primarily Medicare and Medicaid. For the 

year ended December 31, 2023, we derived approximately 59.5% of our net service revenues from state and local governmental agencies, primarily 
through Medicaid state programs and 21.5% from Medicare. However, changes in government healthcare programs may decrease the reimbursement we 
receive or limit access to, or utilization of, our services. As federal healthcare expenditures continue to increase and as many state governments navigate 
budgetary pressures, federal and state governments have made, and may continue to make, significant changes to the Medicare and Medicaid programs and 
reimbursement received for services rendered to beneficiaries of such programs. For example, the Budget Control Act of 2011 (“BCA”) requires automatic 
spending reductions to reduce the federal deficit, resulting in a uniform reduction across all Medicare programs of 2% per fiscal year that extends through 
the first seven months of 2032. As a result of the American Rescue Plan Act of 2021 (“ARPA”), an additional Medicare payment reduction of up to 4% was 
required to take effect in January 2022, although Congress has delayed implementation of this reduction until 2025. It is difficult to predict whether, when, 
or what other deficit reduction initiatives may be proposed by Congress, but future legislation may include additional Medicare spending reductions.

The Medicaid program, which is jointly funded by the federal and state governments, is often a state’s largest program. Governmental agencies 
generally condition their agreements upon a sufficient budgetary appropriation. Almost all of the states in which we operate have experienced periodic 
financial pressures and budgetary shortfalls due to challenging economic conditions and the rising costs of healthcare, among other factors. Reductions to 
federal support for state Medicaid or other programs could also result in budgetary shortfalls. As a result, many states have made, are considering or may 
consider making changes in their Medicaid or other state and local medical and social programs, including enacting legislation designed to reduce Medicaid 
expenditures.

Changes that may occur at the federal or state level to contain costs include, for example:

•

•

limiting increases in, or decreasing, reimbursement rates;

redefining eligibility standards or coverage criteria for social and medical programs or the receipt of services under those programs;

21

 
Table of Contents

•

•

•

•

•

•

•

increasing consumer responsibility, including through increased co-payment requirements;

decreasing benefits, such as limiting the number of hours of personal care services that will be covered;

changing reimbursement methodology and program participation eligibility;

slowing payments to providers;

increasing utilization of self-directed care alternatives or “all inclusive” programs;

shifting beneficiaries to managed care organizations; and

implementing demonstration projects and alternative payment models.

Certain of these measures have been implemented by, or are proposed in, states in which we operate. For example, we provide support services as a 

fiscal intermediary to the New York Consumer Directed Personal Assistance Program (“CDPAP”), a self-directed care alternative program that allows 
eligible individuals who need help with activities of daily living or skilled nursing services to choose their caregivers. In 2019, New York initiated a new 
Request For Offer (“RFO”) process to competitively procure CDPAP fiscal intermediaries. The Company was not selected in the initial RFO process. We 
submitted a formal protest in response to the selection process, which was filed and accepted in March 2021. In April 2022, the New York legislature 
passed its fiscal year 2023 state budget, which amended the Fiscal Intermediary RFO process to authorize all fiscal intermediaries that submitted an RFO 
application and served at least 200 clients in New York City or 50 clients in other counties between January 1, 2020, and March 31, 2020, but that were not 
initially awarded a contract, to contract with the New York State Department of Health (“NYSDOH”). These fiscal intermediaries are permitted to continue 
operating in all counties contained in their RFO application, provided they submitted an attestation and supporting information to the NYSDOH no later 
than November 29, 2022. The Company submitted an attestation on November 22, 2022, which allowed the Company to continue its CDPAP fiscal 
intermediary operations. However, the Company decided at that time to suspend materially all of its new fee-for-service patient admissions in the CDPAP 
through County Social Service Departments. On June 6, 2023, the NYSDOH notified the Company that it had received a contract award. Under this 
contract, the Company is providing services to all current payors and has resumed new fee-for-service patient admissions through County Social Service 
Departments in the CDPAP. The CDPAP continues to be targeted for changes by New York governmental authorities, however. For example, the 
governor’s most recent update on the state budget contained proposals that could adversely affect the Company’s ability to participate in the CDPAP. These 
proposals may not be adopted in their current form, or at all. The Company recognized approximately $40.7 million and $3.5 million in net service revenue 
and operating income, respectively, from the CDPAP for the year ended December 31, 2023.

In 2023, we derived approximately 44.5% of our net service revenues from services provided in Illinois, 17.0% of our net service revenues in New 

Mexico and 8.7% of our net service revenues in New York. Because a substantial portion of our business is concentrated in these states, any significant 
reduction in state expenditures that pay for our services or other significant changes in these states may have a disproportionately negative impact on our 
future operating results. We cannot predict whether states material to our operating results will experience changes or other challenges that negatively 
impact our ability to be reimbursed for our services in a timely manner.

Changes in the volume of uninsured patients could adversely affect our cash flows and results of operations. In recent years, federal and state 
legislatures have considered or passed various proposals impacting the size of the uninsured population. For example, Medicaid enrollment increased as a 
result of COVID-19 relief legislation that authorized a temporary increase in federal funds for certain Medicaid expenditures in states that maintained 
continuous Medicaid enrollment, among other requirements. The end of the continuous enrollment condition in 2023, including the resumption of 
redeterminations for Medicaid enrollees, has resulted in significant coverage disruptions and dis-enrollments of enrollees, and Medicaid enrollment is 
generally expected to decline through fiscal year 2024 (which ends June 30, 2024, in most states). While we believe the population targeted by our model 
will be less affected than other Medicaid enrollees, there is uncertainty regarding how enrollment will ultimately change as unwinding continues and states 
return to normal eligibility and enrollment operations.

Congress, CMS and state authorities may implement changes to reimbursement for or coverage of items and services that affect our business and 

operations. For example, from time to time, CMS revises the reimbursement systems used to reimburse healthcare providers, including through changes to 
the home health and hospice reimbursement systems, which may result in reduced Medicare and/or Medicaid payments. The shift toward value-based care 
continues, including through the implementation of alternative payment models and various demonstration projects. Some states have obtained CMS 
approval to test new or existing approaches to payment and delivery of Medicaid benefits. Payment policies for different types of providers and for various 
items and services continue to evolve, and future health reform efforts could impact both federal and state programs.

22

 
 
Table of Contents

If changes in Medicare, Medicaid or other state and local medical and social programs result in a reduction in available funds for the services we 

offer, a reduction in the number of beneficiaries eligible for our services or a reduction in the number of hours or amount of services that beneficiaries 
eligible for our services may receive, then our revenues and profitability could be negatively impacted. Our profitability depends principally on the levels 
of government-mandated payment rates and our ability to manage the cost of providing services. In some cases, commercial insurance companies and other 
private payors rely on government payment systems to determine payment rates and policies. As a result, changes to government healthcare programs that 
reduce Medicare, Medicaid or other payments may negatively impact payments from private payors, as well. Any reduction in reimbursements from 
governmental or private payors or policies that negatively affect utilization of our services, such as the imposition of copayments or prior authorization 
requirements, could also materially adversely affect our profitability.

Federal and state regulation may impair our ability to consummate acquisitions or open new agencies.

Federal and state laws and regulations may adversely impact our ability to acquire or open new start-up agencies, and the change of ownership 

processes for Medicare, Medicaid and other payors can be complex. For example, a Medicare regulation known as the “36 Month Rule” restricts buyers 
from assuming Medicare billing privileges of Medicare-certified home health agencies and, effective January 1, 2024, hospices. The 36 Month Rule applies 
if the acquired home health agency or hospice either enrolled in Medicare or underwent a change in majority ownership fewer than 36 months prior to the 
acquisition, subject to certain exceptions. Instead, the buyer must enroll as a new provider with Medicare. The 36 Month Rule can increase competition for 
acquisition targets that are not subject to the rule and may cause significant Medicare billing delays for the purchases of home health agencies and hospices 
that are subject to the rule. Home health agencies and (effective January 1, 2024) hospices undergoing changes of ownership are considered a “high-risk” 
provider type, subjecting provider enrollment applications to increased scrutiny, which may result in delays in processing. Further, in the past, CMS has 
limited enrollment of new home health agencies. If another moratorium is imposed on enrollment of new providers in a geographic area we desire to 
service, our ability to expand operations may be impacted.

Our ability to expand operations in a state will also depend, where required, on our ability to obtain a state license to operate and, in some cases, 

CON approval. States may limit the number of licenses they issue. In addition, some states require disclosures by healthcare entities to state attorneys 
general or other designated entities in advance of sales or other transactions. The failure to obtain any required CON or license or other required approvals 
could impair our ability to operate or expand our business. The increasingly challenging regulatory environment may negatively impact our ability to 
acquire healthcare businesses if they are found to have material unresolved compliance issues. Resolving any such issues and completing applicable review 
or approval processes could significantly delay or prevent us from acquiring other businesses and increase our acquisition costs.

The implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may 
limit our market share and could adversely affect our revenues.

Many government and commercial payors are transitioning providers to alternative payment models that are designed to promote cost-efficiency, 
quality and coordination of care. For example, accountable care organizations (“ACOs”) incentivize hospitals, physician groups, and other providers to 
organize and coordinate patient care while reducing unnecessary costs. Several states have implemented, or plan to implement, accountable care models for 
their Medicaid populations. If we are not included in these programs, or if ACOs establish programs that overlap with our services, we are at risk for losing 
market share and for a loss of our current business. Further, if we fail to effectively provide or coordinate the efficient delivery of quality services, our 
reputation may be negatively impacted, we may receive reduced reimbursement amounts and we may owe repayments to payors, which could cause our 
revenues to decline.

We may be similarly impacted by increased enrollment of Medicare and Medicaid beneficiaries in managed care plans, which is part of the general 

shift away from traditional fee-for-service models. Under the managed Medicare program, also known as Medicare Advantage, the federal government 
contracts with private health insurers to provide Medicare benefits. Insurers may choose to offer supplemental benefits, including in-home support services, 
and impose higher plan costs on beneficiaries. Approximately half of Medicare beneficiaries are enrolled in a Medicare Advantage plan, a figure that 
continues to grow. While hospice services are currently reimbursed as a traditional fee-for-service program under Medicare Part A, CMS is testing the 
inclusion of the Part A hospice benefit with the Medicare Advantage benefits package. Under the Hospice Benefit Component of the Value-Based 
Insurance Design Model, Medicare Advantage plans are financially responsible for all traditional Medicare services, including hospice care. If hospice 
services are offered more widely under Medicare Advantage plans, the change could result in reduced reimbursement, limited utilization, and increased 
competition for managed care contracts.

23

 
 
Table of Contents

Enrollment in managed Medicaid plans is also growing, as states are increasingly relying on managed care organizations to deliver Medicaid 

program services as a strategy to control costs and manage resources. We may experience increased competition for managed care contracts due to state 
regulation and limitations. For instance, New York law limits the number of home care providers with which a managed Medicaid long-term care plan can 
contract. We cannot assure you that we will be successful in our efforts to be included in plan networks, that we will be able to secure favorable contracts 
with all or some of the managed care organizations, that our reimbursement under these programs will remain at current levels, that the authorizations for 
services will remain at current levels or that our profitability will remain at levels consistent with past performance. In addition, operational processes may 
not be well defined as a state transitions beneficiaries to managed care. For example, membership, new referrals and the related authorization for services to 
be provided may be delayed, which may result in delays in service delivery to consumers or in payment for services rendered. Difficulties with operational 
processes may negatively affect our revenue growth rates, cash flow and profitability for services provided. Other alternative payment models may be 
presented by the government and commercial payors that subject our Company to financial risk. It is difficult to predict the nature and success of any such 
models. We cannot predict at this time what effect alternative payment models may have on our Company.

Our industry is highly competitive, fragmented and market-specific.

The healthcare and long-term care industries are highly competitive among service providers and care models. We compete with personal care 

service providers, hospice providers, home health providers, private caregivers, publicly held companies, privately held companies, privately held single-
site agencies, hospital-based agencies, not-for-profit organizations, community-based organizations and self-directed care programs. Some of these 
providers and competitive care models may have greater financial, technical, political and marketing resources, name recognition or a larger number of 
consumers and payors than we do. In addition, some of our competitors offer more services than we do in the markets in which we operate. These 
competitive advantages may limit our ability to attract and retain referrals in local markets and to increase our overall market share.

In many states, there are limited barriers to entry in providing personal care services. However, some states require entities to obtain a license before 

providing home care services. Licensure is generally required of agencies providing home health and hospice services, though requirements vary by state. 
Some states also require a provider to obtain a CON before establishing certain health services, operations or facilities. CON restrictions may reduce the 
level of competition in a given industry or in a particular geographic region. In addition, economic changes such as increases in minimum wage and 
changes in Department of Labor rules can also impact the ease of entry into a market. These factors may affect competition in the states in which we 
operate.

Often our contracts with payors are not exclusive. Local competitors may develop strategic relationships with referral sources and payors. Further, 

consolidation within the payor industry, vertical integration efforts involving payors and healthcare providers, and cost-reduction strategies by payors 
continue to increase, which may affect our competitive position. In addition, existing competitors may offer new or enhanced services that we do not 
provide or be viewed by consumers as a more desirable local alternative. These and other factors could impact our ability to contract with payors on 
favorable terms, result in pricing pressures, loss of or failure to gain market share or loss of consumers or payors, or otherwise affect our competitive 
position. Further, the introduction of new and enhanced service offerings, in combination with the development of strategic relationships by our 
competitors, could cause a decline in revenue, a loss of market acceptance of our services and a negative impact on our results of operations.

Trends toward price transparency and value-based purchasing may have an impact on our competitive position, ability to obtain and maintain 

favorable contract terms, and consumer volumes. For example, health insurers must provide online price comparison tools to help individuals get 
personalized cost estimates for covered items and services. HHS also requires health insurers to publish online the charges negotiated with providers for 
healthcare services. In addition, the CMS Care Compare website makes publicly available certain data on home health agency and hospice performance on 
quality measures and patient satisfaction. It is unclear how price transparency requirements, value-based purchasing and similar initiatives will affect 
consumer behavior, our relationships with payors, or our ability to set and negotiate prices.

We expect these competitive trends to continue. If we are unable to compete effectively, consumers may seek services from other providers, which 

could have a negative impact on our business and results of operations.

If we fail to comply with the laws and extensive regulations governing our business, we could be subject to penalties or be required to make changes 
to our operations, which could negatively impact our profitability.

The federal government and the states in which we operate regulate our industry extensively. The laws and regulations governing our operations, 
along with the terms of participation in various government programs, impose certain requirements on the way in which we do business, the services we 
offer, and our interactions with providers and consumers. These requirements include matters related to:

•

•

licensure and certification and enrollment with government programs;

eligibility for services;

24

 
Table of Contents

•

•

•

•

•

•

•

•

•

•

•

•

appropriateness and necessity of services provided;

adequacy and quality of services;

qualifications and training of personnel;

confidentiality, maintenance, interoperability, data breach, identity theft, security, access and exchange of medical records and other health-
related and personal information including information blocking, data breach, ransomware, identify theft and online tracking of personal 
information;

environmental protection, health and safety;

relationships with physicians, other referral sources and recipients of referrals;

operating policies and procedures;

addition of, and changes to, facilities and services;

adequacy and manner of documentation for services provided;

billing and coding for services;

timely and proper handling of overpayments; and

debt collection and communications with consumers.

These laws include, but are not limited to the federal Anti-Kickback Statute, the federal Stark Law, the federal FCA, the federal Civil Monetary 

Penalties Law, other federal and state fraud and abuse, insurance fraud, and fee-splitting laws, which may extend to services reimbursable by any payor, 
including private insurers, the No Surprises Act, and federal and state laws governing the security and privacy of health information.

We currently have contractual relationships with current and potential referral sources and recipients, including hospitals and health systems, skilled 

nursing facilities and certain physicians who provide medical director and clinical services to our Company. We attempt to structure our relationships to 
meet applicable regulatory requirements, but we cannot provide assurance that every relationship is fully compliant. Further, we may fail to discover 
instances of noncompliance by businesses we acquire.

If we fail to comply with applicable laws and regulations, which are subject to change, we could be subject to civil sanctions and criminal penalties, 
including substantial monetary penalties, the termination of rights to participate in federal and state healthcare programs, exclusion from federal healthcare 
programs, the suspension or revocation of licenses, and we could face nonpayment or encounter delays in our ability to bill and collect for services 
provided, any of which could adversely affect our business, results of operations, or financial results. Actions taken against one of our entities may subject 
our other entities to adverse consequences. While we endeavor to comply with applicable laws and regulations, we cannot ensure you that our practices are 
fully compliant or that courts or regulatory agencies will not interpret those laws and regulations in ways that will adversely affect our practices. Further, 
the laws and regulations governing our business are subject to change, interpretations may evolve and enforcement focus may shift. These changes could 
subject us to allegations of impropriety or illegality, require restructuring of relationships with referral sources and recipients or otherwise require changes 
to our operations. The costs of compliance with, and the other burdens imposed by, applicable laws and regulations may be substantial and could increase 
our operational costs, result in interruptions or delays in the availability of systems and/or result in a patient volume decline.

Federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts throughout the healthcare industry. 

We may face audits or investigations by government agencies or third parties, including under certain of our contractual relationships. An adverse outcome 
under any such audit or investigation, a determination that we have violated applicable laws and regulations, or a public announcement that we are being 
investigated for possible violations could result in liability, result in adverse publicity, require us to change our operations to implement plans of correction 
for alleged deficiencies, and result in other negative consequences that could adversely affect our business, financial condition, or results of operations.

25

 
 
Table of Contents

We are subject to federal, state and local laws and regulations that govern our employment practices, including minimum wage, living wage, and 
paid time-off requirements. Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our 
employment-related expenses, could adversely impact our operations.

We are required to comply with all applicable federal, state and local laws and regulations relating to employment, including OSHA requirements, 

wage and hour and other compensation requirements (including disclosure requirements), employee benefits, providing leave and sick pay, employment 
insurance, proper classification of workers as employees or independent contractors, immigration and equal employment opportunity laws. These laws and 
regulations can vary significantly among jurisdictions and can be highly technical. Costs and expenses related to these requirements are a significant 
operating expense and may increase as a result of, among other things, changes in federal, state or local laws or regulations, or the interpretation thereof, 
requiring employers to provide specified benefits or rights to employees, increases in the minimum wage and local living wage ordinances, increases in the 
level of existing benefits or the lengthening of periods for which unemployment benefits are available. Each of our subsidiaries that employ an average of 
at least 50 full-time employees in a calendar year are required to offer a minimum level of health coverage for 95% of our full-time employees in 2023 or 
be subject to an annual penalty, for example. Since our personal care operations are concentrated in Illinois, New Mexico and New York, we are also 
particularly sensitive to changes in laws and regulations in these states. Additionally, the current presidential administration has signaled its support for 
increases in minimum wage. We may not be able to offset any increased costs and expenses. Furthermore, any failure to comply with these laws, including 
even a seemingly minor infraction, can result in significant penalties which could harm our reputation and have a material adverse effect on our business. 
The COVID-19 pandemic increased some of these risks, with certain states modifying occupational health and safety guidelines in a manner that increases 
scrutiny and complexity of operations with respect to appropriate training and use in the workplace of PPE and the possibility of corresponding regulatory 
audit activity with respect to the adequacy of our practices and procedures. The COVID-19 pandemic also resulted in states modifying standards associated 
with payment amounts and required justifications to qualify for sick leave and unemployment benefits. These modifications may result in increased 
operational costs to us, which may adversely impact our financial performance.

In addition, certain individuals and entities, known as excluded persons, are prohibited from receiving payment for their services rendered to 
Medicaid, Medicare and other federal and state healthcare program beneficiaries. If we inadvertently hire or contract with an excluded person, or if any of 
our current employees or contractors becomes an excluded person in the future without our knowledge, we may be subject to substantial civil penalties, 
including civil monetary penalties, an assessment of up to three times the amount claimed and exclusion from the program. 

Our business may be adversely impacted by healthcare reform efforts. 

In recent years, the healthcare industry has undergone significant changes, many of which have been aimed at reducing costs and government 
spending. The U.S. Congress and certain state legislatures have considered and passed a large number of laws affecting the healthcare industry, including 
laws intended to impact access to health insurance. The most prominent of these legislative reform efforts, the ACA affects how healthcare services are 
covered, delivered, and reimbursed, and expanded health insurance coverage through a combination of public program expansion and private sector health 
insurance reforms. However, the ACA has been, and continues to be, subject to legislative and regulatory changes and court challenges. It is possible that 
changes by Congress or government agencies could eliminate or alter provisions beneficial to us, while leaving in place provisions reducing our 
reimbursement or otherwise negatively impacting our business.

In addition, CMS administrators may make changes to Medicaid payment models or impose new limitations on the use of Medicaid funds. For 
example, in May 2023, CMS published a proposed rule that, if finalized in its current form, would require that a minimum of 80% of Medicaid payments in 
a state for home health aide, personal care services and some similar services be spent on compensation to direct care workers, in addition to related 
payment transparency requirements. If adopted, this requirement could negatively impact our business and financial performance by, among other things, 
increasing our labor costs. Likewise, CMS administrators may grant various flexibilities to states in the administration of state Medicaid programs, 
including by modifying the scope of waivers under which states may implement Medicaid expansion provisions, impose different eligibility or enrollment 
restrictions, or otherwise implement programs that vary from federal standards. Some of these program changes may reduce the number of Medicaid 
enrollees in certain states.

Other recent reform initiatives and proposals at the federal and state levels include those focused on price transparency and value-based pricing, 
which may impact our competitive position, patient volumes, and the relationships between providers, patients, and payors. For example, the CMS Care 
Compare website makes publicly available certain data on home health agency and hospice performance on quality measures and patient satisfaction. 
Medicare reimbursement is tied to reporting of quality measures. In addition, among other consumer protections, the No Surprises Act imposes various 
requirements on providers and health plans that are intended to prevent “surprise” medical bills. The law generally requires providers to send an insured 
patient’s health plan a good faith estimate of expected charges, including billing and diagnostic codes, prior to when the patient is scheduled to receive the 
item or service.

26

 
Table of Contents

There is uncertainty regarding whether, when and what other health reform measures will be adopted through governmental avenues and/or the 

private sector, the timing and implementation of any such efforts, and the impact of those efforts on providers as well as other healthcare industry 
participants. Some members of Congress have proposed expanding government-funded coverage, including proposals to expand coverage of federally-
funded insurance programs as an alternative to private insurance or to establish a single payor system (such reforms are often referred to as “Medicare for 
All”), and some states have implemented or proposed public health insurance options. We are unable to predict the nature and success of current and future 
healthcare reform initiatives, any of which may have an adverse effect on our business, financial condition, and operating results.

The industry trend toward value-based purchasing may negatively impact our revenues.

There is a trend in the healthcare industry toward value-based purchasing of healthcare services among both government and commercial payors. 

Generally, value-based purchasing programs emphasize quality of outcome and efficiency of care provided, rather than quantity of care provided. For 
example, Medicare requires hospices and home health agencies to report certain quality data in order to receive full reimbursement. Failure to report quality 
data or poor performance may negatively impact the amount of reimbursement received. In addition, CMS publishes home health and hospice quality 
measure data online, through its Care Compare website, to allow consumers and others to search and compare data for Medicare-certified providers. 
Alongside this quality and public reporting effort, home health agencies receive, under the HHVBP Model, increases or decreases to their Medicare fee-for-
service payments of up to 5% based on performance against specific quality measures relative to the performance of other home health providers. Data 
collected in each performance year impacts Medicare payments two years later. 

In the future, CMS may establish new value-based purchasing programs affecting a broader range of providers, some of which may be mandatory. 
Initiatives aimed at improving quality and cost of care include alternative payment models, such as ACOs and bundled payment arrangements. The CMS 
Innovation Center is aiming to have all fee-for-service Medicare beneficiaries and most Medicaid beneficiaries in a care relationship with accountability for 
quality and total cost of care by 2030. There are also several state-driven value-based care initiatives. For example, some states have aligned quality metrics 
across payors through legislation or regulation. Commercial payors are shifting toward value-based reimbursement arrangements as well.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more 
common and to involve a higher percentage of reimbursement amounts. It is unclear whether alternative models will successfully coordinate care and 
reduce costs or whether they will decrease overall reimbursement. While we believe we are adapting our business strategies to compete in a value-based 
reimbursement environment, we are unable at this time to predict how this trend will affect our results of operations. If we perform at a level below the 
outcomes demonstrated by our competitors, fail to satisfy quality data reporting requirements, are unable to meet or exceed quality performance standards 
under any applicable value-based purchasing program, or otherwise fail to effectively provide or coordinate the efficient delivery of quality healthcare 
services, our reputation in the industry may be negatively impacted, we may receive reduced reimbursement amounts and we may owe repayments to 
payors, causing our revenues, financial position, results of operations and cash flows to decline.

Liability Risks

Our operations subject us to risk of litigation.

Operating in the healthcare and personal care services industries exposes us to an inherent risk of wrongful death, personal injury, professional 

malpractice and other potential claims or litigation brought by our consumers and employees. From time to time, we are subject to claims alleging that we 
did not properly treat or care for a consumer, that we failed to follow internal or external procedures, resulting in death or harm to a consumer, or that our 
employees mistreated our consumers, resulting in death or harm. We are also subject to claims arising out of accidents involving vehicle collisions brought 
by consumers whom we are transporting, from employees driving to or from home visits or other affected individuals. We may also be subject to lawsuits 
from patients, employees and others exposed to contagious diseases in connection with the services provided by our workforce in client residences and 
third party facilities. Some of the actions brought against us may seek large sums of money as damages and involve significant defense costs. Our 
professional and general liability insurance may not cover all claims against us.

In addition, regulatory agencies have previously brought and may in the future initiate administrative proceedings alleging violations of statutes and 

regulations arising from our services and seek to impose monetary penalties on us. We could be required to pay substantial amounts to respond to 
regulatory investigations or, if we do not prevail, damages or penalties arising from these legal proceedings. We also are subject to potential lawsuits under 
the federal FCA or other federal and state whistleblower statutes designed to combat fraud and abuse in our industry. These and other similar lawsuits can 
involve significant defense costs, as well as significant monetary awards or penalties that may not be covered by our insurance. If our third-party insurance 
coverage and self-insurance coverage reserves are not adequate to cover these claims, it could have a material adverse effect on our business, results of 
operations and financial condition. Even if we are successful in our defense, lawsuits or regulatory proceedings could distract us from running our business 
or irreparably damage our reputation.

27

 
Table of Contents

Our insurance liability coverage may not be sufficient for our business needs.

Although we maintain insurance consistent with industry practice, the insurance we maintain may not be sufficient to satisfy all claims made against 
us. We cannot assure you that claims will not be made in the future in excess of the limits of our insurance, and any such claims, if successful and in excess 
of such limits, may have a material adverse effect on our business or assets. We utilize historical data to estimate our reserves for our insurance programs. If 
losses on asserted claims exceed the current insurance coverage and accrued reserves, our business, results of operations and financial condition could be 
adversely affected. Changes in our annual insurance costs and self-insured retention limits depend in large part on the insurance market, and insurance 
coverage may not continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms.

Data Security and Privacy Risks

Our business depends on the proper functioning, availability, and security of our information systems. Our operations may be disrupted if we are 
unable to effectively integrate, manage and maintain the security of our information systems.

Our business depends on effective and secure information systems that assist us in, among other things, gathering information to improve the quality 
of consumer care, optimizing financial performance, adjusting consumer mix, monitoring regulatory compliance and enhancing staff efficiency. We rely on 
external service providers to provide continual maintenance, upgrading, and enhancement of our primary information systems used for our operational 
needs. The software we license for our various patient information systems supports intake, personnel scheduling, office clinical and centralized billing and 
receivables management in an integrated database, enabling us to standardize the care delivered across our network of offices and monitor our performance 
and consumer outcomes. Information systems may be vulnerable to damage from a variety of sources, including telecommunications or network failures, 
human acts and natural disasters. The number of administrative employees working remotely has increased substantially in recent years, increasing our 
dependence on systems that facilitate remote access, and we may experience increased risks as a result.

To the extent providers fail to support the software or systems we use, or if we lose our software licenses, our operations could be negatively 

affected. Our business also depends on a comprehensive payroll and human resources system for basic payroll functions and reporting, payroll tax 
reporting, managing wage assignments and garnishments. We rely on an external service provider, ADP, to provide continual maintenance, upgrading and 
enhancement of our primary human resource and payroll systems. To the extent that ADP fails to support the software or systems, or any of the related 
support services provided by them, our internal operations could be negatively affected.

Our business supports the use of EVV to electronically collect visit information when our caregivers and providers deliver home care services. Our 
solution uses a combination of IVR and GPS enabled smartphones to capture time in and time out, mileage and travel time, as well as the completed care 
plan tasks. We license this software through CellTrak and partner with states that utilize other software. We rely on these vendors to provide continual 
maintenance and enhancements, as well as security of any protected data. To the extent that our EVV vendors fail to support these processes, our internal 
operations could be negatively affected. Under the 21st Century Cures Act, states must require the use of EVV for all Medicaid-funded personal care 
services and home health services that require an in-home visit by a provider. States that failed to meet the deadlines for implementation may be subject to 
incremental reductions in federal funding, absent approval of a good faith exemption. If any states in which we operate fail to properly and timely 
implement EVV and lose an amount of their funding, or if those states adopt standards for EVV that are not compatible with our operations, our internal 
operations could be negatively affected. Further, to the extent that the EVV solutions that we use are determined to be noncompliant with federal or state 
EVV requirements, we could be subject to penalties.

The COVID-19 pandemic also led to a substantial increase in administrative employees working remotely and, consequently, accessing our system 

remotely. As a result, we are more dependent on our systems that facilitate remote access and potentially could experience increased risks.

We have taken precautionary measures designed to prevent problems that could affect our information systems. We have implemented backup of our 
key information systems that are designed to allow our operations to failover to our geographically separate disaster recovery datacenter with a quick return 
to operations for all sites and systems in the event our main datacenter becomes inoperable because of a natural disaster, attacks or other cause. All of our 
sites and branch offices have redundant connections to our primary and backup datacenters using data lines and cellular connections through VPN or 
MPLS. The key business functions for our main sites also have redundancies with key functions geographically split between our two main facilities, 
should one not be available due to the above mentioned scenarios. While we believe these measures are reasonable, no system of information security is 
able to eliminate the risk of business disruptions, and we or our third-party vendors that we rely upon may experience system failures.

28

 
 
Table of Contents

If we experience a reduction in the performance, reliability, or availability of our information systems, our operations and ability to process 
transactions and produce timely and accurate reports could be adversely affected. If we experience difficulties with the transition and integration of 
information systems or are unable to implement, maintain, or expand our systems properly, we could suffer from, among other things, operational 
disruptions, regulatory problems, and increases in administrative expenses. The occurrence of any system failure could result in interruptions, delays, the 
loss or corruption of data and cessations or interruptions in the availability of systems, all of which could have a material, adverse effect on our financial 
position and results of operations and harm our business reputation.

A cyber-attack or security breach could cause a loss of confidential consumer data, give rise to remediation and other expenses, expose us to 
liability under HIPAA, consumer protection laws, common law and other legal theories, subject us to litigation and federal and state governmental 
inquiries, damage our reputation, adversely impact our financial results, and otherwise be disruptive to our business.

We rely extensively on computer systems to manage clinical and financial data, to communicate with our consumers, payors, vendors and other third 

parties, and to summarize and analyze our operating results. We frequently exchange clinical and financial data with third parties in connection with our 
routine operations and in order to meet our contractual and regulatory obligations. We are required to comply with the federal and state privacy and security 
laws and requirements, including HIPAA. 

In addition, various states, including California, Colorado, Illinois, Nevada, New York, Massachusetts and Virginia have enacted, and other states 
are expected to enact, laws and regulations concerning privacy, data protection and information security. To the extent we are subject to such legislation, 
including as a result of any creation, use or deployment of artificial intelligence, we may be required to modify our data processing practices and policies 
and to incur substantial costs and expenses in an effort to comply. These laws often provide for civil penalties for violations, as well as a private right of 
action for data breaches that may increase data breach litigation. 

We have invested in security measures designed to protect against the threat of security breaches and cyber-attacks, including email phishing 

schemes, malware and ransomware. However, our technology, and that of our third-party service providers, may fail to adequately secure the protected 
health information and personally identifiable information we create, receive, transmit and maintain in our databases. We may be at increased risk because 
we outsource certain services or functions to, or have systems that interface with, third parties. These third parties may store or have access to our data. The 
information systems of third parties are also subject to various risks, and a breach or attack affecting any of these third parties could harm our business. 
Furthermore, because the techniques used in cyber-attacks change frequently, they may not be immediately recognized, and we may experience or be 
affected by security or data breaches that remain undetected for an extended time.

The current cyber threat environment presents increased risk for all companies, including companies in our industry. We are regularly the target of 
attempted cybersecurity and other threats that could have a security impact, and we expect to continue to experience an increase in cybersecurity threats in 
the future. In spite of our policies, procedures and other security measures used to protect our computer systems and data, occasionally, we have 
experienced breaches that have required us to notify affected consumers and the government, and we have worked with consumers and the government to 
resolve such issues. While these past breaches have not had a significant adverse impact on our business or results of operations, there can be no assurance 
that we will not be subject to additional and/or more severe cyber-attacks or security breaches in the future. If we or any of our third-party service providers 
or certain other third-parties are subject to cyber-attacks or experience security or data breaches in the future, this could result in harm to consumers, loss, 
misappropriation, corruption, or unauthorized access of protected patient medical data or other information subject to privacy laws, disruption to our 
information technology systems and/or business, reputational harm. We may also be subject us to litigation and governmental enforcement actions 
(including under HIPAA and other applicable laws) as a result of cyber-attacks or security or data breaches, which could result in fines, settlement 
agreements, corrective action plans, and of which could have a material adverse effect on our business, financial position and results of operations. Some 
state laws provide a private right of action for data breaches, which may increase data breach litigation. Further, our insurance coverage intended to address 
cybersecurity and data breach risks may not be sufficient to cover all losses or the types of claims that may arise.

29

 
 
Table of Contents

Human Capital Risks

We may not be able to attract and retain qualified personnel or we may incur increased costs in doing so.

We must attract and retain qualified non-executive personnel in the markets in which we operate in order to provide our services. We compete for 
personnel with other providers of social and medical services as well as companies in other service-based industries. As the labor market continues to be 
tight and unemployment remains at low levels, the competition for employees has increased, which will continue to impact our ability to attract and retain 
new caregivers. In addition, the competition for skilled healthcare staff has increased significantly, which continues to impact our ability to attract and 
retain qualified skilled healthcare staff. To the extent that the United States continues to have low unemployment levels and shortages of caregivers and 
skilled healthcare staff, it may continue to hinder our ability to attract and retain sufficient caregivers and skilled healthcare staff to meet the continuing 
demand for both our non-clinical and clinical services. Moreover, the increased staffing challenges have resulted in, and may continue to result in, 
increased labor cost to satisfy our staffing requirements. 

We may not be able to offset higher labor costs by increasing the rates we charge for our services. In addition, if we fail to attract and retain qualified 

and skilled personnel, our ability to conduct our business operations effectively and our results of operations would be harmed.

Competition may be greater for managers, such as regional and agency directors. Our ability to attract and retain personnel depends on several 

factors, including our ability to provide employees with attractive assignments and competitive benefits and salaries. The loss of one or more of the 
members of the executive management team or the inability of a new management team to successfully execute our strategies may adversely affect our 
business. If we are unable to attract and retain qualified personnel, we may be unable to provide our services, the quality of our services may decline, and 
we could lose consumers and referral sources.

We depend on the services of our executive team members.

Our success depends upon the continued employment of certain members of our executive team to manage several of our key functional areas, 

including operations, business development, accounting, finance, human resources, marketing, information systems, contracting and compliance. 
Moreover, the current competitive labor market may make it more difficult to retain or hire members of our executive team. The departure of any member 
of our executive team may materially adversely affect our operations.

Risk Related to Our Indebtedness

Restrictive covenants in the agreements governing our indebtedness may adversely affect us.

Our credit facility contains various covenants that limit our ability to take certain actions, including our ability to:

•

•

•

•

•

•

•

•

•

•

•

•

•

make, create, incur, assume or suffer to exist any lien;

sell or otherwise dispose of assets, including capital stock of subsidiaries;

merge, consolidate, sell or otherwise dispose of all or substantially all our assets;

make restricted payments, including paying dividends and making certain loans and investments;

create, incur, assume, permit to exist, or otherwise become or remain directly or indirectly liable with respect to any additional indebtedness;

enter into transactions with affiliates;

engage in any line of additional line of business;

amend our organization documents;

make a change in accounting treatment or reporting practices, change our name or change our jurisdiction of organization or formation;

make any payment or prepayment of certain subordinated indebtedness;

enter into agreements that restrict dividends and certain other payments from subsidiaries;

engage in a sale leaseback or similar transaction; and

make certain capital expenditures.

In addition, our credit facility contains restrictive covenants and requires us to maintain specified financial ratios and satisfy other financial 
condition tests. Our ability to meet these restrictive covenants and financial ratios and tests may be affected by events beyond our control, and we cannot 
assure you that we will meet those tests.

30

 
Table of Contents

A breach of any of these covenants could result in a default under our credit facility. Upon the occurrence of an event of default under our credit 

facility, all amounts outstanding under our credit facility may become immediately due and payable and all commitments under our credit facility to extend 
further credit may be terminated. The acceleration of any such indebtedness will result in an event of default under all of our other long-term indebtedness.

General Risks

Factors beyond our control, including inclement weather, natural disasters, acts of terrorism, pandemics, riots, civil insurrection or social unrest, 
looting, protests, strikes and street demonstrations, may impact our ability to provide services.

Adverse weather conditions, natural disasters, acts of terrorism, military conflict, pandemics, riots, civil insurrection or social unrest, looting, 

protests, strikes or street demonstrations may prevent our employees from providing authorized services. We are not paid for authorized services that are 
not delivered due to these events. Furthermore, prolonged disruptions as a result of such events in the markets in which we operate could disrupt our 
relationships with consumers, patients, caregivers and employees and referral sources located in affected areas and, in the case of our corporate office, our 
ability to provide administrative support services, including billing and collection services. For example, one of our support centers and a number of our 
agencies are located in the Midwestern United States, New York and California, increasing our exposure to blizzards and other major snowstorms, ice 
storms, tornadoes, flooding, wildfires and earthquakes. The impact of disasters and similar events is inherently uncertain. Moreover, adverse weather 
conditions may become more frequent and/or severe as the result of climate change. Moreover, we could be affected by climate change and other 
environmental issues to the extent such issues adversely affect the general economy, adversely impact our supply chain or increase the costs of supplies 
needed for our operations, or otherwise result in disruptions impacting the communities in which our facilities are located. In addition, legal requirements 
regulating greenhouse gas emissions and energy inputs or otherwise associated with the transition to a lower carbon economy may increase in the future, 
which could increase our costs associated with compliance and otherwise disrupt and adversely affect our operations. The impact of these or other factors 
beyond our control could have an adverse effect on our business, financial position and results of operations.

The emergence and effects related to a potential future pandemic, epidemic, or outbreak of infectious disease could adversely impact our business 
and future results of operations and financial condition.

As a provider of healthcare and personal care services, we have been and continue to be affected by the health and economic effects of COVID-19. 

COVID-19 continues to evolve, and we may not be able to predict or effectively respond to future developments and any such developments could 
materially affect our business, results of operations, financial position, and cash flows. The extent of any ongoing and future impact will depend on, among 
other factors, the duration and severity of any severe or widespread outbreaks of COVID-19; the availability, acceptance and effectiveness of medical 
treatments and vaccines; the impact of any mutations of the virus; and the impact of COVID-19 and related government actions on the healthcare industry 
and broader economy.

Moreover, in response to the COVID-19 pandemic, the federal government authorized financial relief for eligible healthcare providers through the 

Provider Relief Fund. Although recipients are not required to repay funding received, provided that they attest to and comply with certain terms and 
conditions, changes to interpretations of guidance on the underlying terms and conditions may result in derecognition of amounts previously received. We 
received amounts from the Provider Relief Fund and returned any unused funds. We have also acquired and may in the future acquire companies that 
received funds from the Provider Relief Fund. We believe we have structured our use of these funds in accordance with the terms and conditions. However, 
we may be subject to or incur costs from related government actions including payment recoupment, audits and inquiries by governmental authorities, and 
criminal, civil or administrative penalties. 

In addition, if a future pandemic, epidemic, or outbreak of an infectious disease or other public health crisis were to affect our markets, our business 
could be adversely affected. Any such crisis could diminish public trust in healthcare providers, particularly those that are treating or have treated patients 
affected by contagious diseases. Patient volumes may decline or volumes of uninsured and underinsured patients may increase, depending on the economic 
circumstances surrounding the pandemic, epidemic or outbreak. Further, a pandemic, epidemic or outbreak could adversely impact our business by causing 
a temporary shutdown or difficulty accessing patients, particularly facility-based patients, by causing disruption or delays in supply chains for materials and 
products, or by causing staffing shortages. Although we have contingency plans in place, including infection control plans, the potential impact of, as well 
as the public’s response and governmental responses to, any such future pandemic, epidemic or outbreak of infectious disease with respect to our markets is 
difficult to predict and could adversely impact our business and future results of operations and financial condition. 

31

 
 
Table of Contents

We may be more vulnerable to the effects of a public health emergency than other businesses due to the nature of our consumers and the physical 
proximity required by our operations.

The majority of our consumers and patients are older individuals, many of whom may be more vulnerable than the general public during a pandemic 

or in a public health emergency due to complex medical conditions or socioeconomic factors. Our employees may also be at greater risk of contracting 
contagious diseases due to their increased exposure to vulnerable consumers. Due to the physical proximity required to offer many of our services, our 
employees could have difficulty attending to our consumers if social distancing policies or quarantines are instituted in response to a public health 
emergency. In addition, the Company may expand existing internal policies in a manner that may have a similar effect. If another pandemic occurs, we 
could again suffer losses to our consumer population or a reduction in the availability of our employees. Further, we could face litigation if our employees 
or customers contract contagious diseases while our employees perform their duties. Accordingly, certain public health emergencies could have a material 
adverse effect on our financial condition and results of operations.

32

 
 
Table of Contents

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

Risk Management and Strategy

We recognize that cybersecurity threats pose a risk to our business. As part of the Company’s overall risk management systems and processes, we 

employ a risk management framework designed with the goals of identifying, assessing and managing material risks from cybersecurity threats. Key 
aspects of this risk management framework include, but are not limited to:

•

•

•

•

•

•

Maintaining a cybersecurity incident response plan, coordinated by the Company’s IT department and Chief Information Security Officer, 
which includes controls and procedures for identifying, reporting and responding to cybersecurity incidents;

Partnering with outside cybersecurity vendors periodically to gain an independent view of our cybersecurity and information security 
program;

Providing our employees with regular training on cybersecurity and the protection of our information systems;

Maintaining and testing a business continuity and disaster recovery program;

Database activity monitoring, encryption, secure file transfer protocols and application firewalls; and

Maintaining insurance coverage intended to address cybersecurity and data breach risks.

We have also implemented processes to help identify, assess and manage cybersecurity risks associated with our use of third-party service providers.

We do not believe that risks from cybersecurity threats of which we are currently aware, including as a result of any previous cybersecurity 
incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial 
condition. For additional information, see “A cyber-attack or security breach could cause a loss of confidential consumer data, give rise to remediation and 
other expenses, expose us to liability under HIPAA, consumer protection laws, common law and other legal theories, subject us to litigation and federal and 
state governmental inquiries, damage our reputation, adversely impact our financial results, and otherwise be disruptive to our business.” included in Part I, 
Item 1A of this Form 10-K.

Governance

Our cybersecurity risk management program is integrated into our overall risk management system and processes. Together with the Board’s 
standing committees, the Company’s Board of Directors is responsible for ensuring that material risks, including material cybersecurity risks, are identified 
and managed appropriately. The Board receives updates at least bi-annually from our Chief Information Officer concerning our information security and 
cyber risk strategy, cyber defense initiatives, cyber event preparedness and cybersecurity risk assessments. The Chief Information Officer has extensive IT 
and program management experience and works closely with our Chief Information Security Officer, who oversees our cybersecurity program on a day-to-
day basis. The Chief Information Security Officer has extensive cybersecurity experience, including more than 15 years working in senior IT infrastructure 
and IT security roles in the healthcare sector (seven of which years were spent as the Chief Information Security Officer). Our cybersecurity incident 
response plan provides that the Chief Information Security Officer will work with our IT Department and the impacted segment of our business to 
investigate and respond to any identified incident (including by escalating the incident to the Company’s senior management and the Board depending on 
the nature and scope).  

ITEM 2. PROPERTIES

We do not own any real property. We lease administrative offices for our local branches, none of which are individually material. We lease 

approximately 59,000 and 75,000 square feet of office space in Downers Grove, Illinois and Frisco, Texas, respectively, which serve as our support centers. 
We sublease approximately 21,000 and 37,400 square feet of our office space in Downers Grove and Frisco, respectively, to third parties. 

33

 
Table of Contents

ITEM 3. LEGAL PROCEEDINGS

From time to time, we are subject to legal and/or administrative proceedings incidental to our business. It is the opinion of management that the 

outcome of pending legal and/or administrative proceedings will not have a material effect on our financial position and results of operations.

Further information with respect to this item may be found in Note 11 to the Consolidated Financial Statements in Part II, Item 8—“Financial 

Statements and Supplementary Data,” which is incorporated herein by reference.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

34

 
Table of Contents

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF 

EQUITY SECURITIES

Market Information

Our common stock is listed on The Nasdaq Global Market under the symbol “ADUS.” 

Holders

As of December 31, 2023, 2.0% of our shares of common stock were held by our officers and directors and approximately 98.0% of our common 

stock was held by 374 institutional investors. An insignificant amount of common stock is held by individual holders. As of February 16, 2024, Addus 
HomeCare Corporation had approximately 32,080 shareholders of its common stock, including 89 shareholders of record.

Dividends

We have never paid dividends on our common stock, including in the two most recent fiscal years, and we do not intend to pay any dividends on our 
common stock in the foreseeable future. We currently plan to retain any earnings to support the operation, and to finance the growth, of our business rather 
than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, capital requirements, credit facility 
limitations, earnings, as well as other factors deemed relevant by our Board. Our credit facility restricts our ability to declare or pay any dividend or other 
distribution to Holdings unless no default or event of default has occurred and is continuing or would arise as a result thereof and the aggregate amount of 
dividends and distributions paid in any fiscal year does not exceed $7.5 million per annum.

ITEM 6. [Reserved]

35

 
 
Table of Contents

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion together with our Consolidated Financial Statements and the related notes included elsewhere in this 
Annual Report on Form 10-K. This discussion contains forward-looking statements about our business and operations. Our actual results may differ 
materially from those we currently anticipate as a result of the factors we describe under “Risk Factors” and elsewhere in this Annual Report on Form 10-
K and other risks as well as other factors that are not currently known to us, that we currently consider immaterial or that are not specific to us, such as 
general economic conditions. The discussion of our financial condition and results of operations for the year ended December 31, 2022 compared to the 
year ended December 31, 2021, included in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) 
can be found in the Annual Report on Form 10-K for the year ended December 31, 2022.

Overview

We are a home care services provider operating three segments: personal care, hospice and home health. Our services are principally provided in-

home under agreements with federal, state and local government agencies, managed care organizations, commercial insurers and private individuals. Our 
consumers are predominantly “dual eligible,” meaning they are eligible to receive both Medicare and Medicaid benefits. Managed care revenues accounted 
for 36.6%, 36.0% and 37.2% of our revenue during the years ended December 31, 2023, 2022, and 2021 respectively.

A summary of certain consolidated financial and statistical data results for 2023, 2022 and 2021 are provided in the table below. 

Net service revenues
Net income

Total assets

(1)

Adjusted EBITDA 
States served at period end
Locations at period end

2023

For the Years Ended December 31,
2022
(Amounts in Thousands, except States and Locations)

2021

  $
  $
  $

  $

  $
  $
  $

  $

1,058,651  
62,516  

1,024,426  

121,020  
22  
219  

  $
  $
  $

  $

951,120  
46,025  

937,994  

101,480  
22  
202  

864,499  
45,126  

947,585  

97,661  
22  
206  

(1) The Company defines adjusted EBITDA as earnings before interest expense, other non-operating income, taxes, depreciation, amortization, acquisition expense, 
stock-based compensation expense, restructure expenses and other non-recurring costs and loss on the sale of assets and retroactive rate increases from New 
York. The Company defined adjusted EBITDA to exclude net COVID expenses arising from the pandemic from the second quarter of 2020 to the first quarter of 
2021. Adjusted EBITDA is a performance measure used by management that is not calculated in accordance with generally accepted accounting principles in the 
United States (“GAAP”). It should not be considered in isolation or as a substitute for net income, operating income or any other measure of financial 
performance calculated in accordance with GAAP. Additionally, our calculation of Adjusted EBITDA may not be comparable to similarly titled measures 
reported by other companies. Management believes that Adjusted EBITDA is useful to investors, management and others in evaluating the Company’s operating 
performance, to provide investors with insight and consistency in the Company’s financial reporting and to present a basis for comparison of the Company’s 
business operations among periods, and to facilitate comparison with the results of the Company’s peers. Additionally, we believe that Adjusted EBITDA is a 
measure widely used by securities analysts, investors and others to evaluate the financial performance of other public companies. The financial results presented 
in accordance with U.S. GAAP and a reconciliation of this non-GAAP measure included within this Annual Report on Form 10-K should be carefully evaluated.

Acquisitions

In addition to our organic growth, we have grown through acquisitions that have expanded our presence in current markets, with the goal of having 

all three levels of in-home care in our markets, or facilitating our entry into new markets where in-home care has been moving to managed care 
organizations.

On February 1, 2022, we completed the acquisition of the operations of JourneyCare. The purchase price was approximately $86.6 million, 
including the amount of acquired excess cash held by JourneyCare at the closing of the acquisition (approximately $0.4 million). The JourneyCare 
acquisition was funded with a combination of a $35.0 million draw on the Company’s revolving credit facility and available cash. With the JourneyCare 
acquisition, the Company expanded its hospice services in the state of Illinois. 

36

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
     
   
   
   
   
   
   
   
 
Table of Contents

On October 1, 2022, we completed the acquisition of Apple Home for $12.7 million, with funding provided by drawing on the Company’s revolving 

credit facility.  With the purchase of Apple Home, the Company expanded clinical services for its home health segment to Illinois. 

On January 1, 2023, we completed the acquisition of CareStaff for approximately $1.0 million, with funding provided by available cash. With the 

purchase of CareStaff, the Company expanded its personal care services to consumers in Florida. 

On August 1, 2023, we completed the acquisition of Tennessee Quality Care for approximately $111.2 million, with funding primarily provided by 

drawing on the Company’s revolving credit facility. The purchase price is subject to the completion of working capital and related adjustments. With the 
purchase of Tennessee Quality Care, the Company expanded its services within its hospice and home health segment to Tennessee.

Revenue by Payor and Significant States

Our payor clients are principally federal, state and local governmental agencies and managed care organizations. The federal, state and local 
programs under which the agencies operate are subject to legislative and budgetary changes and other risks that can influence reimbursement rates. We are 
experiencing a transition of business from government payors to managed care organizations, which we believe aligns with our emphasis on coordinated 
care and the reduction of the need for acute care.

For the years ended December 31, 2023, 2022 and 2021, our revenue by payor and significant states by segment were as follows:

2023

% of
Segment
Net
Service
Revenues

Amount
(in Thousands)

Personal Care

2022

Amount
(in Thousands)

% of
Segment
Net
Service
Revenues

2021

% of
Segment
Net
Service
Revenues

Amount
(in Thousands)

State, local and other governmental 
programs
Managed care organizations
Private pay
Commercial insurance
Other
Total personal care segment net 
    service revenues
Illinois
New Mexico
New York
All other states
Total personal care segment net 
    service revenues

  $

  $
  $

400,753  
367,557  
16,268  
6,321  
3,819  

794,718  

411,081  
115,986  
92,469  
175,182  

50.4   %   $
46.2    
2.0    
0.8    
0.6    

100.0   %   $
51.7   %   $
14.6    
11.6    
22.1    

348,234  
326,778  
18,301  
7,689  
5,505  

706,507  

360,778  
105,315  
86,592  
153,822  

49.3   %   $
46.3    
2.6    
1.1    
0.7    

100.0   %   $
51.1   %   $
14.9    
12.3    
21.7    

338,325  
311,801  
19,991  
9,820  
5,917  

685,854  

328,619      
97,784      
99,732      
159,719      

  $

794,718  

100.0   %   $

706,507  

100.0   %   $

685,854  

49.3   %
45.5    
2.9    
1.4    
0.9    

100.0   %
47.9   %
14.3    
14.5    
23.3    

100.0   %

With the acquisition of CareStaff in 2023, the Company expanded its personal care services to consumers in the state of Florida.

37

 
 
 
 
   
 
 
   
 
   
 
   
 
 
 
 
   
 
 
 
   
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
Table of Contents

Medicare
Managed care organizations
Other
Total hospice segment net 
    service revenues
Ohio
Illinois
New Mexico
All other states
Total hospice segment net 
    service revenues

2023

Hospice

2022

2021

Amount
(in Thousands)

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

  $

  $
  $

186,317  
7,037  
13,801  

207,155  

74,871  
47,247  
30,782  
54,255  

89.9   %   $
3.4    
6.7    

100.0   %   $
36.1   %   $
22.8    
14.9    
26.2    

183,407      
7,353      
11,012      

201,772      
70,503      
47,181      
30,722      
53,366      

90.9   %   $
3.6    
5.5    

100.0   %   $
35.0   %   $
23.4    
15.2    
26.4    

142,086      
5,664      
4,503      

152,253      
61,415      
—      
36,063      
54,775      

93.3   %
3.7    
3.0    

100.0   %
40.3   %
—    
23.7    
36.0    

  $

207,155  

100.0   %   $

201,772      

100.0   %   $

152,253      

100.0   %

With the acquisition of JourneyCare in 2022, the Company expanded its hospice services to patients in the state of Illinois, and with the acquisition 

of Tennessee Quality Care in 2023, the Company also expanded its hospice services to patients in the state of Tennessee. 

Medicare
Managed care organizations
Other
Total home health segment net 
    service revenues
New Mexico
Illinois
Tennessee
Total home health segment net 
    service revenues

2023

Home Health
2022

2021

Amount
(in Thousands)

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

  $

  $
  $

41,078  
12,613  
3,087  

56,778  

32,949  
12,851  
10,978  

72.3   %   $
22.2    
5.5    

100.0   %   $
58.0   %   $
22.6    
19.4    

31,505      
8,698      
2,638      

42,841      
34,111      
8,730      
—      

73.5   %   $
20.3    
6.2    

100.0   %   $
79.6   %   $
20.4    
—    

20,700      
4,457      
1,235      

26,392      
24,735      
1,657      
—      

78.4   %
16.9    
4.7    

100.0   %
93.7   %
6.3    
—    

  $

56,778  

100.0   %   $

42,841      

100.0   %   $

26,392      

100.0   %

With the acquisition of Tennessee Quality Care in 2023, the Company also expanded its home health services to patients in the state of Tennessee.

We derive a significant amount of our net service revenues in Illinois, which represented 44.5% and 43.8% of our net service revenues for the years 
ended December 31, 2023 and 2022, respectively. A significant amount of our revenue is derived from one payor client, the Illinois Department on Aging, 
the largest payor program for our Illinois personal care operations, which accounted for 20.9% and 20.7% of our net service revenues for the years ended 
December 31, 2023 and 2022, respectively.

Changes in Illinois Reimbursement

On November 26, 2019, the City of Chicago voted to approve increases in the Chicago minimum wage to $14 per hour beginning July 1, 2020 and 
to $15 per hour beginning July 1, 2021. In each subsequent year, the City is required to raise the wage based on the lower of the increases in the Consumer 
Price Index (“CPI”) or 2.5% subject to a cap and other requirements. On July 1, 2023, the rate was adjusted to $15.80.

The Illinois fiscal year 2022 budget included an increase in hourly rates for in-home care services to $24.96, to be effective January 1, 2022. On July 

12, 2021, in connection with the temporary increase in federal funding for Medicaid HCBS authorized by the ARPA, the State of Illinois submitted its 
Initial Spending Plan and Narrative to CMS for approval. That plan included the acceleration by two months of the rate increase to $24.96 from January 1, 
2022, to November 1, 2021. The Company recognized $3.6 million related to the rate increase for the year ended December 31, 2021.  

38

 
 
 
   
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Table of Contents

The Illinois fiscal year 2023 budget included an increase of hourly rates for in-home care services to $25.66, to be effective January 1, 2023. This 

increase offsets the $0.40 increase in Chicago minimum wage that occurred on July 1, 2022. In addition, CMS approved a waiver amendment proposal 
submitted by the Illinois Department of Healthcare and Family Services with regard to its Persons who are Elderly program, further increasing in-home 
care rates to $26.92, effective March 1, 2023. 

The Illinois Medicaid omnibus legislation passed in June 2023 included an increase in hourly rates for in-home care services to $28.07, which took 

effect on January 1, 2024 and required a minimum wage rate of $17.00 per hour.

Our business will benefit from the rate increases noted above as planned for 2024, but there is no assurance that there will be additional offsetting 

rate increases in Illinois for fiscal years beyond fiscal year 2024, and our financial performance will be adversely impacted for any periods in which an 
additional offsetting reimbursement rate increase is not in effect.

Changes in Medicare and Medicaid Reimbursement

Hospice

Hospice services provided to Medicare beneficiaries are paid under the Medicare Hospice Prospective Payment System, under which CMS sets a 

daily rate for each day a patient is enrolled in the hospice benefit. CMS updates these rates each federal fiscal year. Effective October 1, 2023, CMS 
increased hospice payment rates by 3.1%. This reflects a 3.3% market basket increase and a negative 0.2 percentage point productivity adjustment. 
Hospices that do not satisfy quality reporting requirements will be subject to a 4-percentage point reduction to the market basket update. 

Overall payments made by Medicare to each hospice provider number are subject to an inpatient cap and an aggregate cap, which is set each federal 
fiscal year. The inpatient cap limits the number of days of inpatient care to no more than 20% of total patient care days. The aggregate cap, which limits the 
total Medicare reimbursement that a hospice may receive based on an annual per-beneficiary cap amount and the number of Medicare patients served, was 
updated to $33,494.01 for federal fiscal year 2024. If a hospice’s Medicare payments exceed its inpatient or aggregate caps, it must repay Medicare the 
excess amount.

Home Health

Home health services provided to Medicare beneficiaries are paid under the Medicare Home Health Prospective Payment System (“HHPPS”), 
which uses national, standardized 30-day period payment rates for periods of care that meet a certain threshold of home health visits (periods of care that do 
not meet the visit threshold are paid a per-visit payment rate for providing care). Although payment is made for each 30-day period, the HHPPS permits 
continuous 60-day certification periods through which beneficiaries are verified as eligible for the home health benefit. The daily home health payment rate 
is adjusted for case-mix and area wage levels. CMS uses the PDGM as the case-mix classification model to place periods of care into payment categories, 
classifying patients based on clinical characteristics and their resource needs. An outlier adjustment may be paid for periods of care where costs exceed a 
specific threshold amount.

CMS updates the HHPPS payment rates each calendar year. For calendar year 2024, CMS estimates that Medicare payments to home health 
agencies will increase by 0.8%. This is based on a home health payment update percentage of 3.0, which reflects a 3.3% market basket update reduced by a 
productivity adjustment of negative 0.3 percentage points, and an estimated 2.6% decrease associated with the transition to the PDGM, among other 
changes. Home health providers that do not comply with quality data reporting requirements are subject to a 2-percentage point reduction to their market 
basket update. In addition, Medicare requires home health agencies to submit a one-time Notice of Admission (“NOA”) for each patient that establishes 
that the beneficiary is under a Medicare home health period of care. Failure to submit the NOA within five calendar days from the start of care will result in 
a reduction to the 30-day period payment amount for each day from the start of care date until the date the NOA is submitted.

Under the Home Health Value-Based Purchasing (“HHVBP”) Model, home health agencies receive increases or decreases to their Medicare fee-for-

service payments of up to 5% based on performance against specific quality measures relative to the performance of other home health providers. Data 
collected in each performance year will impact Medicare payments two years later.

39

 
 
Table of Contents

In certain states, payment of claims may be impacted by the Review Choice Demonstration for Home Health Services, a program intended to 
identify and prevent fraud, reduce the number of Medicare appeals and improve provider compliance with Medicare program requirements. The program 
currently applies to home health agencies in certain states, including Illinois, Ohio, Oklahoma, North Carolina, Florida and Texas. Providers in states 
subject to the Review Choice Demonstration may initially select from the following claims review and approval processes: pre-claim review, post-payment 
review or a minimal post-payment review with a 25% payment reduction. Home health agencies that maintain high compliance levels will be eligible for 
additional options that may be less burdensome. We are currently unable to predict what impact, if any, this program may have on our result of operations 
or financial position.

The IMPACT Act required HHS, together with MedPAC, to consider and propose a unified payment system for post-acute care services provided by 

home health agencies, inpatient rehabilitation facilities, skilled nursing facilities, and long-term care hospitals. A unified post-acute care payment system 
would pay post-acute care providers under a single framework according to a patient’s characteristics, rather than based on the post-acute care setting 
where the patient receives treatment. As required under the statute, CMS and the HHS Office of the Assistant Secretary for Planning and Evaluation issued 
a report in July 2022 presenting a prototype for a unified post-acute care payment model, and MedPAC submitted a report to Congress in June 2023 
evaluating a prototype design. Although both CMS and MedPAC concluded that designing a unified payment system is feasible, CMS noted that universal 
implementation of a unified payment system would require congressional action and MedPAC cautioned that implementation would be complex. Due to 
the agency resources required to implement a unified model, MedPAC noted that CMS may consider smaller-scale site-neutral policies to address some of 
the overlap in patients treated in different settings and highlighted that recent changes to various post-acute care payment systems address some of the 
concerns underlying the push for a unified model.

New York Consumer Directed Personal Assistance Program (“CDPAP”)

The CDPAP is a self-directed care alternative program that allows eligible individuals who need help with activities of daily living or skilled nursing 
services to choose their caregivers. We provide support services as a CDPAP fiscal intermediary. The Company recognized approximately $40.7 million in 
revenue from the program for the year ended December 31, 2023.

In 2019, New York initiated a new RFO process to competitively procure CDPAP fiscal intermediaries. On February 11, 2021, the NYSDOH 

announced its initial selection of entities to enter into contracts as a Lead Fiscal Intermediary. The Company was not one of the selected entities in the 
initial RFO process. The Company submitted a formal protest in response to this selection process, which was filed and accepted on March 19, 2021. In 
April 2022, the New York legislature passed the fiscal year 2023 state budget, which amended the RFO process to authorize all fiscal intermediaries that 
submitted an RFO application and served at least 200 clients in New York City or 50 clients in other counties between January 1, 2020, and March 31, 
2020, but that were not initially awarded a contract, to contract with the New York State Department of Health. These fiscal intermediaries were permitted 
to continue operating in all counties contained in their RFO application, provided they submitted an attestation and supporting information to the New York 
State Department of Health no later than November 29, 2022. The Company submitted an attestation on November 22, 2022, which allowed the Company 
to continue its CDPAP fiscal intermediary operations. However, the Company decided at that time to suspend materially all of its new fee-for-service 
patient admissions through County Social Service Departments in the CDPAP. On June 6, 2023, the New York State Department of Health notified the 
Company that it had received a contract award. Under this contract, the Company is providing services to all current payors and has resumed new fee-for-
service patient admissions through County Social Service Departments in the CDPAP. The CDPAP continues to be targeted for changes by New York 
governmental authorities, however. For example, the governor’s most recent update on the state budget contained proposals that could adversely affect the 
Company’s ability to participate in the CDPAP.

CMS Proposed Rule: “Ensuring Access to Medicaid Services”

In May 2023, CMS published a proposed rule, intended to improve access to services for Medicaid beneficiaries, that includes provisions related to 

HCBS payments. Specifically, in an effort to address workforce shortages, the proposed rule would (if finalized in its proposed form) require that a 
minimum of 80% of Medicaid payments in a state for home health aide, personal care services and some similar services be spent on compensation to 
direct care workers, in addition to related payment transparency requirements. CMS has proposed allowing states four years to implement changes required 
by a final rule. The ultimate impact of the 80% requirement, if finalized as proposed, could be adverse for periods after implementation, but other aspects 
of the rule could also benefit our business by improving access to services, depending on the policies ultimately set forth in any final rule. The comment 
period for the proposed rule ended July 1, 2023. The Company filed a comment letter on the proposed rule before this deadline, as did many other 
organizations, states and stakeholders. On January 26, 2024, CMS sent a final rule to the Office of Management and Budget (OMB) for review and 
clearance. The contents of the final rule are unknown at this time, and the final rule may be significantly different than the proposed rule. OMB review is 
the last step in the process prior to release of the regulation in the Federal Register. The final rule’s timetable on the OMB website projects a release by 
April 2024.

40

 
Table of Contents

COVID-19 Update

The federal public health emergency declared by HHS as a result of the COVID-19 pandemic expired May 11, 2023. Compared to earlier periods, 

the number of COVID-19 infections and related hospitalizations has significantly declined. However, we may be more vulnerable to the effects of COVID-
19 than other businesses due to the nature of our consumers and patients and the physical proximity required by our operations. 

For the years ended December 31, 2023 and 2022, COVID-19-related expenses in our personal care segment were approximately $2.8 million and 

$4.5 million, respectively. COVID-19 related expenses are included in cost of service revenue on the Consolidated Statements of Income. Additionally, we 
recognized revenue of $1.6 million and $4.3 million attributable to temporary rate increases from certain payors in our personal care segment for the years 
ended December 31, 2023 and 2022, respectively. 

For the years ended December 31, 2023 and 2022, COVID-19-related expenses in our hospice segment were approximately $0.1 million and $0.2 

million, respectively.

As the labor market continues to be tight and unemployment remains at low levels, we expect the competition for new caregivers, including skilled 

healthcare staff to be significant. To the extent that we continue to experience a shortage of caregivers, it may hinder our ability to attract and retain 
sufficient caregivers to meet the continuing demand for both our non-clinical and clinical services. The ongoing staffing challenges may also continue to 
result in increased labor costs to satisfy our staffing requirements.

Components of our Statements of Income

Net Service Revenues

We generate net service revenues by providing our services directly to consumers and primarily on an hourly basis in our personal care segment, on 
a daily basis in our hospice segment and on an episodic basis in our home health segment. We receive payment for providing such services from our payor 
clients, including federal, state and local governmental agencies, managed care organizations, commercial insurers and private consumers.

In our personal care segment, net service revenues are principally provided based on authorized hours, determined by the relevant agency, at an 
hourly rate, which is either contractual or fixed by legislation, and are recognized at the time services are rendered. In our hospice segment, net service 
revenues are provided based on daily rates for each of the levels of care and are recognized as services are provided. In our home health segment, net 
service revenues are based on an episodic basis at a stated rate and recognized based on the number of days elapsed during a period of care within the 
reporting period. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to 
record revenues.

Cost of Service Revenues

We incur direct care wages, payroll taxes and benefit-related costs in connection with providing our services. We also provide workers’ 
compensation and general liability coverage for our employees. Employees are also reimbursed for their travel time and related travel costs in certain 
instances.

General and Administrative Expenses

Our general and administrative expenses include our costs for operating our network of local agencies and our administrative offices. Our agency 

expenses consist of costs for supervisory personnel, our community care supervisors and office administrative costs. Personnel costs include wages, payroll 
taxes and employee benefits. Facility costs include rents, utilities, and postage, telephone and office expenses. Our corporate and support center expenses 
include costs for accounting, information systems, human resources, billing and collections, contracting, marketing and executive leadership. These 
expenses consist of compensation, including stock-based compensation, payroll taxes, employee benefits, legal, accounting and other professional fees, 
travel, general insurance, rents, provision for credit losses and related facility costs. Expenses related to streamlining our operations such as costs related to 
terminated employees, termination of professional services relationships, other contract termination costs and asset write-offs are also included in general 
and administrative expenses.

41

 
 
 
Table of Contents

Depreciation and Amortization Expenses

Depreciable assets consist principally of furniture and equipment, network administration and telephone equipment and operating system software. 
Depreciable and leasehold assets are depreciated or amortized on a straight-line method over their useful lives or, if less and if applicable, their lease terms. 
We amortize our intangible assets with finite lives, consisting of customer and referral relationships, trade names, trademarks and non-competition 
agreements, using straight line or accelerated methods based upon their estimated useful lives.

Interest Expense

Interest expense is reported when incurred and principally consists of interest and unused credit line fees on the credit facility.

Income Tax Expense

All of our income is from domestic sources. We incur state and local taxes in states in which we operate. Our effective income tax rate was 23.1% 

and 23.5% for the years ended December 31, 2023 and 2022, respectively. The difference between our federal statutory and effective income tax rates was 
principally due to the inclusion of state taxes, non-deductible compensation, excess tax expense/benefit and the use of federal employment tax credits.

Results of Operations

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022

The following table sets forth, for the periods indicated, our consolidated results of operations.

Net service revenues
Cost of service revenues
Gross profit
General and administrative expenses
Depreciation and amortization
Total operating expenses
Operating income
Interest income
Interest expense
Total interest expense, net
Income before income taxes
Income tax expense
Net income

2023

Amount
1,058,651      
718,775      
339,876      
234,794      
14,126      
248,920      
90,956      
(1,476 )    
11,106      
9,630      
81,326      
18,810      
62,516      

  $

  $

Net Service
Revenues

2022

Net Service
Revenues

Amount

Change

Amount

%

100.0   %   $
67.9    
32.1    
22.2    
1.3    
23.5    
8.6    
(0.1 )  
1.0    
0.9    
7.7    
1.8    
5.9   %   $

951,120      
651,381      
299,739      
216,942      
14,060      
231,002      
68,737      
(341 )    
8,907      
8,566      
60,171      
14,146      
46,025      

100.0   %  $
68.5    
31.5  
22.8    
1.5  
24.3    
7.2    
—    
0.9    
1.0    
6.2  
1.5    
4.7   %  $

107,531      
67,394      
40,137      
17,852      
66      
17,918      
22,219      
(1,135 )    
2,199      
1,064      
21,155      
4,664      
16,491      

11.3   %
10.3    
13.4    
8.2    
0.5    
7.8    
32.3    
332.6    
24.7    
12.4    
35.2    
33.0    
35.8   %

Net service revenues increased by 11.3% to $1,058.7 million for the year ended December 31, 2023 compared to $951.1 million in 2022. Net service 
revenue increased by $88.2 million, $5.4 million and $13.9 million in our personal care, hospice and home health segments, respectively, for the year ended 
December 31, 2023, compared to 2022. Net service revenue increased due to a 8.2% increase in revenues per billable hour and a 4.2% increase in billable 
hours for the year ended December 31, 2023 in our personal care segment compared to 2022. The increase in our hospice segment revenue was primarily 
due to an increase in average daily census and revenue per patient day, mainly attributed to the acquisition of Tennessee Quality Care on August 1, 2023. 
The increase in our home health segment is primarily due to the full-year effect in 2023 of the acquisition of Apple Home on October 1, 2022 and the 
acquisition of Tennessee Quality Care on August 1, 2023.

Gross profit, expressed as a percentage of net service revenues, increased to 32.1% for the year ended December 31, 2023, from 31.5% in 2022. The 
increase was primarily attributable to the increase in gross profit percentage in our personal care and home health segments of 1.6% and 6.6%, respectively, 
offset by a decline in our hospice segment of 3.2%. The home health increase was primarily attributable to the Tennessee Quality Care acquisition on 
August 1, 2023.

42

 
 
 
 
   
 
 
 
 
   
 
   
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
   
   
 
   
   
 
   
   
   
   
   
   
   
     
   
   
   
   
   
     
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
     
   
   
   
 
Table of Contents

General and administrative expenses increased to $234.8 million for the year ended December 31, 2023 compared to $216.9 million in 2022. The 

increase in general and administrative expenses was primarily due to acquisitions that resulted in an increase in administrative employee wages, taxes and 
benefit costs of $16.3 million. General and administrative expenses, expressed as a percentage of net service revenues, decreased to 22.2% for 2023, from 
22.8% in 2022.

Depreciation and amortization were $14.1 million for each of the years ended December 31, 2023 and 2022.

Total interest expense, net increased to $9.6 million from $8.6 million for the year ended December 31, 2023 compared to 2022. The increase in 

interest expense was primarily due to higher average outstanding borrowings from additional borrowings used to fund acquisitions and increased interest 
rates under our credit facility for the year ended December 31, 2023 compared to 2022.

All of our income is from domestic sources. We incur state and local taxes in states in which we operate. The effective income tax rate was 23.1% 
and 23.5% for the years ended December 31, 2023 and 2022, respectively. Our lower effective income tax rate in 2023 was principally due to the inclusion of state 
taxes and non-deductible compensation, partially offset by excess tax benefit and the use of federal employment tax credits. For the years ended December 31, 2023 and 
2022, the state tax rates were 5.6% and 6.0%, respectively. 

Results of Operations – Segments 

The following tables and related analysis summarize our operating results and business metrics by segment: 

Personal Care Segment 

2023

2022

Change

For the Years Ended December 31,

% of
Segment
Net 
Service
Revenue
s

Amount

% of
Segmen
t
Net 
Service
Revenu
es

Amount

Amount

%

(Amounts in Thousands, Except Percentages)

  $

  $

794,718       100.0   %   $
572,807      
221,911      
64,382      
157,529      

72.1    
27.9    
8.1    
19.8   %   $

706,507       100.0   %  $
520,617       73.7    
185,890       26.3    
60,532      
8.6    
125,358       17.7   %  $

88,211      
52,190      
36,021      
3,850      
32,171      

12.5   %
10.0    
19.4    
6.4    
25.7   %

156      
38,521      
30,658      
66.2      
117,915      
25.86      
12.1   % 

  $

156      
37,482      
29,412      
65.1      
113,122      
23.91      
4.6   % 

  $

1,039      
1,246      
1.1      
4,793      
1.95      

  $

2.8   %
4.2    
1.7    
4.2    
8.2   %

Operating Results
Net service revenues
Cost of services revenues
Gross profit
General and administrative expenses
Segment operating income

(1)

Business Metrics (Actual Numbers, Except
   Billable Hours in Thousands)
Locations at period end
Average billable census * 
Billable hours * 
Average billable hours per census per month * 
Billable hours per business day *
Revenues per billable hour * 
Same store growth revenue % * 

(3) (4)

 (2)

(2)

(2)

(2)

(1)

(2)

Average billable census is the number of unique clients receiving a billable service during the year and is the total census divided by months in operation during the 
period. 
Billable hours is the total number of hours served to clients during the period. Average billable hours per census per month is billable hours divided by average 
billable census. Billable hours per day is total billable hours divided by the number of business days in the period. Revenues per billable hour is revenue, attributed 
to billable hours, divided by billable hours. 

43

 
 
 
 
   
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
   
   
     
   
   
     
   
   
   
   
   
   
   
   
   
   
 
 
       
   
 
       
   
 
     
   
 
 
       
   
 
       
   
 
       
   
   
   
   
   
 
       
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
     
     
 
Table of Contents

(3)

(4)

2023 same store growth reflects the change in year-over-year revenue for the same store base. We define the same store base to include those stores open for at least 
52 full weeks. This measure highlights the performance of existing stores, while excluding the impact of acquisitions, new store openings and closures, and ARPA 
associated revenue from this calculation.
2022 same store growth reflects the change in year-over-year revenue for the same store base. We define the same store base to include those stores open for at least 
52 full weeks. This measure highlights the performance of existing stores, while excluding the impact of acquisitions, new store openings and closures, the New 
York CDPAP and ARPA associated revenue from this calculation.

* Management deems these metrics to be key performance indicators. Management uses these metrics to monitor our performance, both in our existing operations and 
acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these, provide direct correlation to the results of operations from period to 
period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to evaluate current operating results, identify trends 
affecting our business, determine the allocation of resources and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to 
investors in evaluating and understanding our business but should not be used solely in assessing the Company’s performance. These key performance indicators should not 
be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein to fully 
evaluate and understand the business as a whole. These measures may not be comparable to similarly-titled performance indicators used by other companies.

The personal care segment derives a significant amount of net service revenues from operations in Illinois, which represented 51.7% and 51.1% of 
our net service revenues for the years ended December 31, 2023 and 2022, respectively. One payor client, the Illinois Department on Aging, accounted for 
20.9% and 20.7% of net service revenues for the years ended December 31, 2023 and 2022, respectively. Net service revenues from state, local and other 
governmental programs accounted for 50.4% and 49.3% of net service revenues for the years ended December 31, 2023 and 2022, respectively. Managed 
care organizations accounted for 46.2% and 46.3% of net service revenues for the years ended December 31, 2023 and 2022, respectively, with commercial 
insurance, private pay and other payors accounting for the remainder of net service revenues.

Net service revenues increased by 12.5% for the year ended December 31, 2023 compared to the year ended December 31, 2022 primarily as a 

result of an increase in revenues per billable hour of 8.2%, mainly attributed to rate increases discussed above. 

Gross profit, expressed as a percentage of net service revenues, increased from 26.3% for the year ended December 31, 2022 to 27.9% for the year 

ended December 31, 2023 due to a decrease of 1.1% in direct payroll expense as a percentage of net service revenues.

The personal care segment’s general and administrative expenses primarily consist of administrative employee wages, taxes and benefit costs, rent, 
information technology and office expenses. General and administrative expenses, expressed as a percentage of net service revenues, was 8.1% and 8.6% 
for the years ended December 31, 2023 and 2022, respectively. 

44

 
 
 
Table of Contents

Hospice Segment 

Operating Results
Net service revenues
Cost of services revenues
Gross profit
General and administrative expenses
Segment operating income

(1)

(2)

Business Metrics (Actual Numbers)
Locations at period end
Admissions * 
Average daily census * 
Average length of stay * 
Patient days * 
Revenue per patient day * 
Organic growth
(6)
 - Revenue * 
 - Average daily census * 

(5)

(3)

(4)

(6)

2023

% of Segment
Net Service
Revenues

Amount

For the Years Ended December 31,

2022

Change

Amount

% of Segment
Net Service
Revenues

(Amounts in Thousands, Except Percentages)

Amount

%

  $

  $

207,155  
110,219  
96,936  
52,083  
44,853  

39  
12,902  
3,415  
94.4  
    1,203,522  
175.43  
  $

2.0   % 
0.3   % 

100.0   %  $
53.2    
46.8    
25.1    
21.7   %  $

201,772      
100,956      
100,816      
49,742      
51,074      

100.0   %  $
50.0        
50.0        
24.7        
25.3   %  $

5,383      
9,263      
(3,880 )    
2,341      
(6,221 )    

2.7   %
9.2    
(3.8 )  
4.7    
(12.2 ) %

33      
13,171      
3,279      
87.7      
    1,176,193      
171.55      
  $

0.4   % 
1.9   % 

(269 )    
136      
6.7      
27,329      
3.88      

(2.0 ) %
4.1    
7.7    
2.3    
2.3   %

      $

(1)
(2)
(3)

(4)
(5)
(6)

Represents referral process and new patients on service during the period.
Average daily census is total patient days divided by the number of days in the period, adjusted for patient days for acquisitions beginning on date of acquisition. 
Average length of stay is the average number of days a patient is on service, calculated upon discharge, and is total patient days divided by total discharges in the 
period. 
Patient days is days of service for all patients in the period.
Revenue per patient day is hospice revenue divided by the number of patient days in the period.
Revenue organic growth and average daily census organic growth reflect the change in year-over-year revenue and average daily census for the same store base. We 
define the same store base to include those stores open for at least 52 full weeks. These measures highlight the performance of existing stores, while excluding the 
impact of acquisitions, new store openings and closures.

* Management deems these metrics to be key performance indicators. Management uses these metrics to monitor our performance, both in our existing operations and 
acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these, provide direct correlation to the results of operations from period to 
period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to evaluate current operating results, identify trends 
affecting our business, determine the allocation of resources and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to 
investors in evaluating and understanding our business but should not be used solely in assessing the Company’s performance. These key performance indicators should not 
be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein to fully 
evaluate and understand the business as a whole. These measures may not be comparable to similarly-titled performance indicators used by other companies.

45

 
 
 
 
 
   
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
     
 
   
 
     
 
       
     
   
   
   
   
   
   
   
   
   
   
   
   
 
 
       
   
 
       
     
       
   
 
       
   
 
       
     
       
   
   
   
   
   
     
       
   
   
   
   
   
       
   
   
   
   
       
   
   
   
   
       
   
   
       
   
   
 
       
   
 
       
     
       
   
   
   
   
     
       
   
   
   
   
     
       
   
 
 
 
Table of Contents

Hospice generates revenue by providing care to patients with a life expectancy of six months or less, as well as related services for their families. 

Hospice offers four levels of care, as defined by Medicare, to meet the varying needs of patients and their families. The four levels of hospice include 
routine care, continuous care, general inpatient care and respite care. Our hospice segment principally provides routine care.

Net service revenues from Medicare accounted for 89.9% and 90.9% and Medicare Advantage accounted for 3.4% and 3.6% for the years ended 
December 31, 2023 and 2022, respectively. Net service revenues increased by $5.4 million for the year ended December 31, 2023 compared to the year 
ended December 31, 2022 primarily due to increases in average daily census and revenue per patient day, mainly attributed to the organic growth and the 
acquisitions of the operations of Tennessee Quality Care on August 1, 2023 and JourneyCare on February 1, 2022. 

Gross profit, expressed as a percentage of net service revenues, was 46.8% and 50.0% for the years ended December 31, 2023 and 2022, 

respectively. The decrease in gross profit as a percentage of net service revenues was mainly attributed to higher direct employee wages, taxes and benefit 
costs of $6.4 million.

The hospice segment’s general and administrative expenses primarily consist of administrative employee wages, taxes and benefit costs, rent, 
information technology and office expenses. General and administrative expenses, expressed as a percentage of net service revenues, was 25.1% and 24.7% 
for the years ended December 31, 2023 and 2022, respectively. The increase in general and administrative expenses was primarily due to acquisitions that 
resulted in a $2.4 million increase in administrative employee wages for the year ended December 31, 2023.

Home Health Segment 

Operating Results
Net service revenues
Cost of services revenues
Gross profit
General and administrative expenses
Segment operating income

(1)

Business Metrics (Actual Numbers)
Locations at period end
New admissions * 
Recertifications * 
(3)
Total volume * 
Visits * 
Organic growth
(5)
 - Revenue * 

(2)

(4)

2023

% of Segment
Net Service
Revenues

Amount

For the Years Ended December 31,
2022

Amount

% of Segment
Net Service
Revenues

(Amounts in Thousands, Except Percentages)

Change

Amount

%

  $

  $

56,778      
35,749      
21,029      
14,017      
7,012      

100.0   %  $
63.0    
37.0    
24.7    
12.3   %  $

42,841      
29,808      
13,033      
10,251      
2,782      

100.0   %  $
69.6        
30.4        
23.9        
6.5   %  $

13,937      
5,941      
7,996      
3,766      
4,230      

32.5   %
19.9    
61.4    
36.7    
152.0   %

24      
16,251      
9,030      
25,281      
344,919      

(7.1 ) % 

13      
14,452      
5,838      
20,290      
293,381      

8.2   % 

1,799      
3,192      
4,991      
51,538      

12.4   %
54.7    
24.6    
17.6   %

(1)
(2)

(3)
(4)
(5)

Represents new patients during the period.
A home health certification period begins with a start of care visit and continues for 60 days. If at the end of the initial certification, the patient continues to require 
home health services, a recertification is required. This represents the number of recertifications during the period.
Total volume is total admissions and total recertifications in the period.
Represents number of services to patients in the period.
Revenue organic growth and new admissions organic growth reflect the change in year-over-year revenue and new admissions for the same store base. We define the 
same store base to include those stores open for at least 52 full weeks. These measures highlight the performance of existing stores, while excluding the impact of 
acquisitions, new store openings and closures.

46

 
 
 
 
   
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
       
   
 
       
       
     
   
   
   
   
   
   
   
 
 
       
   
 
       
     
       
   
 
       
   
 
       
     
       
   
   
   
   
     
       
   
   
   
   
       
   
   
   
       
   
   
   
       
   
   
   
       
 
       
   
 
       
     
     
     
   
   
   
       
     
   
 
 
Table of Contents

* Management deems these metrics to be key performance indicators. Management uses these metrics to monitor our performance, both in our existing operations and 
acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these, provide direct correlation to the results of operations from period to 
period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to evaluate current operating results, identify trends 
affecting our business, determine the allocation of resources and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to 
investors in evaluating and understanding our business but should not be used solely in assessing the Company’s performance. These key performance indicators should not 
be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein to fully 
evaluate and understand the business as a whole. These measures may not be comparable to similarly-titled performance indicators used by other companies.

Home health generates revenue by providing home health services on a short-term, intermittent or episodic basis to individuals, generally to treat an 
illness or injury. Net service revenues from Medicare accounted for 72.3% and 73.5% and managed care organizations accounted for 22.2% and 20.3% for 
the years ended December 31, 2023 and 2022, respectively. Home health services provided to Medicare beneficiaries are paid under the Medicare HHPPS, 
which uses national, standardized 30-day period payment rates for periods of care. CMS uses the PDGM as the case-mix classification model to place 
periods of care into payment categories, classifying patients based on clinical characteristics. An outlier adjustment may be paid for periods of care in 
which costs exceed a specific threshold amount.

Net service revenues increased by $13.9 million for the year ended December 31, 2023 compared to 2022. Total visits increased for the year ended 
December 31, 2023, mainly attributed to the acquisition of Tennessee Quality Care on August 1, 2023 and the full-year effect in 2023 of the acquisition of 
Apple Home on October 1, 2022.

Gross profit, expressed as a percentage of net service revenues, was 37.0% and 30.4% for the years ended December 31, 2023 and 2022, 

respectively. The increase in gross profit as a percentage of net service revenues was due to a decrease of 6.6% in direct payroll expense as a percentage of 
net service revenues.

The home health segment’s general and administrative expenses consist of administrative employee wages, taxes and benefit costs, rent, information 

technology and office expenses. General and administrative expenses, expressed as a percentage of net service revenues, was 24.7% and 23.9% for the 
years ended December 31, 2023 and 2022, respectively. The increase in general and administrative expenses was primarily due to acquisitions that resulted 
in a $3.1 million increase in administrative employee wages, taxes and benefit costs and a $0.3 million increase in rent expenses for the year ended 
December 31, 2023.

Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP measure that has limitations as an analytical tool, and should not be considered in isolation or as a substitute for 

analysis of our results of operations as reported under generally accepted accounting principles in the United States (“GAAP”). The financial results 
presented in accordance with U.S. GAAP and a reconciliation of this non-GAAP measure included within this Annual Report on Form 10-K should be 
carefully evaluated.

We define Adjusted EBITDA as earnings before interest expense, other non-operating income, taxes, depreciation, amortization, acquisition 
expenses, stock-based compensation expense, restructure expenses and other non-recurring costs, loss on the sale of assets and retroactive rate increases 
from New York. The Company defined adjusted EBITDA to exclude net COVID expenses arising from the pandemic from the second quarter of 2020 to 
the first quarter of 2021. Adjusted EBITDA is a performance measure used by management that is not calculated in accordance with GAAP. It should not 
be considered in isolation or as a substitute for net income, operating income or any other measure of financial performance calculated in accordance with 
GAAP. Additionally, our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

Management believes that Adjusted EBITDA is useful to investors, management and others in evaluating our operating performance for the 

following reasons:

•

•

By reporting Adjusted EBITDA, we believe that we provide investors with insight and consistency in our financial reporting and present a 
basis for comparison of our business operations between current, past and future periods. We believe that Adjusted EBITDA allows 
management, investors and others to evaluate and compare our core operating results, including return on capital and operating 
efficiencies, from period to period, by removing the impact of our capital structure (interest expense), asset base (amortization and 
depreciation), tax consequences, stock-based compensation expense and other identified adjustments.

We believe that Adjusted EBITDA is a measure widely used by securities analysts, investors and others to evaluate the financial 
performance of other public companies.

47

 
 
Table of Contents

•

We recorded stock-based compensation expense of $10.3 million, $10.6 million and $9.4 million for the years ended December 31, 2023, 
2022 and 2021, respectively. By comparing our Adjusted EBITDA in different periods, our investors can evaluate our operating results 
without stock-based compensation expense, which is a non-cash expense which we believe is not a key measure of our operations.

In addition, management has chosen to use Adjusted EBITDA as a performance measure because we believe that the amount of non-cash expenses, 

such as depreciation, amortization and stock-based compensation expense, may not directly correlate to the underlying performance of our business 
operations, and because such expenses can vary significantly from period to period as a result of new acquisitions, full amortization of previously acquired 
tangible and intangible assets or the timing of new stock-based awards, as the case may be. This facilitates internal comparisons to historical operating 
results, as well as external comparisons to the operating results of our competitors and other companies in the personal care services industry. Because 
management believes Adjusted EBITDA is useful as a performance measure, management uses Adjusted EBITDA:

•

•

•

•

•

•

as one of our primary financial measures in the day-to-day oversight of our business to allocate financial and human resources across our 
organization, to assess appropriate levels of marketing and other initiatives and to generally enhance the financial performance of our 
business;

in the preparation of our annual operating budget, as well as for other planning purposes on a quarterly and annual basis, including 
allocations in order to implement our growth strategy, to determine appropriate levels of investments in acquisitions and to endeavor to 
achieve strong core operating results;

to evaluate the effectiveness of business strategies, such as the allocation of resources, the mix of organic growth and acquisitive growth 
and adjustments to our payor mix;

as a means of evaluating the effectiveness of management in directing our core operating performance, which we consider to be 
performance that can be affected by our management in any particular period through their allocation and use of resources that affect our 
underlying revenue and profit-generating operations during that period;

for the valuation of prospective acquisitions, and to evaluate the effectiveness of integration of past acquisitions into our Company; and

in communications with our Board concerning our financial performance.

Although Adjusted EBITDA is frequently used by investors and securities analysts in their evaluations of companies, Adjusted EBITDA has 

limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results of operations as reported under 
GAAP. Some of these limitations include:

•

•

•

•

•

•

•

•

•

•

Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or other contractual 
commitments;

Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

Adjusted EBITDA does not reflect interest expense or interest income;

Adjusted EBITDA does not reflect cash requirements for income taxes;

although depreciation and amortization are non-cash charges, the assets being depreciated or amortized will often have to be replaced in 
the future, and Adjusted EBITDA does not reflect any cash requirements for these replacements;

Adjusted EBITDA does not reflect any acquisition expenses;

Adjusted EBITDA does not reflect any stock-based compensation;

Adjusted EBITDA does not reflect any restructure expense and other non-recurring costs;

Adjusted EBITDA does not reflect any net COVID-19 expense arising from the pandemic from the second quarter of 2020 to the first 
quarter of 2021; and

other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative 
measure.

Management compensates for these limitations by using GAAP financial measures in addition to Adjusted EBITDA in managing the day-to-day and 
long-term operations of our business. We believe that consideration of Adjusted EBITDA, together with a careful review of our GAAP financial measures, 
is the most informed method of analyzing our Company.

48

 
Table of Contents

The following table sets forth a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted EBITDA:

2023

For the Years Ended December 31,
2022
(Amounts In Thousands)

2021

Reconciliation of net income to Adjusted EBITDA 

(a):

Net income
Interest expense, net
Impact of retroactive New York rate increase
Income tax expense
Depreciation and amortization
Acquisition expenses
Stock-based compensation expense
Restructure expense and other related costs
COVID-19 expense, net 
(Gain) loss on sale of assets

(b)

Adjusted EBITDA*

  $

  $

62,516  
9,630  
(868 )
18,810  
14,126  
6,220  
10,319  
269  
—  
(2 )
121,020  

  $

  $

  $

46,025  
8,566  
—  
14,146  
14,060  
7,657  
10,625  
461  
—  
(60 )    
  $

101,480  

45,126  
5,538  
—  
15,272  
14,494  
7,306  
9,434  
1,057  
(591 )
25  
97,661  

(a)

(b)

The selected historical Consolidated Statements of Income data for the fiscal years ended December 31, 2023, 2022 and 2021, were derived from our 
audited Consolidated Financial Statements.

Excludes net COVID expenses arising from the pandemic from the second quarter of 2020 to the first quarter of 2021.

* Management deems Adjusted EBITDA to be a key performance indicator. Management uses key performance indicators to monitor our performance, both in 
our existing operations and acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these, provide direct correlation to the 
results of operations from period to period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to 
evaluate current operating results, identify trends affecting our business, determine the allocation of resources and assess the quality and potential variability of 
our cash flows and earnings. We believe they are useful to investors in evaluating and understanding our business but should not be used solely in assessing the 
Company’s performance. These key performance indicators should not be considered superior to, as a substitute for or as an alternative to, and should be 
considered in conjunction with, the GAAP financial measures presented herein to fully evaluate and understand the business as a whole. These measures may not 
be comparable to similarly-titled performance indicators used by other companies.

Liquidity and Capital Resources

Overview

Our primary sources of liquidity are cash on hand and cash from operations and borrowings under our credit facility. At December 31, 2023 and 
2022, we had cash balances of $64.8 million and $80.0 million, respectively. Cash flows from operating activities represent the inflow of cash from our 
payor clients and the outflow of cash for payroll and payroll taxes, operating expenses, interest and taxes. 

We drew approximately $110.0 million on the revolver portion of our credit facility to fund, in part, the purchase price paid in connection with the 
Tennessee Quality Care acquisition, and repaid $118.5 million under our revolving credit facility in 2023. At December 31, 2023, we had a total of $126.4 
million in revolving loans, with an interest rate of 7.21% outstanding on our credit facility. After giving effect to the amounts drawn on our credit facility, 
approximately $8.0 million of outstanding letters of credit and borrowing limits based on an advance multiple of Adjusted EBITDA (as defined in the 
Credit Agreement), we had $470.0 million of capacity and $335.6 million available for borrowing under our credit facility. At December 31, 2022, we had 
a total of $134.9 million of revolving loans, with an interest rate of 6.13%. During the year ended December 31, 2022, the Company drew approximately 
$47.0 million on the revolver portion of its credit facility to fund, in part, the Journey Care and Apple Home acquisitions on February 1, 2022 and October 
1, 2022, respectively.

Our credit facility requires us to maintain a total net leverage ratio not exceeding 3.75:1.00. At December 31, 2023, we were in compliance with our 

financial covenants under the Credit Agreement. Although we believe our liquidity position remains strong, we can provide no assurance that we will 
remain in compliance with the covenants in our Credit Agreement, and in the future, it may prove necessary to seek an amendment with the bank lending 
group under our credit facility. Additionally, there can be no assurance that we will be able to raise additional funds on terms acceptable to us, if at all.

49

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
   
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
Table of Contents

Borrowing Capacity

The Company’s Credit Agreement provides for a $600.0 million revolving credit facility and a $125.0 million incremental loan facility, which 
incremental loan facility may be for term loans or an increase to the revolving loan commitments. The maturity of the credit facility is July 30, 2026. 
Pursuant to the Third Amendment to Amended and Restated Credit Agreement dated as of April 26, 2023, the Company amended its credit facility to 
replace the London Inter-Bank Offered Rate (“LIBOR”) with the secured overnight financing rate as administered by the Federal Reserve Bank of New 
York (“SOFR”) as the benchmark reference rate for loans under its credit facility. The transition to SOFR did not and is not expected to have a material 
impact on the Company’s results of operations or liquidity. 

See Note 7, Long-Term Debt, to the Notes to Consolidated Financial Statements for additional details of our long-term debt.

Current Macroeconomic Conditions and COVID-19 Relief Funding

Economic conditions in the United States continue to be challenging in various respects. For example, the United States economy continues to 
experience significant inflationary pressures, elevated interest rates, challenging labor market conditions, and disruptions to supply networks. Any resulting 
economic downturn would pose a risk to states’ revenues, which in turn could affect our reimbursements and collections received for services rendered. 
Depending on the severity and length of any potential economic downturn, states could face significant fiscal challenges and revise their revenue forecasts 
and adjust their budgets, and sales tax collections and income tax withholdings could be depressed in fiscal year 2023 (which began July 1 in most states), 
and, potentially, future fiscal years. In this regard, Illinois, New Mexico and New York, our top three personal care markets, previously revised revenue 
estimates downward for the 2022 fiscal year as the result of earlier negative economic conditions arising from the pandemic. Also, in response to reduced 
revenues, the state of New York authorized the issuance of short-term bonds and implemented uniform reductions to Medicaid payments, applicable to 
home health and personal care services (hospice services were exempt). These reductions took effect for dates of service on or after April 2, 2020, and were 
eliminated effective April 1, 2022.

COVID-19 Provider Relief Fund

In response to the COVID-19 pandemic, the federal government took various measures intended to assist healthcare providers, including authorizing 

several forms of financial relief. One of the primary sources of relief for eligible healthcare providers was the Provider Relief Fund, distributions from 
which were intended to compensate healthcare providers for lost revenues and healthcare related expenses incurred in response to the COVID-19 
pandemic. Recipients were not required to repay funding received, provided that they attested to and complied with certain terms and conditions.

In November 2020, the Company received grants in an aggregate principal amount of $13.7 million from the Provider Relief Fund, for which we 

had previously applied. The Company utilized the remaining $12.3 million of these funds during the year ended December 31, 2021, for healthcare related 
expenses, including retention payments attributable to COVID-19 that were unreimbursed by other sources. We were required to properly and fully 
document the use of such funds in reports to HHS. The Company documented the use of such funds in reports to HHS, as required, and submitted the 
reports to HHS prior to the deadline of March 31, 2022. During the year ended December 31, 2022, we submitted an unmodified audit report to HHS in 
accordance with Generally Accepted Government Auditing Standards, as required for commercial organizations that received and expended total awards of 
$750,000 or more.

Payroll tax deferral

The Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) also provides for certain federal income and other tax changes, including 

allowing for the deferral of the employer portion of Social Security payroll taxes through December 31, 2020. The payroll tax deferral requires that the 
deferred payroll taxes be paid over two years, with half of the eligible deferred amount required to be paid by December 31, 2021 and the other half by 
December 31, 2022. The Company received a cash benefit of approximately $7.1 million related to the deferral of employer payroll taxes for 2020 under 
the CARES Act, for the period April 2, 2020 through June 30, 2020. Effective July 1, 2020, the Company began paying its deferred portion of employer 
Social Security payroll taxes and repaid $4.1 million and $3.0 million as of December 31, 2022 and 2021, respectively. 

50

 
 
 
Table of Contents

ARPA Spending Plans

The ARPA became law on March 11, 2021 and provides for $350 billion in relief funding for eligible state, local, territorial, and Tribal governments 

to mitigate the fiscal effects of the COVID-19 public health emergency. Additionally, the law provided for a 10 percentage point increase in federal 
matching funds for Medicaid HCBS from April 1, 2021, through March 31, 2022, provided the state satisfied certain conditions. States are permitted to use 
the state funds equivalent to the additional federal funds through March 31, 2025. States must use the monies attributable to this matching fund increase to 
supplement, not supplant, their level of state spending for the implementation of activities enhanced under the Medicaid HCBS in effect as of April 1, 2021.

HCBS spending plans for the additional matching funds vary by state, but common initiatives in which the Company is participating include those 
aimed at strengthening the provider workforce (e.g., efforts to recruit, retain, and train direct service providers). The Company is required to properly and 
fully document the use of such funds in reports to the state in which the funds originated. Funds may be subject to recoupment if not expended or if they 
are expended on non-approved uses. 

The Company received state funding provided by the ARPA in an aggregate amount of $3.7 million and  $23.4 million for the years ended 
December 31, 2023 and 2022, respectively.   The Company recorded revenue of $0.3 million and $1.9 million and related cost of service revenues of $0.1 
million and $1.5 million for certain states that met the revenue recognition criteria for the years ended December 31, 2023 and 2022, respectively. The 
Company deferred the remaining $3.4 million and $21.5 million, which was received from states with specific spending plans and reporting requirements, 
for the years ended December 31, 2023 and 2022, respectively. The Company utilized $10.5 million and $8.6 million of these funds during the years ended 
December 31, 2023 and 2022, respectively, primarily for caregivers and adding support to recruiting and retention efforts. The deferred portion of ARPA 
funding was $5.8 million and $12.9 million for the years ended December 31, 2023 and 2022, respectively, which is included within Government stimulus 
advances on the Company’s Consolidated Balance Sheets.

Medicare sequester

The CARES Act and related legislation also include other provisions offering financial relief, including, for example, temporarily suspending the 

Medicare sequester, which would have otherwise reduced payments to Medicare providers by 2% as required by the Budget Control Act of 2011. The 
sequestration adjustment resumed with a 1% reduction beginning April 1, 2022, and a 2% reduction beginning July 1, 2022. These sequestration cuts have 
been extended through April 2032. 

In our hospice segment, Medicare sequester relief resulted in an increase in net service revenues of $0.0 million and $1.4 million for the years ended 

December 31, 2023 and 2022, respectively. In our home health segment, Medicare sequester relief resulted in an increase in net service revenues of $0.0 
million and $0.3 million, for the years ended December 31, 2023 and 2022, respectively.

However, the ARPA increased the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the PAYGO 

Act. As a result, an additional Medicare payment reduction of up to 4% was required to take effect in January 2022. However, Congress has delayed 
implementation of this payment reduction until 2025. We cannot currently determine if, or to what extent, our business, results of operations, financial 
condition or liquidity will ultimately be impacted by mandated sequestration triggers under the PAYGO Act, or if or when the mandated sequestration will 
occur. Further, we anticipate that the federal deficit will continue to place pressure on government healthcare programs, and it is possible that future deficit 
reduction legislation will impose additional Medicare spending reductions.

Cash Flows

The following table summarizes historical changes in our cash flows for the years ended December 31, 2023, 2022 and 2021:

Net cash provided by operating activities
Net cash used in investing activities
Net cash (used in) provided by financing activities

  $

2023

112,247  
(119,236 )
(8,181 )

2022
(Amounts in Thousands)
105,110  
  $
(106,590 )
(87,454 )

  $

2021

39,488  
(42,015 )
26,344  

Net cash provided by operating activities was $112.2 million for the year ended December 31, 2023, compared to $105.1 million in 2022 primarily 

due to the timing of receipts on accounts receivable and the timing of government stimulus funds. The changes in accounts receivable were primarily 
related to the growth in revenue and a decrease in days sales outstanding (“DSO”) during the year ended December 31, 2023 compared to 2022, as 
described below. The related receivables due from the Illinois Department on Aging represented 25.8% and 18.0% of net accounts receivable at December 
31, 2023 and 2022, respectively.

51

 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
Table of Contents

Net cash used in investing activities was $119.2 million for the year ended December 31, 2023, compared to $106.6 million for the year ended 

December 31, 2022. Our investing activities for the year ended December 31, 2023 consisted of $1.0 million primarily for the acquisition of CareStaff, 
$111.2 million for the acquisition of Tennessee Quality Care and $9.4 million in purchases of property and equipment primarily related to technology 
infrastructure. Our investing activities for the year ended December 31, 2022 primarily consisted of $86.6 million primarily for the acquisition of 
JourneyCare, $12.7 million for the acquisition of Apple Home and $8.3 million in purchases of property and equipment primarily related to technology 
infrastructure. 

Net cash used in financing activities was $8.2 million for the year ended December 31, 2023 compared to $87.4 million for the year ended 
December 31, 2022. Our financing activities for the year ended December 31, 2023 included borrowings of $110.0 million on the revolver portion of our 
credit facility to fund two acquisitions and the payment of $118.5 million of our revolving loans. Our financing activities for the year ended December 31, 
2022 included borrowings of $47.0 million on the revolver portion of our credit facility to fund two acquisitions and the payment of $137.0 million of our 
revolving loans.

Outstanding Accounts Receivable

Gross accounts receivable as of December 31, 2023 and 2022 were $117.8 million and $127.1 million, respectively. Outstanding accounts 
receivable, net of the allowance for credit losses, decreased by $10.0 million as of December 31, 2023 compared to December 31, 2022. The open 
receivable balance from the Illinois Department on Aging, the largest payor program for the Company’s Illinois personal care operation, increased by $7.3 
million from $22.5 million as of December 31, 2022 to $29.8 million as of December 31, 2023. Our collection procedures include review of account aging 
and direct contact with our payors. We have historically not used collection agencies. An uncollectible amount is written off to the allowance account after 
reasonable collection efforts have been exhausted.

We calculate our DSO by taking the accounts receivable outstanding, net of the allowance for credit losses, divided by the net service revenues for 
the last quarter, multiplied by the number of days in that quarter. Our DSOs were 39 days and 45 days at December 31, 2023 and 2022, respectively. The 
DSOs for our largest payor, the Illinois Department on Aging, at December 31, 2023 and 2022 were 50 days and 42 days, respectively. 

Off-Balance Sheet Arrangements

As of December 31, 2023, we did not have any off-balance sheet guarantees or arrangements with unconsolidated entities.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our Consolidated Financial Statements prepared in 
accordance with GAAP. The preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts of 
assets and liabilities, revenues and expense and related disclosures.

Our significant accounting policies are described in Note 1 to the Notes to Consolidated Financial Statements. An accounting policy is deemed to be 
critical if it involves a significant level of estimation uncertainty and has had or is reasonably likely to have a material impact on our financial condition or 
results of operations. We base our estimates and judgments on historical experience and other sources and factors that we believe to be reasonable under the 
circumstances, however, actual results may differ from these estimates. Our critical accounting policies requiring estimates, assumptions and judgments 
that we believe have the most significant impact on our consolidated financial statements are described below.

52

 
 
Table of Contents

Revenue Recognition, Accounts Receivable and Allowances

Net service revenue is recognized at the amount that reflects the consideration the Company expects to receive in exchange for providing services 

directly to consumers. Receipts are from federal, state and local governmental agencies, managed care organizations, commercial insurers and private 
consumers for services rendered. The Company assesses the consumers’ ability to pay at the time of their admission based on the Company’s verification 
of the customer’s insurance coverage under the Medicare, Medicaid, and other commercial or managed care insurance programs. Laws and regulations 
governing the governmental programs in which we participate are complex and subject to interpretation. Net service revenues related to uninsured 
accounts, or self-pay, is recorded net of implicit price concessions estimated based on historical collection experience to reduce revenue to the estimated 
amount we expect to collect. Amounts collected from all sources may be less than amounts billed due to implicit price concessions resulting from client 
eligibility issues, insufficient or incomplete documentation, services at levels other than authorized, pricing differences and other reasons unrelated to credit 
risk. We monitor our net service revenues and collections from these sources and record any necessary adjustment to net service revenues based upon 
management’s assessment of historical write offs and expected net collections, business and economic conditions, trends in federal, state and private 
employer healthcare coverage and other collection indicators. 

Accounts receivable is reduced to the amount expected to be collected in future periods for services rendered to customers prior to the balance sheet 

date. Management estimates the value of accounts receivable, net of allowances for implicit price concessions based upon historical experience and other 
factors, including an aging of accounts receivable, evaluation of expected adjustments, past adjustments and collection experience in relation to amounts 
billed, current contract and reimbursement terms, shifts in payors and other relevant information. Collection of net service revenues we expect to receive is 
normally a function of providing complete and correct billing information to the payors within the various filing deadlines. The evaluation of these 
historical and other factors involves complex, subjective judgments impacting the determination of the implicit price concession assumption. In addition, 
we compare our cash collections to recorded net service revenues and evaluate our historical allowances, including implicit price concessions, based upon 
the ultimate resolution of the accounts receivable balance.

Goodwill and Intangible Assets

Under business combination accounting, assets and liabilities are generally recognized at their fair values and the difference between the 

consideration transferred, excluding transaction costs, and the fair values of the assets and liabilities is recognized as goodwill. The Company’s significant 
identifiable intangible assets consist of customer and referral relationships, trade names and trademarks and state licenses. The Company uses various 
valuation techniques to determine initial fair value of its intangible assets, including relief-from-royalty, income approach, discounted cash flow analysis, 
and multi-period excess earnings, which use significant unobservable inputs, or Level 3 inputs, as defined by the fair value hierarchy. Under these valuation 
approaches, we are required to make estimates and assumptions about future market growth and trends, forecasted revenue and costs, expected periods over 
which the assets will be utilized, appropriate discount rates and other variables. The Company estimates the fair values of the trade names using the relief-
from-royalty method, which requires assumptions such as the long-term growth rates of future revenues, the relief from royalty rate for such revenue, the 
tax rate and the discount rate. The Company estimates the fair value of existing indefinite-lived state licenses based on a blended approach of the 
replacement cost method and cost savings method, which involves estimating the total process costs and opportunity costs to obtain a license, by estimating 
future earnings before interest and taxes and applying an estimated discount rate, tax rate and time to obtain the license. The Company estimates the fair 
value of existing finite-lived state licenses based on a method of analyzing the definite revenue streams with the license and without the license, which 
involves estimating revenues and expenses, estimated time to build up to a current revenue base, which is market specific, and the non-licensed revenue 
allocation, revenue growth rates, discount rate and tax amortization benefits. The Company estimates the fair value of customer and referral relationships 
based on a multi-period excess earnings method, which involves identifying revenue streams associated with the assets, estimating the attrition rates based 
upon historical financial data, expenses and cash flows associated with the assets, contributory asset charges, rates of return for specific assets, growth 
rates, discount rate and tax amortization benefits. The Company estimates the fair value of non-competition agreements based on a method of analyzing the 
factors to compete and factors not to compete, which involves estimating historical financial data, forecasted financial statements, growth rates, tax 
amortization benefit, discount rate, review of factors to compete and factors not to compete as well as an assessment of the probability of successful 
competition for each non-competition agreement.

53

 
 
Table of Contents

As of December 31, 2023 and 2022, goodwill was $663.0 million and $582.8 million, respectively, included in our Consolidated Balance Sheets. 

The carrying value of our goodwill is the excess of the purchase price over the fair value of the net assets acquired from various acquisitions. In accordance 
with ASC Topic 350, Goodwill and Other Intangible Assets, goodwill and intangible assets with indefinite useful lives are not amortized. We test goodwill 
for impairment at the reporting unit level on an annual basis, as of October 1, or whenever potential impairment triggers occur, such as a significant change 
in business climate or regulatory changes that would indicate that an impairment may have occurred. We may elect to use a qualitative test to determine 
whether impairment has occurred, focused on various factors including macroeconomic conditions, market trends, specific reporting unit financial 
performance and other entity specific events, to determine if it is more likely than not that the fair value of a reporting unit exceeds its carrying value, 
including goodwill. We may also bypass the qualitative assessment and perform a quantitative test. Additionally, it is our policy to update the fair value 
calculation of our reporting units and perform the quantitative goodwill impairment test on a periodic basis. The quantitative goodwill impairment test 
involves comparing the fair value of a reporting unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying 
value, then goodwill is not impaired. If the fair value of a reporting unit is less than its carrying value, then goodwill is impaired to the extent of the 
difference. 

For the years ended December 31, 2023, 2022 and 2021, we performed the quantitative analysis to evaluate whether an impairment occurred. Since 

quoted market prices for our reporting units are not available, we rely on widely accepted valuation techniques to determine fair value, including 
discounted cash flow and market multiple approaches, which capture both the future income potential of the reporting unit and the market behaviors and 
actions of market participants in the industry that includes the reporting unit. These types of models require us to make assumptions and estimates 
regarding future cash flows, industry-specific economic factors and the profitability of future business strategies. The discounted cash flow model uses a 
projection of estimated operating results and cash flows that are discounted using a weighted average cost of capital. The market multiple model estimates 
fair value based on market multiples of earnings before interest, taxes and depreciation and amortization. Under the discounted cash flow model, the 
projection uses management’s best estimates of economic and market conditions over the projected period for each reporting unit using significant 
assumptions such as revenue growth rates, operating margins and the weighted-average cost of capital.

Based on the totality of the information available, we concluded that it was more likely than not that the estimated fair values of our reporting units 
were greater than their carrying values. Consequently, we concluded that there were no impairments for the years ended December 31, 2023, 2022 or 2021. 
For the fiscal year 2023 impairment tests, the fair value of the reporting units exceeded their respective carrying values (commonly referred to as 
“headroom”) by at least 100% in the personal care and in the home health reporting unit, and 20% in the hospice reporting unit. The headroom percentage 
for the hospice reporting unit decreased as compared to the prior year primarily due to the result of labor shortages with rising costs adding pressure to 
gross margin and patient volumes have not rebounded as quickly following the acute phase of the COVID-19 pandemic as previously anticipated. We 
performed a sensitivity analysis on this reporting unit and determined that a more than 1.2% increase to the weighted- average cost of capital, the most 
sensitive assumption used in the estimate, would result in the fair value being lower than the carrying value. The Company bases its fair value estimates on 
assumptions management believes to be reasonable but which are unpredictable and inherently uncertain. Actual future results may differ from those 
estimates.

As of December 31, 2023 and 2022, intangibles, net of accumulated amortization, was $92.0 million and $72.2 million, respectively, included in our 

Consolidated Balance Sheets. Our identifiable intangible assets consist of customer and referral relationships, trade names, trademarks, state licenses and 
non-competition agreements. Definite-lived intangible assets are amortized using straight-line and accelerated methods based upon the estimated useful 
lives of the respective assets, which range from one to twenty-five years, and assessed for impairment whenever events or changes in circumstances 
indicate that the carrying amount may not be recoverable. Customer and referral relationships are amortized systematically over the periods of expected 
economic benefit, which range from five to ten years. We would recognize an impairment loss when the estimated future non-discounted cash flows 
associated with the intangible asset are less than the carrying value. An impairment charge would then be recorded for the excess of the carrying value over 
the fair value. We estimate the fair value of these intangible assets using the income approach. In accordance with ASC Topic 350, Goodwill and Other 
Intangible Assets, intangible assets with indefinite useful lives are not amortized. We test intangible assets with indefinite useful lives for impairment at the 
reporting unit level on an annual basis, as of October 1, or whenever potential impairment triggers occur, such as a significant change in business climate or 
regulatory changes that would indicate that an impairment may have occurred. No impairment charge was recorded for the years ended December 31, 
2023, 2022 or 2021. Amortization of intangible assets is reported in the statement of income caption, “Depreciation and amortization” and not included in 
the income statement caption cost of service revenues.

Recent Accounting Pronouncements

Refer to Note 1 to the Notes to Consolidated Financial Statements for further discussion.

54

 
Table of Contents

Standby Letters of Credit

We had outstanding letters of credit of $8.0 million at December 31, 2023. These standby letters of credit benefit our third-party insurer for our high 
deductible workers’ compensation insurance program. The amount of the letters of credit is negotiated annually in conjunction with the insurance renewals.

Material Cash Requirements

We believe that our existing cash on hand, our anticipated cash flows from operations and amounts available under our Credit Agreement will be 

sufficient to fund our anticipated operating and investing needs for the next 12 months and for the foreseeable future thereafter. Cash from operations could 
also be affected by various risks and uncertainties, including, but not limited to the effects of risks detailed in Part I, Item 1A—”Risk Factors”

Debt

As of December 31, 2023, the Company had outstanding debt on our revolving loan under our credit facility of $126.4 million, payable on July 30, 

2026. Interest payments associated with the debt aggregate to $27.1 million, with $10.8 million payable within 12 months. As described in Note 7 to the 
Notes to Consolidated Financial Statements, interest on borrowings under the revolving loan are variable. The calculated interest payable amounts use 
actual rates available through January 2024 and assumes the January rates of 7.21%, respectively, for all future interest payable on the revolving loans. See 
Note 7, Long-Term Debt, to the Notes to Consolidated Financial Statements for additional details of our long-term debt.

Leases

The Company has lease arrangements for local branches, our corporate headquarters and certain equipment. As of December 31, 2023, the Company 

had fixed lease payment obligations aggregating to $61.2 million, with $13.8 million payable within 12 months. See Note 2, Leases, to the Notes to 
Consolidated Financial Statements for additional details of our leases.

Impact of Inflation

The United States has recently experienced high rates of inflation. These inflationary conditions have resulted in, and may continue to result in, 

increased operating costs, particularly as the result of increased wages we have paid and may continue to pay our caregivers and other personnel and our 
ability to attract and retain personnel. Increased price levels might allow us to increase our fees to private pay clients, but our ability to realize rate increases 
from government programs might be limited despite inflation. Inflation may also raise our financing costs. For additional information regarding the risks to 
us from the current competitive labor market and increasing labor costs, see Item 1A—Risk Factors — “We may not be able to attract and retain qualified 
personnel or we may incur increased costs in doing so.”

55

 
Table of Contents

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk associated with changes in interest rates on our variable rate long-term debt. As of December 31, 2023, we had 
outstanding borrowings of approximately $126.4 million on our credit facility, all of which was subject to variable interest rates. As of December 31, 2022, 
we had outstanding borrowings of approximately $134.9 million on our credit facility, all of which was subject to variable interest rates. If the variable 
rates on this debt were 100 basis points higher than the rate applicable to the borrowing during the year ended December 31, 2023, our net income would 
have decreased by $1.0 million, or $0.06 per diluted share. We do not currently have any derivative or hedging arrangements, or other known exposures, to 
changes in interest rates.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Our Consolidated Financial Statements together with the related Notes to Consolidated Financial Statements and the report of our independent 

registered public accounting firm, are set forth on the pages indicated in Part IV, Item 15—”Exhibits  and Financial Statement Schedules.”

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.  CONTROLS AND PROCEDURES 

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of our disclosure 

controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange 
Act”). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed 
by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods 
specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the issuer’s management, including its principal 
executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. 
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving 
their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. 

Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our 

disclosure controls and procedures were effective as of December 31, 2023.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in 
Exchange Act Rule 13a-15(f). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Under 
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an 
assessment of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued 
by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on our assessment under the framework in Internal 
Control — Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2023. 

56

 
 
Table of Contents

Under SEC Staff guidance, companies are permitted to exclude acquisitions from their first assessment of internal control over financial reporting 

which covers the period in which such acquisition was completed. We excluded Coastal Nursecare of Florida, Inc. (“CareStaff”) and American Home Care, 
LLC, a Tennessee limited liability company (“AHC”), and its subsidiaries, Homecare, LLC, a Tennessee limited liability company (“Homecare”), 
Tennessee Valley Home Care, LLC (d/b/a Tennessee Quality Care – Home Health), a Tennessee limited liability company (“TQC – Home Health”), and 
Tri-County Home Health and Hospice, LLC (d/b/a Tennessee Quality Care - Hospice), a Tennessee limited liability company (“TQC – Hospice”, and 
collectively with AHC, Homecare, and TQC – Home Health “Tennessee Quality Care”) each of which are wholly-owned subsidiaries, from our assessment 
of internal control over financial reporting as of December 31, 2023 because they were acquired in purchase business combinations on January 1, 2023 and 
August 1, 2023, respectively.

•

•

CareStaff represented 0.2% of our revenues and 0.4% of our operating income, respectively, for the year ended December 31, 2023.

Tennessee Quality Care represented 1.5% of our revenues and 3.3% of our operating income, respectively, for the year ended December 31, 
2023.

The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by PricewaterhouseCoopers LLP, an 

independent registered public accounting firm, as stated in its report which appears within Part IV, Item 15—“Exhibits and Financial Statement 
Schedules.”.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 
15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended December 31, 2023 that have materially affected, or are reasonably likely to 
materially affect, our internal control over financial reporting.

ITEM 9B.  OTHER INFORMATION

Not applicable. Without limiting the generality of the foregoing, during the quarter ended December 31, 2023, no director or Section 16 officer 

adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements, as such terms are defined in Item 408 of 
Regulation S-K.

ITEM 9C.  DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 

Not applicable.

57

 
 
 
 
 
Table of Contents

PART III

Certain information required by Part III is omitted from this Annual Report on Form 10-K as we intend to file our definitive Proxy Statement for the 

2023 Annual Meeting of Stockholders pursuant to Regulation 14A of the Exchange Act not later than 120 days after the end of the fiscal year covered by 
this Annual Report, and certain information included in the Proxy Statement is incorporated herein by reference.

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item is incorporated by reference to the 2024 Proxy Statement to be filed with the SEC not later than 120 days after 

the end of the fiscal year ended December 31, 2023.

We have adopted a Code of Business Conduct and Ethics (“Code of Conduct”) that is applicable to all of our employees, officers and members of 

our Board of Directors, and our subsidiaries. The Code of Conduct addresses, among other things, legal compliance, conflicts of interest, corporate 
opportunities, protection and proper use of Company assets, confidential and proprietary information, integrity of records, compliance with accounting 
principles and relations with government agencies. A copy of the current version of our Code of Conduct is available in the Investors—Corporate 
Governance section of our internet website located at www.addus.com. A copy of the Code of Conduct is also available in print, free of charge, to any 
stockholder who requests it by writing to Addus HomeCare Corporation, 6303 Cowboys Way, Suite 600, Frisco, TX 75034. We intend to post amendments 
to or waivers from, if any, our Code of Conduct at this location on our website, in each case to the extent such amendment or waiver would otherwise 
require the filing of a Current Report on Form 8-K pursuant to Item 5.05 thereof.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this item is incorporated by reference to the 2024 Proxy Statement to be filed with the SEC not later than 120 days after 

the end of the fiscal year ended December 31, 2023.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER 

MATTERS

The information required by this item is incorporated by reference to the 2024 Proxy Statement to be filed with the SEC not later than 120 days after 

the end of the fiscal year ended December 31, 2023.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this item is incorporated by reference to the 2024 Proxy Statement to be filed with the SEC not later than 120 days after 

the end of the fiscal year ended December 31, 2023.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item is incorporated by reference to the 2024 Proxy Statement to be filed with the SEC not later than 120 days after 

the end of the fiscal year ended December 31, 2023.

58

 
Table of Contents

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

PART IV

(a)

(1), (2) The Financial Statements listed on the index on page F-1 following are included herein. All schedules are omitted, either because they 
are not applicable or because the required information is shown in the financial statements or the notes thereto.

(b) Exhibits

Exhibit
Number   

EXHIBIT INDEX

Incorporated by Reference

Description of Document

Form

File No.

Date Filing  

    3.1

    3.2

    4.1

    4.2

Amended and Restated Certificate of Incorporation of Addus HomeCare 
Corporation dated as of October 27, 2009.

10-Q

001-34504

11/20/2009

Amended and Restated Bylaws of Addus HomeCare Corporation, as amended 
by the First Amendment to Amended and Restated Bylaws.

10-Q

  001-34504  

05/9/2013

   Form of Common Stock Certificate.

S-1

  333-160634  

10/2/2009

Description of Securities of Addus HomeCare Corporation Registered under 
Section 12 of the Exchange Act.

10-K   001-34504  

8/10/2020

Exhibit
Number

3.1

3.2

4.1

4.2

  10.1*

   Addus Holding Corporation 2006 Stock Incentive Plan.

S-1

  333-160634  

7/17/2009

10.12

  10.2*

  10.3*

Director Form of Non-Qualified Stock Option Certificate under the 2006 Stock 
Incentive Plan.

S-1

  333-160634  

7/17/2009

10.13

Executive Form of Non-Qualified Stock Option Certificate under the 2006 
Stock Incentive Plan.

S-1

  333-160634  

7/17/2009

10.14

   10.4

   2009 Form of Indemnification Agreement.

 10.5*

   Form of Addus HomeCare Corporation 2009 Stock Incentive Plan.

S-1

S-1

  333-160634  

7/17/2009

  333-160634  

9/21/2009

10.16

10.20

 10.6*

 10.7*

  10.8

  10.9

Form of Nonqualified Stock Option Award Agreement pursuant to the 2009 
Stock Incentive Plan.

S-1

  333-160634  

9/21/2009

  10.20(a)

Form of Restricted Stock Award Agreement pursuant to the 2009 Stock 
Incentive Plan.

S-1

  333-160634  

9/21/2009

  10.20(b)

Securities Purchase Agreement, dated as of April 24, 2015, by and among 
Addus HealthCare, Inc., Margaret Coffey, Carol Kolar, South Shore Home 
Health Service, Inc. and Acaring Home Care, LLC.

Credit Agreement, dated as of May 8, 2017, by and among Addus Healthcare, 
Inc., as the Borrower, the other parties from time to time a party thereto, and 
Capital One, National Association, as a Lender and Swing Lender and as Agent 
for all Lenders, Suntrust Bank, as Documentation Agent, Bank of the West, 
Compass Bank, Fifth Third Bank and JPMorgan Chase Bank, N.A., as Co-
Syndication Agents, the other financial institutions party thereto, as Lenders, 
Capital One, National Association, Bank of the West, Compass Bank, Fifth 
Third Bank and JPMorgan Chase Bank, N.A. and Suntrust Robinson Humphrey 
as Joint Lead Arrangers and Capital One, National Association, as Sole 
Bookrunner.

10-Q

  001-34504  

5/8/2015

10.1

10-Q

  001-34504  

5/9/2017

10.3

 10.10*

Addus HomeCare Corporation’s 2017 Omnibus Incentive Plan, effective as of 
April 27, 2017.

8-K

  001-34504  

6/16/2017

10.1

59

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

 10.11*

 10.12*

  10.13

  10.14

 10.15*

 10.16*

 10.17*

 10.18*

  10.19

 10.20*

 10.21*

 10.22*

  10.23

  10.24

Form of Nonqualified Stock Option Award Agreement pursuant to the 2017 
Omnibus Incentive Plan.

10-K

  001-34504  

3/14/2018

10.28

Form of Restricted Stock Award Agreement pursuant to the 2017 Omnibus 
Incentive Plan.

10-K

  001-34504  

3/14/2018

10.29

Stock Purchase Agreement, dated February 27, 2018, by and among Addus 
Healthcare, Inc., Michael J. Merrell and Mary E. Merrell, individually, Michael 
J. Merrell and Mary E. Merrell, as Trustees of the Merrell Revocable Trust UTA 
dated June 3, 2012, and Michael J. Merrell and Mary E. Merrell, as Trustees of 
the Ambercare Corporation Employee Stock Ownership Plan Trust.

Amended and Restated Credit Agreement by and among Addus HealthCare, 
Inc., as borrower, the Company, the other Credit Parties party thereto, the 
Lenders and L/C Issuers party thereto, and Capital One, National Association, 
as administrative agent.

Second Amended and Restated Employment and Non-Competition Agreement, 
dated November 5, 2018, by and between Addus HealthCare, Inc. and R. Dirk 
Allison.

Second Amended and Restated Employment and Non-Competition Agreement, 
dated November 5, 2018, by and between Addus HealthCare, Inc. and Brian 
Poff.

Second Amended and Restated Employment and Non-Competition Agreement, 
dated November 5, 2018, by and between Addus HealthCare, Inc. and Darby 
Anderson.

Second Amended and Restated Employment and Non-Competition Agreement, 
dated November 5, 2018, by and between Addus HealthCare, Inc. and W. 
Bradley Bickham.

Amended and Restated Credit Agreement, dated as of October 31, 2018, by and 
among Addus HealthCare, Inc., as borrower, the Company, the other Credit 
Parties party thereto, the Lenders and L/C Issuers party thereto, and Capital 
One, National Association, as administrative agent.

8-K

  001-34504  

3/5/2018

10.1

10-Q

  001-34504  

8/11/2018

10.2

10-Q

  001-34504  

8/11/2018

10.3

10-Q

  001-34504  

8/11/2018

10.4

10-Q

  001-34504  

8/11/2018

10.6

10-Q

  001-34504  

8/11/2018

10.7

10-Q

  001-34504  

11/8/2018

10.2

Employment and Non-Competition Agreement, effective April 29, 2019, by and 
between Addus HealthCare, Inc. and Sean Gaffney.

8-K

  001-34504  

4/8/2019

99.2

Employment and Non-Competition Agreement, effective November 7, 2019, by 
and between Addus HealthCare, Inc. and David Tucker.

10-K

  001-34504  

8/10/2020

10.40

Employment and Non-Competition Agreement, effective November 7, 2019, by 
and between Addus HealthCare, Inc. and Mike Wattenbarger.

10-K

  001-34504  

8/10/2020

10.41

Equity Purchase Agreement, dated August 25, 2019, by and among Addus 
Healthcare, Inc., Hospice Partners of America, LLC, New Capital Partners II – 
HS, Inc., Senior Care Services, LLC, Eastside Partners II, L.P., and New Capital 
Partners II, LLC.

First Amendment to Amended and Restated Credit Agreement, dated as of 
September 12, 2019, by and among Addus HealthCare, Inc., as the Borrower, 
Addus HomeCare Corporation, other Credit Parties party thereto, Capital One, 
National Association, as administrative agent and as a Lender, and the other 
Lenders party thereto.

60

S-3ASR   333-233600  

9/3/2019

2.1

10-Q

  001-34504  

9/13/2019

10.1

 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  10.25

  10.26

 10.27*

10.28**

 10.30*

 10.31*

 10.32

 10.33*

 10.34**

Table of Contents

Unit Purchase Agreement, dated November 10, 2020, by and among Addus 
Healthcare, Inc., Queen City Hospice, LLC, Miracle City Hospice, LLC, and 
QCH Holdings LLC.

Amendment to Unit Purchase Agreement, dated December 3, 2020, by and 
among Addus Healthcare, Inc., Queen City Hospice, LLC, Miracle City 
Hospice, LLC, and QCH Holdings LLC.

10-K

  001-34504  

3/1/2021

10.45

10-K

  001-34504  

3/1/2021

10.46

Employment and Non-Competition Agreement, effective June 14, 2021, by and 
between Addus HealthCare, Inc. and Roberton James Stevenson.

10-Q

  001-34504  

8/4/2021

10.2

Second Amendment to Amended and Restated Credit Agreement, dated as of 
July 30, 2021, by and among Addus HealthCare, Inc., as the Borrower, Addus 
HomeCare Corporation, the other Credit Parties party thereto, Capital One, 
National Association, as administrative agent and as a Lender, and the other 
Lenders party thereto.

 10.29*

   2022 Form of Indemnification Agreement.

Amended and Restated Employment and Non-Competition Agreement, 
effective March 1, 2022, by and between Addus HealthCare, Inc. and Monica 
Raines.

8-K

  001-34504  

8/4/2021

10.1

10-K

  001-34504  

2/25/2022

10-Q  

001-34504  

5/23/2022

10.50

10.1

Employment and Non-Competition Agreement, effective April 20, 2022, by and 
between Addus HealthCare, Inc. and Cliff Blessing.

10-Q  

001-34504  

8/2/2022

10.1

Third Amendment to Amended and Restated Credit Agreement, dated as of 
April 26, 2023, by and among Addus HealthCare, Inc., as the Borrower, Addus 
HomeCare Corporation, the other Credit Parties party thereto, Capital One, 
National Association, as administrative agent and as a Lender, and the other 
Lenders party thereto.

10-Q  

001-34504  

5/2/2023

10.1

Addus HomeCare Corporation Amended and Restated 2017 Omnibus Incentive 
Plan.

10-Q  

001-34504  

8/1/2023

10.1

Membership Interests Purchase Agreement, dated June 28, 2023, by and among 
Addus HealthCare, Inc., HHH Newco Holdings, LLC, American Health 
Companies, LLC, American Home Care, LLC, Homecare, LLC, Tennessee 
Valley Home Care, LLC, and Tri-County Home Health and Hospice, LLC.

10-Q  

001-34504  

8/1/2023

10.1

   21.1

   Subsidiaries of Addus HomeCare Corporation.

   23.1

   31.1

   31.2

   32.1

   32.2

 97.1***

Consent of PricewaterhouseCoopers LLP, Independent Registered Public 
Accounting Firm.

Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the 
Securities Exchange Act of 1934 as Adopted Pursuant to Section  302 of the 
Sarbanes-Oxley Act of 2002.

Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the 
Securities Exchange Act of 1934 as Adopted Pursuant to Section  302 of the 
Sarbanes-Oxley Act of 2002.

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as 
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as 
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Addus Homecare Corporation Compensation Recoupment Policy

61

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

101.INS

Inline XBRL Instance Document (the instance document does not appear in the 
Interactive Data File because its XBRL tags are embedded within the Inline 
XBRL document).

101.SCH

   Inline XBRL Taxonomy Extension Schema Document.

101.CAL

   Inline XBRL Taxonomy Calculation Linkbase Document.

101.LAB

   Inline XBRL Taxonomy Label Linkbase Document.

101.PRE

   Inline XBRL Presentation Linkbase Document.

101.DEF

   Inline XBRL Taxonomy Extension Definition Linkbase Document.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document 
and contained in Exhibit 101).

* Management compensatory plan or arrangement

** Schedules and exhibits have been omitted pursuant to Item 601 of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of 
any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission.

***Filed herewith

ITEM 16. FORM 10-K SUMMARY

None.

62

 
 
 
 
 
 
 
 
 
 
 
  
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
  
   
   
   
   
 
Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed 

on its behalf by the undersigned, thereunto duly authorized.

Addus HomeCare Corporation

By:

/s/    R. DIRK ALLISON        
R. Dirk Allison,
Chief Executive Officer and 
Chairman of the Board

Date: February 27, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the 

registrant and in the capacities and on the date indicated:

Signature

Title

Date

  Chief Executive Officer and Chairman of the Board 

February 27, 2024

(Principal Executive Officer)

  Chief Financial Officer (Principal Financial and 

February 27, 2024

Accounting Officer)

/s/    R. DIRK ALLISON        
R. Dirk Allison

/s/    BRIAN POFF        
Brian Poff

/s/    HEATHER DIXON        
Heather Dixon

/s/    MICHAEL EARLEY        
Michael Earley

/s/    MARK L. FIRST        
Mark L. First

/s/    DARIN J. GORDON        
Darin J. Gordon

/s/    ESTEBAN LÓPEZ, M.D.         
Esteban López, M.D.

/s/    VERONICA HILL-MILBOURNE        
Veronica Hill-Milbourne

/s/    JEAN RUSH        
Jean Rush

  Director

  Director

  Director

  Director

  Director

  Director

  Director

/s/    SUSAN T. WEAVER, M.D., FACP         
Susan T. Weaver, M.D., FACP

  Director

63

February 27, 2024

February 27, 2024

February 27, 2024

February 27, 2024

February 27, 2024

February 27, 2024

February 27, 2024

February 27, 2024

 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
 
 
 
 
   
 
 
 
 
   
 
 
 
 
   
 
 
 
 
   
 
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
 
Table of Contents

INDEX TO CONSOLIDATED FINANCIAL INFORMATION

Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements

Page

F-2
F-5
F-6
F-7
F-8
F-9

All schedules for which provision is made in the applicable accounting regulation of the Securities and Exchange Commission are not required 

under the related instructions or are inapplicable and therefore have been omitted.

F-1

 
 
 
 
 
 
 
 
 
 
Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Addus HomeCare Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Addus HomeCare Corporation and its subsidiaries (the “Company”) as of December 31, 
2023 and 2022, and the related consolidated statements of income, of stockholders’ equity and of cash flows for each of the three years in the period ended 
December 31, 2023, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's 
internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued 
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of 
December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in 
conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material 
respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated 
Framework (2013) issued by the COSO.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, 
and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control Over 
Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the 
Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting 
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities 
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable 
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective 
internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial 
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, 
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used 
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal 
control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness 
exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing 
such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As described in Management’s Annual Report on Internal Control Over Financial Reporting, management has excluded Coastal Nursecare of Florida, Inc. 
(“CareStaff”) and American Home Care, LLC, a Tennessee limited liability company (“AHC”), and its subsidiaries, Homecare, LLC, a Tennessee limited 
liability company (“Homecare”), Tennessee Valley Home Care, LLC (d/b/a Tennessee Quality Care – Home Health), a Tennessee limited liability company 
(“TQC – Home Health”), and Tri-County Home Health and Hospice, LLC (d/b/a Tennessee Quality Care - Hospice), a Tennessee limited liability company 
(“TQC – Hospice”, and collectively with AHC, Homecare, and TQC – Home Health “Tennessee Quality Care”), from its assessment of internal control 
over financial reporting as of December 31, 2023, because they were acquired by the Company in purchase business combinations during 2023.  We have 
also excluded Carestaff and Tennessee Quality Care from our audit of internal control over financial reporting. Carestaff and Tennessee Quality Care are 
wholly-owned subsidiaries whose total revenues and total operating income excluded from management’s assessment and our audit of internal control over 
financial reporting represent approximately 0.2% and 1.5% of total revenues, respectively, and approximately 0.4% and 3.3% of total operating income, 
respectively, of the related consolidated financial statement amounts for the year ended December 31, 2023.

F-2

 
 
 
 
 
 
 
 
 
Table of Contents

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting 
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control 
over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly 
reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit 
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are 
being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding 
prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial 
statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of 
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of 
compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were 
communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated 
financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not 
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, 
providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Valuation of Accounts Receivable, Net of Allowances for Implicit Price Concessions

As described in Note 1 to the consolidated financial statements, net service revenue is recognized at the amount that reflects the consideration the Company 
expects to receive in exchange for providing services directly to consumers. Amounts collected may be less than amounts billed due to implicit price 
concessions, resulting from client eligibility issues, insufficient or incomplete documentation, services at levels other than authorized, pricing differences 
and other reasons unrelated to credit risk. Management estimates the value of accounts receivable, net of allowances for implicit price concessions, based 
upon historical experience and other factors, including an aging of accounts receivable, evaluation of expected adjustments, past adjustments and collection 
experience in relation to amounts billed, current contract and reimbursement terms, shifts in payors and other relevant information. The evaluation of these 
historical and other factors involves complex, subjective judgments. Accounts receivable, net of allowances for implicit price concessions (before the 
allowance for credit losses) were $117.8 million as of December 31, 2023.  

The principal considerations for our determination that performing procedures relating to the valuation of accounts receivable, net of allowances for 
implicit price concessions is a critical audit matter are (i) the significant judgment by management when developing the estimate of accounts receivable, net 
of allowances for implicit price concessions and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating 
audit evidence related to the estimate.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated 
financial statements. These procedures included testing the effectiveness of controls relating to management’s estimate of accounts receivable, net of 
implicit price concessions, including controls over the allowance for implicit price concessions. These procedures also included, among others (i) testing 
management’s process for developing the estimate of accounts receivable, net of allowances for implicit price concessions; (ii) evaluating the relevance and 
use of historical experience data as an input into management’s estimate; (iii) testing the completeness and accuracy of underlying historical collection data 
used as an input into management’s estimate; (iv) testing, on a sample basis, the accuracy of revenue transactions and cash collections from the billing and 
collection data used as an input into the estimate; (v) evaluating the historical accuracy of management’s estimate of the amount expected to be collected by 
performing a retrospective comparison of actual cash collections to the related accounts receivable; and (vi) performing a comparison of the remaining 
uncollected accounts receivable balance as of a date subsequent to year end, to expected future cash collections based on the Company's historical 
collection patterns.

F-3

 
 
 
 
 
 
 
 
 
 
 
Table of Contents

Goodwill Impairment Assessment – Hospice Reporting Unit

As described in Notes 1 and 5 to the consolidated financial statements, the Company’s goodwill balance was $663.0 million as of December 31, 2023, and 
the goodwill associated with the Hospice reporting unit was $432.8 million. Management tests goodwill for impairment at the reporting unit level on an 
annual basis, as of October 1, or whenever potential impairment triggers occur, such as a significant change in business climate or regulatory changes that 
would indicate that an impairment may have occurred. The goodwill impairment test involves comparing the fair value of a reporting unit with its carrying 
value, including goodwill. Management estimated the fair value of the Hospice reporting unit using the discounted cash flow and market multiple 
approaches. These types of models require management to make assumptions and estimates regarding future cash flows, industry-specific economic factors 
and the profitability of future business strategies. The discounted cash flow model uses a projection of estimated operating results and cash flows that are 
discounted using a weighted-average cost of capital. The market multiple model estimates fair value based on market multiples of earnings before interest, 
taxes and depreciation and amortization (EBITDA). Under the discounted cash flow model, the projection uses management’s best estimates of economic 
and market conditions over the projected period for each reporting unit using significant assumptions such as revenue growth rates, operating margins, and 
the weighted-average cost of capital.

The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of the Hospice reporting unit 
is a critical audit matter are (i) the significant judgment by management  when developing the fair value estimate of the Hospice reporting unit; (ii) a high 
degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to the revenue 
growth rates, operating margins, and the weighted-average cost of capital used in the discounted cash flow model, and the market multiples of EBITDA 
used in the market multiple model; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated 
financial statements. These procedures included testing the effectiveness of controls relating to management’s goodwill impairment assessment, including 
controls over the valuation of the Hospice reporting unit. These procedures also included, among others (i) testing management’s process for developing 
the fair value estimate of the Hospice reporting unit; (ii) evaluating the appropriateness of the discounted cash flow model and market multiple model used 
by management; (iii) testing the completeness and accuracy of underlying data used by management in the discounted cash flow model and market multiple
model; and (iv) evaluating the reasonableness of the significant assumptions used by management related to the revenue growth rates, operating margins, 
and the weighted-average cost of capital used in the discounted cash flow model and the market multiples of EBITDA used in the market multiple model. 
Evaluating management’s assumptions related to the revenue growth rates and operating margins involved evaluating whether the assumptions used by 
management were reasonable considering (i) the current and past performance of the Hospice reporting unit; (ii) the consistency with external market and 
industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill 
and knowledge were used to assist in the evaluation of the appropriateness of the discounted cash flow model and market multiples model, and the 
reasonableness of the weighted-average cost of capital and market multiples of EBITDA significant assumptions.

/s/ PricewaterhouseCoopers LLP

Dallas, Texas
February 27, 2024

We have served as the Company’s auditor since 2019.

F-4

 
 
 
 
 
 
 
 
Table of Contents

ADDUS HOMECARE CORPORATION
AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
As of December 31, 2023 and 2022
(amounts and shares in thousands, except per share data)

2023

2022

Assets
Current assets

Cash
Accounts receivable, net of allowances for credit losses
Prepaid expenses and other current assets

Total current assets
Property and equipment, net of accumulated depreciation and amortization
Other assets
Goodwill
Intangibles, net of accumulated amortization
Operating lease assets, net

Total other assets
Total assets

Liabilities and stockholders’ equity
Current liabilities

Accounts payable
Accrued payroll
Accrued expenses
Operating lease liabilities, current portion
Government stimulus advances
Accrued workers’ compensation insurance

Total current liabilities
Long-term liabilities

Long-term debt, net of debt issuance costs
Long-term operating lease liabilities
Other long-term liabilities

Total long-term liabilities
Total liabilities
Stockholders’ equity

Common stock—$.001 par value; 40,000 authorized and 16,227 and 16,128 shares
   issued and outstanding as of December 31, 2023 and 2022, respectively
Additional paid-in capital
Retained earnings

Total stockholders’ equity
Total liabilities and stockholders’ equity

  $

  $

  $

  $

  $

  $

  $

64,791  
115,499  
19,714  
200,004  
24,011  

662,995  
91,983  
45,433  
800,411  
1,024,426  

26,183  
56,551  
33,236  
11,339  
5,765  
12,043  
145,117  

124,132  
39,711  
8,772  
172,615  
317,732  

16  
403,846  
302,832  
706,694  
1,024,426  

  $

  $

  $

  $

  $

79,961  
125,501  
17,345  
222,807  
21,182  

582,837  
72,188  
38,980  
694,005  
937,994  

22,092  
44,937  
27,507  
10,801  
12,912  
12,897  
131,146  

131,772  
35,479  
6,057  
173,308  
304,454  

16  
393,208  
240,316  
633,540  
937,994  

See accompanying Notes to Consolidated Financial Statements

F-5

 
 
 
 
 
 
 
   
 
   
 
   
 
   
 
   
   
   
   
   
   
   
   
   
 
   
 
   
   
   
   
   
   
   
   
   
 
   
 
   
 
   
 
   
   
   
   
   
   
   
   
   
   
   
   
 
     
   
   
   
   
   
   
   
   
   
   
 
   
 
   
   
   
   
   
   
 
Table of Contents

Net service revenues
Cost of service revenues
Gross profit
General and administrative expenses
Depreciation and amortization
Total operating expenses

Operating income
Interest income
Interest expense
Total interest expense, net
Income before income taxes
Income tax expense
Net income

Net income per common share
Basic net income per share
Diluted net income per share

ADDUS HOMECARE CORPORATION
AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
For the years ended December 31, 2023, 2022 and 2021
(amounts and shares in thousands, except per share data)

For the Years Ended December 31,
2022

  $

  $

  $
  $

  $

2023
1,058,651  
718,775  
339,876  
234,794  
14,126  
248,920  
90,956  
(1,476 )    
11,106  
9,630  
81,326  
18,810  
62,516  

  $

3.91  
3.83  

  $
  $

  $

951,120  
651,381  
299,739  
216,942  
14,060  
231,002  
68,737  

(341 )    
8,907  
8,566  
60,171  
14,146  
46,025  

  $

2.90  
2.84  

  $
  $

Weighted average number of common shares and potential common shares
   outstanding:
Basic
Diluted

15,996  
16,311  

15,861  
16,181  

See accompanying Notes to Consolidated Financial Statements

F-6

2021

864,499  
594,651  
269,848  
189,418  
14,494  
203,912  
65,936  
(268 )
5,806  
5,538  
60,398  
15,272  
45,126  

2.87  
2.81  

15,737  
16,064  

 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
     
     
   
 
     
     
   
   
   
   
   
   
   
 
Table of Contents

ADDUS HOMECARE CORPORATION
AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
For the years ended December 31, 2023, 2022 and 2021
(amounts and shares in thousands)

Balance at January 1, 2021
Issuance of shares of common stock under
   restricted stock award agreements
Forfeiture of shares of common stock under
   restricted stock award agreements
Stock-based compensation
Shares issued for exercise of stock options
Net income
Balance at December 31, 2021
Issuance of shares of common stock under
   restricted stock award agreements
Forfeiture of shares of common stock under
   restricted stock award agreements
Stock-based compensation
Shares issued for exercise of stock options
Net income
Balance at December 31, 2022
Issuance of shares of common stock under
   restricted stock award agreements
Stock-based compensation
Shares issued for exercise of stock options
Net income
Balance at December 31, 2023

Common Stock

Shares

Amount

Additional
Paid in
Capital

Retained
Earnings

Total
Stockholders’
Equity

15,826       

89       

(7 )    
—       
32  
—       
  $

15,940  

129       

(4 )    
—       
63  
—       
  $

16,128  

86  
—  
13  
—  
16,227  

  $

16  

—  

—  
—  
—  
—  
16  

—  

—  
—  
—  
—  
16  

—  
—  
—  
—  
16  

  $

  $

  $

369,495      

149,165      

518,676  

—  

—  

—  

—  
9,434      
1,108      
—      
380,037     $

—  
—      
—      
45,126      
194,291     $

—  
9,434  
1,108  
45,126  
574,344  

—  

—  

—  

—  
10,625      
2,546      
-      
393,208     $

—      
10,319      
319      
—  
403,846     $

—  
—      
—      
46,025      
240,316     $

—      
—      
—      

62,516  
302,832     $

—  
10,625  
2,546  
46,025  
633,540  

—  
10,319  
319  
62,516  
706,694  

See accompanying Notes to Consolidated Financial Statements

F-7

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
Table of Contents

ADDUS HOMECARE CORPORATION
AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
For the years ended December 31, 2023, 2022 and 2021
(amounts in thousands)

Cash flows from operating activities:

Net income
Adjustments to reconcile net income to net cash provided by 
   operating activities, net of acquisitions:

Depreciation and amortization
Deferred income taxes
Stock-based compensation
Amortization of debt issuance costs under the credit facility
Provision for credit losses
Impairment of operating lease assets
Gain on termination of operating leases
Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable
Prepaid expenses and other current assets
Government stimulus advances
Accounts payable
Accrued payroll
Accrued expenses and other liabilities

Net cash provided by operating activities
Cash flows from investing activities:

Business acquisition, net of cash acquired
Purchases of property and equipment
Proceeds on disposal of property and equipment

Net cash used in investing activities
Cash flows from financing activities:

Borrowings on revolver — credit facility
Payments on revolver — credit facility
Payments on term loan — credit facility
Payments for debt issuance costs under the credit facility
Cash received from exercise of stock options
Net cash (used in) provided by financing activities
Net change in cash
Cash, at beginning of period
Cash, at end of period

Supplemental disclosures of cash flow information:

Cash paid for interest
Cash paid for income taxes

Supplemental disclosures of non-cash investing and financing activities

Leasehold improvements acquired through tenant allowances
Licensing fees included in Fixed assets
Tax benefit related to the amortization of tax goodwill in excess of book basis

For the Years
Ended  December 31,
2022

2023

2021

  $

62,516  

  $

46,025  

  $

45,126  

14,126  
2,819  
10,319  
860  
731  
13  
(23 )    

15,666  
(3,113 )    
(7,577 )    
2,025  
9,176  
4,709  
112,247  

(109,797 )    
(9,454 )    
15  
(119,236 )    

110,000  
(118,500 )    
—  
—  
319  
(8,181 )    
(15,170 )    
79,961  
64,791  

  $

14,060  
3,908  
10,625  
860  
678  
1,174  
—  

20,592  
1,471  
8,739  
2,514  
(918 )    
(4,618 )    

105,110  

(98,290 )    
(8,300 )    
—  
(106,590 )    

47,000  
(137,000 )    
—  
—  
2,546  
(87,454 )    
(88,934 )    
168,895  
79,961  

  $

  $

10,254  
14,985  

  $

7,985  
1,483  

—  
4,000  
—  

295  
4,000  
—  

14,494  
7,282  
9,434  
804  
962  
—  
—  

(3,916 )
(8,599 )
(27,914 )
(4,810 )
7,888  
(1,263 )
39,488  

(37,370 )
(4,645 )
—  

(42,015 )

46,395  
—  
(18,130 )
(3,029 )
1,108  
26,344  
23,817  
145,078  
168,895  

5,094  
17,820  

—  
—  
61  

  $

  $

See accompanying Notes to Consolidated Financial Statements

F-8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
 
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
 
   
 
   
   
   
   
   
   
   
 
   
 
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
 
   
 
   
   
   
   
 
   
 
   
 
   
   
   
   
   
   
   
   
   
 
 
ADDUS HOMECARE CORPORATION
AND SUBSIDIARIES

Notes to Consolidated Financial Statements

1. Significant Accounting Policies

Basis of Presentation and Description of Business

The Consolidated Financial Statements include the accounts of Addus HomeCare Corporation (“Holdings”) and its subsidiaries (together with 
Holdings, the “Company,” “we,” “us,” or “our”). The Company operates as a multi-state provider of three distinct but related business segments providing 
in-home services. In its personal care services segment, the Company provides non-medical assistance with activities of daily living, primarily to persons 
who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. In its hospice segment, the Company 
provides physical, emotional and spiritual care for people who are terminally ill as well as related services for their families. In its home health segment, the 
Company provides services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and 
include skilled nursing and physical, occupational and speech therapy. The Company’s payor clients include federal, state and local governmental agencies, 
managed care organizations, commercial insurers and private individuals. 

Principles of Consolidation

All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

Net service revenue is recognized at the amount that reflects the consideration the Company expects to receive in exchange for providing services 

directly to consumers. Receipts are from federal, state and local governmental agencies, managed care organizations, commercial insurers and private 
consumers for services rendered. The Company assesses the consumers’ ability to pay at the time of their admission based on the Company’s verification 
of the customer’s insurance coverage under the Medicare, Medicaid, and other commercial or managed care insurance programs. Laws and regulations 
governing the governmental programs in which the Company participates are complex and subject to interpretation. Net service revenues related to 
uninsured accounts, or self-pay, is recorded net of implicit price concessions estimated based on historical collection experience to reduce revenue to the 
estimated amount the Company expects to collect. Amounts collected from all sources may be less than amounts billed due to implicit price concessions, 
resulting from client eligibility issues, insufficient or incomplete documentation, services at levels other than authorized, pricing differences and other 
reasons unrelated to credit risk. The Company monitors our net service revenues and collections from these sources and records any necessary adjustment 
to net service revenues based upon management’s assessment of historical write offs and expected net collections, business and economic conditions, trends 
in federal, state and private employer healthcare coverage and other collection indicators.

The initial estimate of net service revenues is determined by reducing the standard charge by any contractual adjustments, discounts and implicit 

price concessions. Subsequent changes to the estimate of net service revenues are generally recorded in the period of the change. Subsequent changes that 
are determined to be the result of an adverse change in the patient’s ability to pay are recorded as bad debt expense.

Personal Care

The majority of the Company’s net service revenues are generated from providing personal care services directly to consumers under contracts with 

state, local and other governmental agencies, managed care organizations, commercial insurers and private consumers. Generally, these contracts, which 
are negotiated based on current contracting practices as appropriate for the payor, establish the terms of a customer relationship and set the broad range of 
terms for services to be performed at a stated rate. However, the contracts do not give rise to rights and obligations until an order is placed with the 
Company. When an order is placed, it creates the performance obligation to provide a defined quantity of service hours, or authorized hours, per consumer. 
The Company satisfies its performance obligations over time, given that consumers simultaneously receive and consume the benefits provided by the 
Company as the services are performed. As the Company has a right to consideration from customers commensurate with the value provided to customers 
from the performance completed over a given invoice period, the Company has elected to use the practical expedient for measuring progress toward 
satisfaction of performance obligations and recognizes patient service revenue in the amount to which the Company has a right to invoice.

F-9

 
Table of Contents

Hospice Revenue

The Company generates net service revenues from providing hospice services to consumers who are terminally ill as well as related services for 
their families. Net service revenues are recognized as services are provided and costs for delivery of such services are incurred. The estimated payment 
rates are daily rates for each of the levels of care the Company delivers. Hospice companies are subject to two specific payment limit caps under the 
Medicare program each federal fiscal year, the inpatient cap and the aggregate cap. The inpatient cap limits the number of inpatient care days provided to 
no more than 20% of the total days of hospice care provided to Medicare patients for the year. If a hospice exceeds the number of allowable inpatient care 
days, the hospice must refund any amounts received for inpatient care that exceed the total of: (i) the product of the total reimbursement paid to the hospice 
for inpatient care multiplied by the ratio of the maximum number of allowable inpatient days to the actual number of inpatient care days furnished by the 
hospice to Medicare patients; and (ii) the product of the number of actual inpatient days in excess of the limitation multiplied by the routine home care rate. 
The aggregate cap, which is calculated each federal fiscal year, limits the amount of Medicare reimbursement a hospice may receive, based on the number 
of Medicare patients served. If a hospice’s Medicare payments exceed its aggregate cap, it must repay Medicare for the excess amount. In federal fiscal 
year 2024, the aggregate cap is $33,494.01. For the years ended December 31, 2023 and 2022, the Company recorded a liability of $0.8 million and $0.9 
million, respectively, related to the Medicare aggregate cap limit.

Home Health Revenue

The Company also generates net service revenues from providing home healthcare services directly to consumers mainly under contracts with 

Medicare and managed care organizations. Generally, these contracts, which are negotiated based on current contracting practices as appropriate for the 
payor, establish the terms of a relationship and set the broad range of terms for services to be performed on an episodic basis at a stated rate. Home health 
Medicare services are paid under the Medicare Home Health Prospective Payment System (“HHPPS”), which is based on 30-day periods of care as a unit 
of service. The HHPPS permits multiple, continuous periods per patient. Medicare payment rates for periods under HHPPS are determined through use of a 
case-mix classification system, the Patient-Driven Groupings Model (“PDGM”), which assigns patients to resource groups based on a patient’s clinical 
characteristics.

The Company elects to use the same 30-day periods that Medicare recognizes as standard but accelerates revenue upon discharge to align with a 

patient’s episode length if less than the expected 30 days, which depicts the transfer of services and related benefits received by the patient over the term of 
the contract necessary to satisfy the obligations. The Company recognizes revenue based on the number of days elapsed during a period of care within the 
reporting period. The Company satisfies its performance obligations as consumers receive and consume the benefits provided by the Company as the 
services are performed. As the Company has a right to consideration from Medicare commensurate with the services provided to customers from the 
performance completed over a given episodic period, the Company has elected to use the practical expedient for measuring progress toward satisfaction of 
performance obligations. Under this method recognizing revenue ratably over the episode based on beginning and ending dates is a reasonable proxy for 
the transfer of benefit of the service.

Accounts Receivable and Allowances

Accounts receivable is reduced to the amount expected to be collected in future periods for services rendered to customers prior to the balance sheet 
date. Management estimates the value of accounts receivable, net of allowances for implicit price concessions, based upon historical experience and other 
factors, including an aging of accounts receivable, evaluation of expected adjustments, past adjustments and collection experience in relation to amounts 
billed, current contract and reimbursement terms, shifts in payors and other relevant information. Collection of net service revenues the Company expects 
to receive is normally a function of providing complete and correct billing information to the payors within the various filing deadlines. The evaluation of 
these historical and other factors involves complex, subjective judgments impacting the determination of the implicit price concession assumption. In 
addition, the Company compares its cash collections to recorded net service revenues and evaluates its historical allowance, including implicit price 
concessions, based upon the ultimate resolution of the accounts receivable balance.

Subsequent adjustments to accounts receivable determined to be the result of an adverse change in the payor’s ability to pay are recognized as 

provision for credit losses. The majority of what historically was classified as provision for credit losses under operating expenses is now treated as an 
implicit price concession factored into the determination of net service revenues discussed above. Our collection procedures include review of account 
aging and direct contact with our payors. We have historically not used collection agencies. An uncollectible amount is written off to the allowance account 
after reasonable collection efforts have been exhausted. As of December 31, 2023 and 2022, the allowance for credit losses balance was $2.3 million and 
$1.6 million, respectively, which is included in accounts receivable, net of allowances for credit losses on the Company’s Consolidated Balance Sheets.

F-10

 
Table of Contents

Activity in the allowance for credit losses is as follows (in thousands):

Allowance for credit losses
Year ended December 31, 2023
Allowance for credit losses
Year ended December 31, 2022
Allowance for credit losses
Year ended December 31, 2021
Allowance for credit losses

(1)  Write-offs, net of recoveries

Property and Equipment

Balance at
beginning of
period

Additions/
charges

Deductions 

(1)

Balance at
end of period

  $

  $

  $

1,634      

731      

55     $

2,310  

1,433      

678      

477     $

1,634  

973      

962      

502     $

1,433  

Property and equipment are recorded at cost and depreciated over the estimated useful lives of the related assets by use of the straight-line method. 

Maintenance and repairs are charged to expense as incurred. The estimated useful lives of the property and equipment are as follows:

Computer equipment
Furniture and equipment
Transportation equipment
Computer software
Leasehold improvements

Leases

3-5 years
5-7 years
5 years
3-10 years
Lesser of useful life or lease term

The Company recognizes a lease liability and a right-of-use (“ROU”) asset for all leases, including operating leases, with a term greater than twelve 

months on the balance sheet. We have historically entered into operating leases for local branches, our corporate headquarters and certain equipment. The 
Company’s current leases have expiration dates through 2031. Certain of our arrangements have free rent periods and/or escalating rent payment 
provisions. We recognize rent expense on a straight-line basis over the lease term. Certain of the Company’s leases include termination options and renewal 
options for periods ranging from one to five years. Renewal options generally are not considered in determining the lease term, and payments associated 
with the option years are excluded from lease payments unless we are reasonably certain to exercise the renewal option. 

The operating lease liabilities are calculated using the present value of lease payments. If available, we use the rate implicit in the lease to discount 

lease payments to present value; however, most of our leases do not provide a readily determinable implicit rate. Therefore, we must estimate our 
incremental borrowing rate to discount the lease payments based on information available at lease commencement. 

Operating lease assets are valued based on the initial operating lease liabilities plus any prepaid rent, reduced by tenant improvement allowances. 

Operating lease assets are tested for impairment in the same manner as our long-lived assets. For the years ended December 31, 2023 and 2022, the 
Company recorded $13,000 and $1.2 million, respectively, in impairment charges on operating lease assets, included within general administrative 
expenses. For the year ended December 31, 2021, the Company recorded no material impairment charges.

F-11

 
 
 
 
 
 
 
 
 
 
 
 
     
     
   
 
 
 
 
     
     
   
 
 
 
 
     
     
   
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

Goodwill and Intangible Assets

Under business combination accounting, assets and liabilities are generally recognized at their fair values and the difference between the 

consideration transferred, excluding transaction costs, and the fair values of the assets and liabilities is recognized as goodwill. The Company’s significant 
identifiable intangible assets consist of customer and referral relationships, trade names and trademarks and state licenses. The Company uses various 
valuation techniques to determine initial fair value of its intangible assets, including relief-from-royalty, income approach, discounted cash flow analysis, 
and multi-period excess earnings, which use significant unobservable inputs, or Level 3 inputs, as defined by the fair value hierarchy. Under these valuation 
approaches, we are required to make estimates and assumptions about future market growth and trends, forecasted revenue and costs, expected periods over 
which the assets will be utilized, appropriate discount rates and other variables. The Company estimates the fair values of the trade names using the relief-
from-royalty method, which requires assumptions such as the long-term growth rates of future revenues, the relief from royalty rate for such revenue, the 
tax rate and the discount rate. The Company estimates the fair value of existing indefinite-lived state licenses based on a blended approach of the 
replacement cost method and cost savings method, which involves estimating the total process costs and opportunity costs to obtain a license, by estimating 
future earnings before interest and taxes and applying an estimated discount rate, tax rate and time to obtain the license. The Company estimates the fair 
value of existing finite-lived state licenses based on a method of analyzing the definite revenue streams with the license and without the license, which 
involves estimating revenues and expenses, estimated time to build up to a current revenue base, which is market specific, and the non-licensed revenue 
allocation, revenue growth rates, discount rate and tax amortization benefits. The Company estimates the fair value of customer and referral relationships 
based on a multi-period excess earnings method, which involves identifying revenue streams associated with the assets, estimating the attrition rates based 
upon historical financial data, expenses and cash flows associated with the assets, contributory asset charges, rates of return for specific assets, growth 
rates, discount rate and tax amortization benefits. The Company estimates the fair value of non-competition agreements based on a method of analyzing the 
factors to compete and factors not to compete, which involves estimating historical financial data, forecasted financial statements, growth rates, tax 
amortization benefit, discount rate, review of factors to compete and factors not to compete as well as an assessment of the probability of successful 
competition for each non-competition agreement.

As of December 31, 2023 and 2022, goodwill was $663.0 million and $582.8 million, respectively, included on the Company’s Consolidated 

Balance Sheets. The Company’s carrying value of goodwill is the excess of the purchase price over the fair value of the net assets acquired from various 
acquisitions. In accordance with Accounting Standards Codification (“ASC”) Topic 350, Goodwill and Other Intangible Assets, goodwill and intangible 
assets with indefinite useful lives are not amortized. The Company tests goodwill for impairment at the reporting unit level on an annual basis, as of 
October 1, or whenever potential impairment triggers occur, such as a significant change in business climate or regulatory changes that would indicate that 
an impairment may have occurred. The Company may elect to use a qualitative test to determine whether impairment has occurred, focused on various 
factors including macroeconomic conditions, market trends, specific reporting unit financial performance and other entity specific events, to determine if it 
is more likely than not that the fair value of a reporting unit exceeds its carrying value, including goodwill. The Company may also bypass the qualitative 
assessment and perform a quantitative test. Additionally, it is the Company’s policy to update the fair value calculation of our reporting units and perform 
the quantitative goodwill impairment test on a periodic basis. The quantitative goodwill impairment test involves comparing the fair value of a reporting 
unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, then goodwill is not impaired. If the fair 
value of a reporting unit is less than its carrying value, then goodwill is impaired to the extent of the difference. 

For the years ended December 31, 2023, 2022 and 2021, the Company performed the quantitative analysis to evaluate whether an impairment 

occurred. Since quoted market prices for our reporting units are not available, the Company relies on widely accepted valuation techniques to determine 
fair value, including discounted cash flow and market multiple approaches, which capture both the future income potential of the reporting unit and the 
market behaviors and actions of market participants in the industry that includes the reporting unit. These types of models require us to make assumptions 
and estimates regarding future cash flows, industry-specific economic factors and the profitability of future business strategies. The discounted cash flow 
model uses a projection of estimated operating results and cash flows that are discounted using a weighted average cost of capital. The market multiple 
model estimates fair value based on market multiples of earnings before interest, taxes and depreciation and amortization. Under the discounted cash flow 
model, the projection uses management’s best estimates of economic and market conditions over the projected period for each reporting unit using 
significant assumptions such as revenue growth rates, operating margins and the weighted-average cost of capital. 

Based on the totality of the information available, the Company concluded that it was more likely than not that the estimated fair values of our 

reporting units were greater than their carrying values. Consequently, the Company concluded that there were no impairments for the years ended 
December 31, 2023, 2022 or 2021. The Company bases its fair value estimates on assumptions management believes to be reasonable but which are 
unpredictable and inherently uncertain. Actual future results may differ from those estimates.

F-12

 
Table of Contents

As of December 31, 2023 and 2022, intangibles, net of accumulated amortization, was $92.0 million and $72.2 million, respectively, included on the 

Company’s Consolidated Balance Sheets. The Company’s identifiable intangible assets consist of customer and referral relationships, trade names, 
trademarks, state licenses and non-competition agreements. Definite-lived intangible assets are amortized using straight-line and accelerated methods based 
upon the estimated useful lives of the respective assets, which range from one to twenty-five years, and assessed for impairment whenever events or 
changes in circumstances indicate that the carrying amount may not be recoverable. Customer and referral relationships are amortized systematically over 
the periods of expected economic benefit, which range from five to ten years. The Company would recognize an impairment loss when the estimated future 
non-discounted cash flows associated with the intangible asset are less than the carrying value. An impairment charge would then be recorded for the 
excess of the carrying value over the fair value. The Company estimates the fair value of these intangible assets using the income approach. In accordance 
with ASC Topic 350, Goodwill and Other Intangible Assets, intangible assets with indefinite useful lives are not amortized. We test intangible assets with 
indefinite useful lives for impairment at the reporting unit level on an annual basis, as of October 1, or whenever potential impairment triggers occur, such 
as a significant change in business climate or regulatory changes that would indicate that an impairment may have occurred. No impairment charge was 
recorded for the years ended December 31, 2023, 2022 or 2021. Amortization of intangible assets is reported in the statement of income caption, 
“Depreciation and amortization” and not included in the income statement caption cost of service revenues. 

Debt Issuance Costs

The Company amortizes debt issuance costs on a straight-line method over the term of the related debt. This method approximates the effective 
interest method. In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, the Company has classified the debt issuance costs 
as a direct deduction from the carrying amount of the related liability.

Workers’ Compensation Program

The Company’s workers’ compensation insurance program has a $0.4 million deductible component. The Company recognizes its obligations 

associated with this program in the period the claim is incurred. The cost of both the claims reported and claims incurred but not reported, up to the 
deductible, have been accrued based on historical claims experience, industry statistics and an actuarial analysis. The future claims payments related to the 
workers’ compensation program are secured by letters of credit. These letters of credit totaled $8.0 million and $8.2 million at December 31, 2023 and 
2022, respectively. The Company monitors its claims quarterly and adjusts its reserves as necessary in the current period. These costs are recorded 
primarily as cost of services on the Consolidated Statements of Income. As of December 31, 2023 and 2022, the Company recorded $12.0 million and 
$12.9 million, respectively, in accrued workers’ compensation insurance on the Company’s Consolidated Balance Sheets. As of December 31, 2023 and 
2022, the Company recorded $0.6 million and $0.7 million, respectively, in workers’ compensation insurance receivables. The workers’ compensation 
insurance receivable is included in prepaid expenses and other current assets on the Company’s Consolidated Balance Sheets.

Interest Expense

Interest expense is reported in the Consolidated Statements of Income when incurred and consists of interest and unused credit line fees on the credit 

facility. 

Income Tax Expense

The Company accounts for income taxes under the provisions of ASC Topic 740, Income Taxes. The objective of accounting for income taxes is to 

recognize the amount of taxes payable or refundable for the current year and deferred tax assets and liabilities for the future tax consequences of events that 
have been recognized in its financial statements or tax returns. Deferred taxes, resulting from differences between the financial and tax basis of the 
Company’s assets and liabilities, are also adjusted for changes in tax rates and tax laws when changes are enacted. ASC Topic 740 also requires that 
deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. 
ASC Topic 740 also prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or 
expected to be taken in a tax return. In addition, ASC Topic 740 provides guidance on derecognition, classification, accounting in interim periods and 
disclosure requirements for uncertain tax positions. The Company recognizes interest and penalties accrued related to uncertain tax positions in interest 
expense and penalties within operating expenses on the Consolidated Statements of Income. Uncertain tax positions are immaterial for all periods 
presented.

F-13

 
Table of Contents

Stock-based Compensation

The Company currently has one stock incentive plan, the Amended and Restated 2017 Omnibus Incentive Plan (the “A&R 2017 Plan”), under 

which new grants of stock-based employee compensation are made. The Company accounts for stock-based compensation in accordance with ASC Topic 
718, Stock Compensation. Compensation expense is recognized on a straight-line basis under the A&R 2017 Plan over the vesting period of the equity 
awards based on the grant date fair value of the options and restricted stock awards. The Company utilizes the Black-Scholes Option Pricing Model to 
value the Company’s options. Forfeitures are recognized when they occur. Stock-based compensation expense was $10.3 million, $10.6 million and $9.4 
million for the years ended December 31, 2023, 2022 and 2021, respectively, included within general and administrative expenses on the Consolidated 
Statements of Income. 

Diluted Net Income Per Common Share

Diluted net income per common share, calculated on the treasury stock method, is based on the weighted average number of shares outstanding 

during the period. The Company’s outstanding securities that may potentially dilute the common stock are stock options and restricted stock awards.

Included in the Company’s calculation of diluted earnings per share for the year ended December 31, 2023 were approximately 455,000 stock 
options outstanding, of which approximately 234,000 were dilutive. In addition, there were approximately 201,000 restricted stock awards outstanding, of 
which approximately 82,000 were dilutive for the year ended December 31, 2023.

Included in the Company’s calculation of diluted earnings per share for the year ended December 31, 2022 were approximately 468,000 stock 
options outstanding, of which approximately 248,000 were dilutive. In addition, there were approximately 210,000 restricted stock awards outstanding, of 
which approximately 72,000 were dilutive for the year ended December 31, 2022.

Included in the Company’s calculation of diluted earnings per share for the year ended December 31, 2021 were approximately 493,000 stock 
options outstanding, of which approximately 282,000 were dilutive. In addition, there were approximately 159,000  restricted stock awards outstanding, of 
which approximately 44,000 were dilutive for the year ended December 31, 2021.

Use of Estimates

The financial statements are prepared by management in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) and include 
estimated amounts and certain disclosures based on assumptions about future events. The Company’s critical accounting estimates include the following 
areas: revenue recognition, goodwill and intangibles and business combinations and when required, the quantitative assessment of goodwill. Actual results 
could differ from those estimates.

Fair Value Measurements

The Company’s financial instruments consist of cash, accounts receivable, payables and debt. The carrying amounts reported on the Company’s 

Consolidated Balance Sheets for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature 
of these instruments. The carrying value of the Company’s long-term debt with variable interest rates approximates fair value based on instruments with 
similar terms using level 2 inputs as defined under ASC Topic 820, Fair Value Measurement.

The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to goodwill, if 

required, and indefinite-lived intangible assets and also when determining the fair value of contingent consideration, if applicable. To determine the fair 
value in these situations, the Company uses Level 3 inputs, under ASC Topic 820 and defined as unobservable inputs in which little or no market data 
exists; therefore requiring an entity to develop its own assumptions, such as discounted cash flows, or if available, what a market participant would pay on 
the measurement date.

The Company uses various valuation techniques to determine fair value of its intangible assets, including relief-from-royalty, income approach, 

discounted cash flow analysis, and multi-period excess earnings, which use significant unobservable inputs, or Level 3 inputs, as defined by the fair value 
hierarchy. Under these valuation approaches, we are required to make estimates and assumptions about future market growth and trends, forecasted revenue 
and costs, expected periods over which the assets will be utilized, appropriate discount rates and other variables.

F-14

 
Table of Contents

Going Concern

In connection with the preparation of the financial statements for the years ended December 31, 2023 and 2022, the Company conducted an 
evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to the entity’s ability to continue 
as a going concern within one year after the date of the issuance, of the financial statements. Based on the evaluation, we believe that cash flows from 
operations will be sufficient to meet our ongoing liquidity requirements for at least twelve months from the date of issuance.

Recently Adopted Accounting Pronouncements

In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update ASU 2021-10, Government 

Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. ASU 2021-10 requires entities to disclose certain information about 
the nature of certain governmental assistance received, including the nature of the transaction and the related accounting policy, the financial statement line 
items impacted by the assistance, as well as the significant terms and conditions of the transactions. The ASU was adopted as of January 1, 2022 and did 
not have a material impact on the Company’s results of operations or liquidity.

In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers 

(Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) 
from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had 
originated the acquired contracts. The ASU was adopted prospectively on January 1, 2023. The additional disclosures required did not have a material 
impact on our consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on 
Financial Reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, 
and other transactions subject to meeting certain criteria, that reference the London Inter-Bank Offered Rate (“LIBOR”) or another reference rate expected 
to be discontinued. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from 
reference rates that are expected to be discontinued. Therefore, it was in effect for a limited time through December 31, 2022. The ASU could be adopted 
no later than December 1, 2022 with early adoption permitted. As discussed further in Note 8 and pursuant to the Third Amendment to Amended and 
Restated Credit Agreement dated as of April 26, 2023, the Company amended its credit facility to replace LIBOR with the secured overnight financing rate 
as administered by the Federal Reserve Bank of New York (“SOFR”) as the benchmark reference rate for loans under its credit facility. The transition to 
SOFR did not and is not expected to have a material impact on the Company’s results of operations or liquidity.

Recently Issued Accounting Pronouncements 

In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures, which expands reportable segment 
disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in the ASU require, among other 
things, disclosure of significant segment expenses that are regularly provided to an entity's chief operating decision maker (“CODM”) and a description of 
other segment items (the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each 
reported measure of segment profit or loss) by reportable segment, as well as disclosure of the title and position of the CODM, and an explanation of how 
the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Annual 
disclosures are required for fiscal years beginning after December 15, 2023 and interim disclosures are required for periods within fiscal years beginning 
after December 15, 2024. Retrospective application is required, and early adoption is permitted. These requirements will result in expanded disclosures.

In December 2023, the FASB issued ASU 2023-09, Improvement to Income Tax Disclosures, which requires disclosure of disaggregated income 
taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. 
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, may be applied prospectively or retrospectively, and allows for early 
adoption. These requirements are not expected to have an impact on the Company's financial statements and will expand income tax disclosures. 

F-15

 
Table of Contents

2. Leases

Amounts reported on the Company’s Consolidated Balance Sheets for operating leases were as follows:

Operating lease assets, net
Short-term operating lease liabilities (in accrued expenses)
Long-term operating lease liabilities
Total operating lease liabilities

Lease Costs

December 31,

2023

2022

(Amounts in Thousands)

  $

  $

45,433     $
11,339    
39,711    
51,050     $

38,980  
10,801  
35,479  
46,280  

Components of lease costs were reported in general and administrative expenses in the Company’s Consolidated Statements of Income as follows:

Operating lease costs
Short-term lease costs
Total lease costs
Less: sublease income
Total lease costs, net

For the Years Ended December 31,
(Amounts in Thousands)
2022

2021

2023

  $

  $

  $

13,026  
1,147  
14,173      
(2,770 )    
11,403     $

11,354     $
2,885    
14,239    
(951 )  
13,288     $

11,150  
739  
11,889  
(679 )
11,210  

Lease Term and Discount Rate

Weighted average remaining lease terms and discount rates were as follows:

Operating leases:
Weighted average remaining lease term
Weighted average discount rate

Maturity of Lease Liabilities

Remaining operating lease payments as of December 31, 2023 were as follows:

2023

December 31,
2022

2021

6.26      
5.47 %   

5.82      
3.98 %   

6.39  
3.91 %

Due in 12-month period ended December 31,
2024
2025
2026
2027
2028
Thereafter
Total future minimum rental commitments
Less: Imputed interest

Total lease liabilities

F-16

Operating Leases
(Amounts in Thousands)

  $

  $

13,809  
10,580  
8,284  
6,101  
5,274  
17,154  
61,202  
(10,152 )
51,050  

 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
   
 
   
 
 
   
   
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

Supplemental Cash Flow Information

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases

Right-of-use assets obtained in exchange for lease obligations:

Operating leases

  $

  $

14,396     $

13,015     $

11,288  

17,221     $

14,746     $

7,705  

The Company sublet a portion of its corporate headquarters space in Frisco, Texas in November 2022 to a third party under a two-year sublease term 

For the Years Ended December 31,
(Amounts in Thousands)
2022

2021

2023

for a monthly base rent of $0.1 million. 

3. Acquisitions 

The Company’s acquisitions have been accounted for in accordance with ASC Topic 805, Business Combinations, and the resulting goodwill and 

other intangible assets were accounted for under ASC Topic 350, Goodwill and Other Intangible Assets. Under business combination accounting, the assets 
and liabilities are generally recognized at their fair values and the difference between the consideration transferred, excluding transaction costs, and the fair 
values of the assets and liabilities is recognized as goodwill. The results of each business acquisition are included on the Consolidated Statements of 
Income from the date of the acquisition.

Management’s assessment of qualitative factors affecting goodwill for each acquisition includes estimates of market share at the date of purchase, 

ability to grow in the market, synergy with existing Company operations and the payor profile in the markets.

Tennessee Quality Care  

          On August 1, 2023, the Company completed the acquisition of Tennessee Quality Care. The purchase price was approximately $111.2 million, 
including the amount of acquired excess cash held by Tennessee Quality Care at the closing of the acquisition (approximately $2.4 million), and is subject 
to the completion of working capital and related adjustments. The Tennessee Quality Care acquisition was funded with a combination of a $110.0 million 
draw on the Company’s revolving credit facility and available cash. With the purchase of Tennessee Quality Care, the Company expanded its services 
within its hospice and home health segments to Tennessee. The related acquisition and integration costs were $2.1 million and $1.0 million, respectively, 
for the year ended December 31, 2023. These costs are included in general and administrative expenses on the Consolidated Statements of Income and 
were expensed as incurred.

Based upon management’s valuations, which are preliminary and subject to completion of working capital adjustments, the fair values of the assets 

and liabilities acquired are as follows:

Goodwill
Identifiable intangible assets
Cash
Accounts receivable
Property and equipment
Operating lease assets, net
Other assets
Accrued expenses
Accrued payroll
Long-term operating lease liabilities
Total purchase price

F-17

Total 
(Amounts in Thousands)

79,346  
26,740  
2,357  
5,940  
307  
194  
200  
(1,407 )
(2,368 )
(80 )
111,229  

  $

  $

 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
     
   
 
 
 
 
     
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

Identifiable intangible assets acquired included $7.5 million in a trade name and $19.2 million of indefinite-lived state licenses. The preliminary 
estimated fair value of identifiable intangible assets was determined with the assistance of a valuation specialist, using Level 3 inputs as defined under ASC 
Topic 820. The fair value analysis and related valuations reflect the conclusions of management. All estimates, key assumptions, and forecasts were either 
provided by or reviewed by the Company. The goodwill and intangible assets acquired are deductible for tax purposes.

The Tennessee Quality Care acquisition accounted for $16.3 million of net service revenues and $3.0 million of operating income for the year ended 

December 31, 2023.

JourneyCare  

          On February 1, 2022, the Company completed the acquisition of the hospice and palliative operations of JourneyCare. The purchase price was 
approximately $86.6 million, including the amount of acquired excess cash held by JourneyCare at the closing of the acquisition (approximately $0.4 
million) plus the finalization of net working capital payable to seller of $1.6 million. The JourneyCare acquisition was funded with a combination of a 
$35.0 million draw on the Company’s revolving credit facility and available cash. With the JourneyCare acquisition, the Company expanded its hospice 
services to patients in the state of Illinois. The related acquisition and integration costs were $0.5 million and $4.3 million, respectively, for the year ended 
December 31, 2022. These costs are included in general and administrative expenses on the Consolidated Statements of Income and were expensed as 
incurred.

Based upon management’s valuations, which are preliminary and subject to completion of working capital adjustments, the fair values of the assets 

and liabilities acquired are as follows:

Goodwill
Identifiable intangible assets
Cash
Accounts receivable
Property and equipment
Operating lease assets, net
Other assets
Accrued expenses
Accrued payroll
Long-term operating lease liabilities
Total purchase price

Total 
(Amounts in Thousands)

69,446  
13,792  
421  
7,747  
1,194  
3,728  
317  
(5,002 )
(1,511 )
(3,537 )
86,595  

  $

  $

Identifiable intangible assets acquired included $9.0 million in a trade name and $4.8 million of indefinite-lived state licenses. The estimated fair 
value of identifiable intangible assets was determined with the assistance of a valuation specialist, using Level 3 inputs as defined under ASC Topic 820. 
The fair value analysis and related valuations reflect the conclusions of management. All estimates, key assumptions, and forecasts were either provided by 
or reviewed by the Company. The goodwill and intangible assets acquired are deductible for tax purposes.

JourneyCare accounted for $47.2 million of net service revenues and $9.1 million of operating income for the year ended December 31, 2022.

Armada Skilled Homecare

On August 1, 2021, we completed the acquisition of Armada Skilled Homecare of New Mexico LLC, Armada Hospice of New Mexico LLC and 

Armada Hospice of Santa Fe LLC (collectively, “Armada”) for approximately $29.7 million, including the amount of acquired excess cash held by Armada 
at the closing of the acquisition (approximately $0.7 million). The purchase of Armada was funded with the Company’s revolving credit facility. With the 
purchase of Armada, the Company expanded its home health and hospice services in the state of New Mexico. The related acquisition and integration costs 
were $0.4 million and $0.5 million, respectively, for the year ended December 31, 2021. These costs are included in general and administrative expenses on 
the Consolidated Statements of Income and were expensed as incurred.

F-18

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents

Based upon management’s final valuations, the fair values of the assets and liabilities acquired are as follows:

Goodwill
Identifiable intangible assets
Cash
Property and equipment
Other assets
Accounts payable
Accrued payroll
Total purchase price

Total 
(Amounts in
Thousands)

28,287  
990  
676  
40  
24  
—  
(361 )
29,656  

  $

  $

Identifiable intangible assets acquired included $0.6 million of non-competition agreements with estimated useful lives of five years and $0.4 

million of indefinite-lived state licenses. The estimated fair value of identifiable intangible assets was determined with the assistance of a valuation 
specialist, using Level 3 inputs as defined under ASC Topic 820. The fair value analysis and related valuations reflect the conclusions of management. All 
estimates, key assumptions, and forecasts were either provided by or reviewed by the Company. The goodwill and intangible assets acquired are deductible 
for tax purposes.

Other Acquisitions

On January 1, 2023, we completed the acquisition of CareStaff for approximately $1.0 million, with funding provided by available cash. With the 

purchase of CareStaff, the Company expanded its personal care services segment in Florida and recorded goodwill of $0.6 million. 

On October 1, 2022, we completed the acquisition of Apple Home for approximately $12.7 million, with funding provided by drawing on the 
Company’s revolving credit facility. The additional contingent consideration of up to approximately $2 million was settled without further payment. With 
the purchase of Apple Home, the Company expanded clinical services for its home health segment in Illinois and recorded goodwill of $8.9 million. 

On October 1, 2021, we completed the acquisition of Summit Home Health, LLC (“Summit”) for approximately $8.1 million, with funding 
provided by available cash. With the purchase of Summit, we added clinical services to our home health segment in Illinois and recorded goodwill of $6.5 
million. 

For the year ended December 31, 2023, the following table contains unaudited pro forma Consolidated Income Statement information of the 
Company as if the acquisition of Tennessee Quality Care closed on January 1, 2022. For the year ended December 31, 2022, the following table contains 
unaudited pro forma Consolidated Income Statement information of the Company as if the acquisition of JourneyCare closed on January 1, 2021. For the 
year ended December 31, 2021, the following table contains unaudited pro forma Consolidated Income Statement information of the Company as if the 
acquisition of Armada closed on January 1, 2020. 

Net service revenues
Operating income from continuing operations
Net income from continuing operations
Net income per common share
Basic income per share
Diluted income per share

  $

  $
  $

For the Years Ended December 31,
(Amounts in Thousands, Unaudited)
2022

  $

  $

991,566  
73,353  
46,270  

2023
1,084,759  
96,679  
65,436  

2021

936,601  
69,081  
47,622  

4.09  
4.01  

  $
  $

2.92  
2.86  

  $
  $

3.03  
2.96  

The pro forma disclosures in the table above include adjustments for amortization of intangible assets, tax expense and acquisition costs to reflect 
results that are more representative of the combined results of the transactions. This pro forma information is presented for illustrative purposes only and 
may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results 
reflected in the pro forma information. The unaudited pro forma financial information does not reflect the impact of future events that may occur after the 
acquisition, such as anticipated cost savings from operating synergies. 

F-19

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
 
     
     
   
 
Table of Contents

4. Property and Equipment

Property and equipment consisted of the following:

Computer software
Computer equipment
Leasehold improvements
Furniture and equipment
Transportation equipment

Less: accumulated depreciation and amortization

December 31,

2023

2022

(Amounts in Thousands)

23,936     $
10,430    
11,110    
5,758    
258    
51,492    
(27,481 )  
24,011     $

19,675  
12,343  
10,746  
5,534  
194  
48,492  
(27,310 )
21,182  

  $

  $

Computer software includes $1.6 million of internally developed software for both years ended December 31, 2023 and 2022. Depreciation and 

amortization expense totaled $6.9 million, $6.8 million and $5.9 million for the years ended December 31, 2023, 2022 and 2021, respectively.

5. Goodwill and Intangible Assets

A summary of goodwill by segment and related adjustments is provided below:

Hospice

Personal Care

Home Health

Total

Goodwill

Goodwill at December 31, 2021
Additions for acquisitions
Adjustments to previously recorded goodwill
Goodwill at December 31, 2022
Additions for acquisitions
Adjustments to previously recorded goodwill
Goodwill at December 31, 2023

  $

  $

  $

328,334  
69,446  
(52 )
397,728  
35,071  
—  
432,799     $

  $

(Amounts In Thousands)
152,688  
—  
—  
152,688  
601  
(13 )    
153,276     $

  $

23,370  
8,910  
141  
32,421  
44,274  
225  
76,920     $

504,392  
78,356  
89  
582,837  
79,946  
212  
662,995  

In 2023, the Company recognized goodwill in the hospice and home health segments of $35.0 million and $44.3 million, respectively, related to the 
acquisition of Tennessee Quality Care and $0.6 million related to the acquisition of CareStaff in the personal care services segment. In connection with the 
acquisition of JourneyCare in 2022, the Company recognized goodwill in its hospice segment of $69.4 million and $8.9 million with the acquisition of 
Apple Home in 2022 in our home health segment.

Goodwill adjustments to previously recorded goodwill are generally related to accounts receivable and accrued expenses based on the final 
valuations. See Note 3 to the Notes to Consolidated Financial Statements for additional information regarding the acquisitions made by the Company in 
2022 and 2023.

The Company’s identifiable intangible assets consist of customer and referral relationships, trade names and trademarks, non-competition 

agreements and state licenses. Amortization is computed using straight-line and accelerated methods based upon the estimated useful lives of the respective 
assets, which range from one to twenty-five years. Customer and referral relationships are amortized systematically over the periods of expected economic 
benefit, which range from five to ten years.

F-20

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
Table of Contents

Goodwill and certain state licenses are not amortized pursuant to ASC Topic 350. We test intangible assets with indefinite useful lives for 

impairment at the reporting unit level on an annual basis, as of October 1, or whenever potential impairment triggers occur, such as a significant change in 
business climate or regulatory changes that would indicate that an impairment may have occurred. The Company estimates the fair value of the reporting 
unit using both a discounted cash flow model as well as a market multiple model. The cash flow forecasts are adjusted by an appropriate discount rate 
based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate 
of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential 
acquirer would be required to pay, in the form of a control premium. The determination of fair value in the Company’s goodwill impairment analysis is 
based on an estimate of fair value for each reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are 
not limited to, the most recent price of the Company’s common stock and fair value of long term debt, estimates of future revenue and expense growth, 
estimated market multiples, expected capital expenditures, income tax rates and cost of invested capital. Significant assumptions used in the analysis 
included a 10.0% discount rate and long-term revenue growth rates that ranged from 3.5% to 5.8%. The Company did not record any impairment charges 
for the years ended December 31, 2023, 2022 or 2021.

The carrying amount and accumulated amortization of each identifiable intangible asset category consisted of the following at December 31, 2023 

and 2022:

Estimated Useful 
Life

Gross carrying 
value

December 31, 2023

(Amounts in Thousands)
Accumulated 
amortization

Net carrying 
value

Gross carrying 
value

December 31, 2022

(Amounts in Thousands)
Accumulated 
amortization

Net carrying 
value

Customer and referral 
relationships
Trade names and trademarks
Non-competition agreement
State Licenses
State Licenses

Total intangible assets

5-10 years
1-20 years
3-5 years
6-10 years
Indefinite

  $

  $

  $

44,672  
59,566  
6,785  
12,671  
46,328  
170,022     $

(39,566 )   $
(23,857 )    
(5,601 )    
(9,015 )    
—      
(78,039 )   $

5,106     $
35,709      
1,184      
3,656      
46,328      
91,983     $

44,672     $
52,046      
6,785      
12,517      
27,108      
143,128     $

(38,088 )   $
(21,058 )    
(4,785 )    
(7,009 )    
—      
(70,940 )   $

6,584  
30,988  
2,000  
5,508  
27,108  
72,188  

During the year ended December 31, 2023, the Company acquired indefinite-lived state licenses and a trade name of $7.6 million and $2.1 million, 

respectively, in its hospice segment related to the acquisition of Tennessee Quality Care. The Company also acquired indefinite-lived state licenses and 
trade name of $11.6 million and $5.4 million, respectively, in its home health segment in connection with the Tennessee Quality Care acquisition. 

During the year ended December 31, 2022, the Company acquired indefinite-lived state licenses and trade names of $4.8 million and $9.0 million, 

respectively, related to the acquisition of JourneyCare. During the year ended December 31, 2022, the Company acquired indefinite lived state licenses and 
trade names of $1.2 million and $0.1 million, respectively, related to the acquisition of Apple Home. 

Amortization expense related to the identifiable intangible assets amounted to $7.1 million, $7.2 million and $8.5 million for the years ended 

December 31, 2023, 2022 and 2021, respectively.

The weighted average remaining useful life of identifiable intangible assets as of December 31, 2023 is 10.23 years.

F-21

 
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
   
   
   
   
   
 
 
 
   
   
 
   
   
 
   
   
 
   
   
 
 
 
 
Table of Contents

The estimated future intangible amortization expense is as follows:

For the year ended December 31,
2024
2025
2026
2027
2028
Thereafter
Total, intangible assets subject to amortization

6. Details of Certain Balance Sheet Accounts

Prepaid expenses and other current assets consisted of the following:

Prepaid payroll
Prepaid workers’ compensation and liability insurance
Prepaid licensing fees
Workers’ compensation insurance receivable
Other
Total prepaid expenses and other current assets

Accrued expenses consisted of the following:

(1)

Accrued health benefits
Payor advances 
Accrued professional fees
Accrued payroll and other taxes
Other
Total accrued expenses

  $

  $

  $

  $

Total 
(Amount in
Thousands)

  $

  $

December 31,

2023

2022

(Amounts in Thousands)

  $

8,735  
3,696    
4,481  

577       

2,225  
19,714      $

December 31,

2023

2022

(Amounts in Thousands)

  $

7,400  
1,218  
7,304  
8,572       
8,742  
33,236  

  $

7,047  
5,424  
4,800  
4,178  
3,285  
20,921  
45,655  

7,566  
3,399  
3,722  
666  
1,992  
17,345  

5,152  
4,473  
3,576  
6,175  
8,131  
27,507  

(1)

Represents the deferred portion of payments received from payors for COVID-19 reimbursements which will be recognized as we incur specific COVID-19 related 
expenses (including expenses related to securing and maintaining adequate personnel) or will be returned to the extent such related expenses are not incurred.

7. Long-Term Debt

Long-term debt consisted of the following:

Revolving loan under the credit facility
Term loan under the credit facility
Less unamortized issuance costs
Total
     Less current maturities
Long-term debt

  $

  $

F-22

December 31,

2023

2022

  $

(Amounts in Thousands)
126,353  
—  
(2,221 )
124,132  
—  
124,132  

  $

134,853  
—  
(3,081 )
131,772  
—  
131,772  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
    
   
   
   
   
    
 
 
 
 
 
 
 
 
   
 
 
 
 
   
   
   
   
   
   
   
   
 
Table of Contents

Amended and Restated Senior Secured Credit Facility

On October 31, 2018, the Company entered into the Amended and Restated Credit Agreement, with certain lenders and Capital One, National 

Association, as a lender and as agent for all lenders, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of 
September 12, 2019, as further amended by the Second Amendment to Amended and Restated Credit Agreement, dated as of July 30, 2021, and as further 
amended by the Third Amendment to Amended and Restated Credit Agreement, dated as of April 26, 2023 (as described below, the “Third Amendment”)  
(as amended, the “Credit Agreement”, as used throughout this Annual Report on Form 10-K, “credit facility” shall mean the credit facility evidenced by the 
Credit Agreement). The credit facility consists of a $600.0 million revolving credit facility and a $125.0 million incremental loan facility, which 
incremental loan facility may be for term loans or an increase to the revolving loan commitments. The maturity of this credit facility is July 30, 2026.

 On April 26, 2023, the Company entered into the Third Amendment to replace LIBOR with SOFR as the benchmark reference rate for loans under 

its credit facility. The Third Amendment did not amend any other terms of the Credit Agreement. The transition to SOFR did not and is not expected to 
have a material impact on the Company’s results of operations or liquidity.

Interest on the credit facility may be payable at (x) the sum of (i) an applicable margin ranging from 0.75% to 1.50% based on the applicable senior 
net leverage ratio plus (ii) a base rate equal to the greatest of (a) the rate of interest last quoted by The Wall Street Journal as the “prime rate,” (b) the sum 
of the federal funds rate plus a margin of 0.50% and (c) the sum of Term SOFR (as published by the CME Group Benchmark Administrative Limited) for 
an interest period of one month for such applicable day plus 0.10% (not to be less than 0.00%), plus a margin of 1.00% or (y) the sum of (i) an applicable 
margin ranging from 1.75% to 2.50% based on the applicable senior net leverage ratio plus (ii) the rate per annum equal to the sum of Term SOFR (as 
published by the CME Group Benchmark Administrative Limited) for the applicable interest period plus 0.10% (not to be less than zero). Swing loans may 
not be SOFR loans.

Addus HealthCare, Inc. (“Addus HealthCare”) is the borrower, and its parent, Holdings, and substantially all of Holdings’ subsidiaries are 
guarantors under this credit facility, and it is collateralized by a first priority security interest in all of the Company’s and the other credit parties’ current 
and future tangible and intangible assets, including the shares of stock of the borrower and subsidiaries. The Credit Agreement contains affirmative and 
negative covenants customary for credit facilities of this type, including limitations on the Company with respect to liens, indebtedness, guaranties, 
investments, distributions, mergers and acquisitions and dispositions of assets. The availability of additional draws under this credit facility is conditioned, 
among other things, upon (after giving effect to such draws) the Total Net Leverage Ratio (as defined in the Credit Agreement) not exceeding 3.75:1.00. In 
certain circumstances, in connection with a Material Acquisition (as defined in the Credit Agreement), the Company can elect to increase its Total Net 
Leverage Ratio compliance covenant to 4.25:1.00 for the then current fiscal quarter and the three succeeding fiscal quarters.

The Company pays a fee ranging from 0.20% to 0.35% based on the applicable senior net leverage ratio times the unused portion of the revolving 

loan portion of the credit facility.

The Credit Agreement contains customary affirmative covenants regarding, among other things, the maintenance of records, compliance with laws, 

maintenance of permits, maintenance of insurance and property and payment of taxes. The Credit Agreement also contains certain customary financial 
covenants and negative covenants that, among other things, include a requirement to maintain a minimum Interest Coverage Ratio (as defined in the Credit 
Agreement), a requirement to stay below a maximum Total Net Leverage Ratio (as defined in the Credit Agreement) and a requirement to stay below a 
maximum permitted amount of capital expenditures. The Credit Agreement also contains restrictions on guarantees, indebtedness, liens, investments and 
loans, subject to customary carve outs, a restriction on dividends (provided that Addus HealthCare may make distributions to the Company in an amount 
that does not exceed $7.5 million in any year absent of an event of default, plus limited exceptions for tax and administrative distributions), a restriction on 
the ability to consummate acquisitions (without the consent of the lenders) under its credit facility subject to compliance with the Total Net Leverage Ratio 
(as defined in the Credit Agreement) thresholds, restrictions on mergers, dispositions of assets, and affiliate transactions, and restrictions on fundamental 
changes and lines of business. As of December 31, 2023, the Company was in compliance with all financial covenants under the Credit Agreement.

During the twelve months ended December 31, 2023, the Company drew approximately $110.0 million under its credit facility to fund, in part, the 
Tennessee Quality Care acquisition. At December 31, 2023, the Company had a total of $126.4 million of revolving loans, with an interest rate of 7.21%, 
outstanding on its credit facility. After giving effect to the amount drawn on its credit facility, approximately $8.0 million of outstanding letters of credit 
and borrowing limits based on an advance multiple of Adjusted EBITDA (as defined in the Credit Agreement), the Company had $470.0 million of 
capacity and $335.6 million available for borrowing under its credit facility.

F-23

 
 
Table of Contents

During the twelve months ended December 31, 2022, the Company drew approximately $47.0 million under its credit facility to fund in part, the 

JourneyCare and Apple Home acquisitions. At December 31, 2022, the Company had a total of $134.9 million of revolving loans, with an interest rate of 
6.13%, outstanding on its credit facility. After giving effect to the amount drawn on its credit facility, approximately $8.2 million of outstanding letters of 
credit and borrowing limits based on an advance multiple of Adjusted EBITDA (as defined in the Credit Agreement), the Company had $380.2 million of 
capacity and $237.2 million available for borrowing under its credit facility.

8. Income Taxes

The current and deferred federal and state income tax provision from continuing operations, are comprised of the following:

Current

Federal
State
Deferred
Federal
State

Provision for income taxes

For the Years Ended December 31,
(Amounts in Thousands)
2022

2023

2021

  $

  $

11,839     $
4,139    

2,306    
526    
18,810     $

7,075     $
3,090    

3,118    
863    
14,146     $

4,603  
2,398  

6,407  
1,864  
15,272  

The tax effects of certain temporary differences between the Company’s book and tax bases of assets and liabilities give rise to significant portions 

of the deferred income tax assets (liabilities) at December 31, 2023 and 2022. The deferred tax assets (liabilities) consisted of the following:

Deferred tax assets

Long-term

Accounts receivable allowances
Operating lease liabilities
Accrued compensation
Accrued workers’ compensation
Transaction costs
Stock-based compensation
Net operating loss
Restructuring costs
Other

Total long-term deferred tax assets

Deferred tax liabilities

Long-term

Goodwill and intangible assets
Operating lease assets, net
Property and equipment
Insurance premiums

Total long-term deferred tax liabilities

Total net deferred tax (liabilities) assets

For the Years Ended December 31,
(Amounts in Thousands)

2023

2022

  $

21,480  
13,562  
4,957  
3,046  
2,390  
1,456  
87  
26  
2,908  
49,912  

(42,980 )    
(11,650 )    
(2,829 )    
(982 )    
(58,441 )    
(8,529 )   $

18,515  
12,472  
3,676  
3,296  
2,056  
1,473  
—  
54  
1,420  
42,962  

(34,310 )
(10,323 )
(3,123 )
(916 )
(48,672 )
(5,710 )

  $

  $

Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate 
realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences 
become deductible. Management considers all available evidence in making this assessment.

F-24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
   
 
     
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
     
   
 
     
   
   
   
   
   
   
 
Table of Contents

A reconciliation for continuing operations of the statutory federal tax rate of 21.0% to the effective income tax rate is summarized as follows:

Federal income tax at statutory rate
State and local taxes, net of federal benefit
162(m) disallowance for executive compensation
Nondeductible penalties
Excess tax benefit
Jobs tax credits, net
Nondeductible permanent items
Federal/state return to provision

Other
Effective income tax rate

2023

For the Years Ended December 31,
2022

2021

21.0   %    
5.6    
2.2    
0.1    
(0.5 )  
(4.0 )  
0.1    
(1.3 )  
(0.1 )  
23.1   %    

21.0   %    
5.9    
3.2    
—    
(0.4 )  
(5.1 )  
—    
(1.0 )  
(0.1 )  
23.5   %    

21.0   %
6.3    
3.5    
0.6    
(2.0 )  
(4.1 )  
—    

—    
(0.1 )  
25.2   %

The effective income tax rate was 23.1%, 23.5% and 25.2% for the years ended December 31, 2023, 2022 and 2021, respectively. The difference 

between our federal statutory and effective income tax rates was principally due to the inclusion of state taxes and non-deductible compensation, partially 
offset by an excess tax benefit and the use of federal employment tax credits. The excess tax expense/benefit is a discrete item, related to the vesting of 
equity shares, which requires the Company to recognize the expense or benefit fully in the period. 

The Company is subject to taxation in the jurisdictions in which it operates. The Company continues to remain subject to examination by U.S. 

federal authorities for the years 2020 through 2022 and for various state authorities for the years 2018 through 2022.

9. Stock Options and Restricted Stock Awards

The Board approved the A&R 2017 Plan as of April 13, 2023 and our shareholders approved it as of June 14, 2023. The A&R 2017 Plan amended 
and restated our 2017 Omnibus Incentive Plan (the “2017 Plan”), which in turn was intended to replace our 2009 Stock Incentive Plan (the “2009 Plan”). 
All awards are now granted from the A&R 2017 Plan. Outstanding awards under the 2009 Plan will continue to be governed by the 2009 Plan and the 
agreements under which they were granted.

The A&R 2017 Plan allows us to grant performance-based incentive awards and equity-based awards (each, an “Award”) to eligible employees, 

directors and consultants in the form of Stock Options, Stock Appreciation Rights (“SARs”), Restricted Stock Restricted Stock Units, Performance Awards 
and Other Stock Unit Awards. The Board believes that the A&R 2017 Plan is necessary to continue the Company’s effectiveness in attracting, motivating 
and retaining employees, directors and consultants with appropriate experience and to increase the grantees’ alignment of interest with the Company’s 
shareholders.

Under the A&R 2017 Plan, Awards may be made in shares of our common stock. Subject to adjustment as provided by the terms of the A&R 2017 

Plan, the maximum aggregate number of shares of common stock with respect to which awards may be granted under the A&R 2017 Plan is 864,215, 
comprised of 274,215 shares (the number of shares that were available for issuance under the 2017 Plan as of April 13, 2023) and 590,000 shares (the 
number of shares newly authorized by the Company’s shareholders upon their approval of the A&R 2017 Plan).. The aggregate awards granted during any 
calendar year to any single Participant cannot exceed 500,000 shares subject to stock options or SARs. These individual annual limitations are cumulative 
in that any shares of common stock or cash for which Awards are permitted to be granted to a Participant during a fiscal year are not covered by an Award 
in that fiscal year (such shortfall, the “Shortfall Amount”), the number of shares of common stock (or amount of cash, as the case may be) will 
automatically increase in the subsequent fiscal years during the term of the A&R 2017 Plan until the earlier of the time when the Shortfall Amount has 
been granted to the Participant, or the end of the third fiscal year following the year to which such Shortfall Amount relates. At December 31, 2023, there 
were 854,003 shares of common stock available for future grant under the A&R 2017 Plan.

F-25

 
 
 
 
   
 
 
   
 
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
Table of Contents

Awards made under the 2017 Plan (and the 2009 Plan) that are forfeited, canceled, settled in cash or otherwise terminated without a distribution of 

shares to a Participant will be deemed available for Awards under the A&R 2017 Plan; provided, that the A&R 2017 Plan explicitly prohibits shares 
withheld for payment of taxes for awards, the exercise price for appreciation awards, shares acquired with the proceeds of appreciation awards, and shares 
from stock settled SARs from being added back to the share reserve. Stock options are awarded with an exercise price equal to the fair market value based 
on the closing price of our common stock on the date of grant. Options granted typically vest over a service period ranging from three to four years and 
expire ten years from the date of grant. Restricted shares typically vest over a service period ranging from one to four years and expire ten years from date 
of grant.

Stock options are awarded with an exercise price equal to the fair market value based on the closing price of our common stock on the date of grant. 
Options granted typically vest over a service period ranging from three to four years and expire ten years from the date of grant. Restricted shares typically 
vest over a service period ranging from one to four years and expire ten years from date of grant.

The exercise prices of stock options outstanding on December 31, 2023 range from $19.71 to $92.00. Restricted stock awards are full-value awards.

Stock Options

A summary of stock option activity for the year ended December 31, 2023 follows:

Outstanding, beginning of period
Granted
Exercised
Forfeited/Cancelled
Outstanding, end of period

Exercisable, end of period

Options
(Amounts in
Thousands)

Weighted
Average
Exercise Price

Weighted Average 
Remaining 
Contractual Terms 
(Years)

468     $
—    
(13 )  
—    
455     $
415     $

45.72    
—    
24.38    
—    

46.33    
42.21      

5.2  

4.3  
4.0  

The weighted-average estimated fair value of employee stock options granted was calculated using the Black-Scholes Option Pricing Model in 2022 

and 2021. The Company did not grant any stock options in 2023. The related assumptions follow:

Weighted average fair value
Risk-free discount rate
Expected life
Dividend yield
Volatility

2023
Grants

$

$

—    
—    
—    
—  
—    

2022
Grants

1.76% - 2.86%
4.2 years

43%

32.96     $

—  

2021
Grants

0.65%
4.1 years

45%

32.71  

—  

Stock option compensation expense totaled $0.9 million, $1.2 million and $1.4 million for the years ended December 31, 2023, 2022 and 2021, 

respectively. As of December 31, 2023, there was $1.0 million of total unrecognized compensation cost that is expected to be recognized over a weighted 
average period of 2.0 years.

The intrinsic value of exercisable and outstanding stock options was $21.0 million and $21.2 million, respectively, as of December 31, 2023.

As of December 31, 2023, there were 415,000 and 40,000 shares of stock options vested and unvested, respectively.

The intrinsic value of stock options exercised during the years ended December 31, 2023, 2022 and 2021 was $0.8 million, $3.5 million and $1.8 

million, respectively.

F-26

 
 
 
 
 
 
 
 
 
   
   
 
   
   
 
   
   
 
   
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
 
 
 
   
 
 
 
 
 
 
 
 
 
   
 
 
Table of Contents

Restricted Stock Awards

A summary of unvested restricted stock awards activity and weighted average grant date fair value for the year ended December 31, 2023 follows:

Restricted
Stock
Awards
(Amounts in
Thousands)

Weighted
Average
Grant Date
Fair Value

Unvested restricted stock awards, beginning of period
Awarded
Vested
Forfeited
Unvested restricted stock awards, end of period

  $

210  
87  
(95 )    
(1 )    
  $

201  

88.22  
103.24  
89.92  
84.00  

93.93  

The fair value of restricted stock awards that vested during the year ended December 31, 2023 was $9.9 million.

Restricted stock award compensation expense totaled $9.4 million, $9.4 million and $8.0 million for the years ended December 31, 2023, 2022 and 

2021, respectively. As of December 31, 2023, there was $10.4 million of total unrecognized compensation cost that is expected to be recognized over a 
weighted average period of 1.4 years.

10. Employee Benefit Plans

The 401(k) retirement plan is a defined contribution plan that provides for matching contributions by the Company to all non-union employees. 

Matching contributions are discretionary and subject to change by management. Under the provisions of the 401(k) plan, employees can contribute up to 
the maximum percentage and limits allowable under the U.S. Revenue Code. The Company provided contributions totaling $0.6 million, $0.4 million and 
$0.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. 

11. Commitments and Contingencies 

          Legal Proceedings

From time to time, the Company is subject to legal and/or administrative proceedings incidental to its business.

It is the opinion of management that the outcome of pending legal and/or administrative proceedings will not have a material effect on the 

Company’s Consolidated Balance Sheets and Consolidated Statements of Income.

Concentration of Cash

The Company owns financial instruments that potentially subject the Company to significant concentrations of credit risk, including cash. The 

Company maintains cash with financial institutions which, at times, may exceed federally insured limits. The Company believes it is not exposed to any 
significant credit risk on cash.

12. Segment Information

Operating segments are defined as components of a company that engage in business activities from which it may earn revenues and incur expenses, 

and for which separate financial information is available and is regularly reviewed by the Company’s chief operating decision makers, to assess the 
performance of the individual segments and make decisions about resources to be allocated to the segments. The Company operates as a multi-state 
provider of three distinct but related business segments providing in-home services.

In its personal care segment, the Company provides non-medical assistance with activities of daily living, primarily to persons who are at increased 

risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. In its hospice segment, the Company provides physical, 
emotional and spiritual care for people who are terminally ill as well as related services for their families. In its home health segment, the Company 
provides services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and include skilled 
nursing and physical, occupational and speech therapy.

F-27

 
 
 
 
 
 
 
   
   
   
   
   
   
 
Table of Contents

The tables below set forth information about the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 along with 

the items necessary to reconcile the segment information to the totals reported in the accompanying consolidated financial statements. Segment assets are 
not reviewed by the Company’s chief operating decision maker function and therefore are not disclosed below.

Segment operating income consists of revenue generated by a segment, less the direct costs of service revenues and general and administrative 

expenses that are incurred directly by the segment. Unallocated general and administrative costs are those costs for functions performed in a centralized 
manner and therefore not attributable to a particular segment. These costs include accounting, finance, human resources, legal, information technology, 
corporate office support and facility costs and overall corporate management.

For the Year Ended December 31, 2023
(Amounts in Thousands)

Net service revenues
Cost of services revenues
Gross profit
General and administrative expenses

Segment operating income

Net service revenues
Cost of services revenues
Gross profit
General and administrative expenses

Segment operating income

Net service revenues
Cost of services revenues
Gross profit
General and administrative expenses

Segment operating income

Segment reconciliation:
Total segment operating income

Items not allocated at segment level:
Other general and administrative expenses
Depreciation and amortization
Interest income
Interest expense

Income before income taxes

  $

  $

  $

  $

  $

  $

F-28

  Home Health
  $

Personal Care

Hospice

794,718  
572,807  
221,911  
64,382  
157,529  

  $

  $

207,155  
110,219  
96,936  
52,083  
44,853  

For the Year Ended December 31, 2022
(Amounts in Thousands)

  Home Health
  $

Personal Care

Hospice

706,507  
520,617  
185,890  
60,532  
125,358  

  $

  $

201,772  
100,956  
100,816  
49,742  
51,074  

For the Year Ended December 31, 2021
(Amounts in Thousands)

  Home Health
  $

Personal Care

Hospice

685,854  
502,024  
183,830  
61,565  
122,265  

  $

  $

152,253  
75,186  
77,067  
34,632  
42,435  

56,778  
35,749  
21,029  
14,017  
7,012  

42,841  
29,808  
13,033  
10,251  
2,782  

26,392  
17,441  
8,951  
5,713  
3,238  

Total
1,058,651  
718,775  
339,876  
130,482  
209,394  

Total

951,120  
651,381  
299,739  
120,525  
179,214  

Total

864,499  
594,651  
269,848  
101,910  
167,938  

  $

  $

  $

  $

  $

  $

  $

  $

  $

For the Years Ended December 31,
(Amounts in Thousands)
2022

2023

2021

  $

209,394  

  $

179,214  

  $

167,938  

104,312  
14,126  
(1,476 )    
11,106  
81,326  

  $

96,417  
14,060  
(341 )
8,907  
60,171  

  $

87,508  
14,494  
(268 )
5,806  
60,398  

  $

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
 
   
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
 
   
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
   
 
   
 
 
     
   
 
   
 
     
   
 
   
   
   
   
   
   
   
   
   
   
   
   
 
Table of Contents

13. Significant Payors

For 2023, 2022 and 2021, the Company’s revenue by payor type was as follows:

2023

% of
Segment
Net
Service
Revenues

Amount
(in Thousands)

Personal Care
For the Years Ended December 31,
2022

Amount
(in Thousands)

% of
Segment
Net
Service
Revenues

2021

% of
Segment
Net
Service
Revenues

Amount
(in Thousands)

State, local and other governmental 
programs
Managed care organizations
Private pay
Commercial insurance
Other
Total personal care segment net service 
revenues

  $

400,753  
367,557  
16,268  
6,321  
3,819  

50.4   %   $
46.2    
2.0    
0.8    
0.6    

348,234  
326,778  
18,301  
7,689  
5,505  

49.3   %   $
46.3    
2.6    
1.1    
0.7    

338,325  
311,801  
19,991  
9,820  
5,917  

49.3   %
45.5    
2.9    
1.4    
0.9    

  $

794,718  

100.0   %   $

706,507  

100.0   %   $

685,854  

100.0   %

2023

Amount
(in Thousands)

  $

186,317  
7,037  
13,801  

Hospice
For the Years Ended December 31,
2022

2021

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

89.9   %   $
3.4    
6.7    

183,407      
7,353      
11,012      

90.9   %  $
3.6    
5.5    

142,086      
5,664      
4,503      

93.3   %
3.7    
3.0    

  $

207,155  

100.0   %   $

201,772      

100.0   %  $

152,253      

100.0   %

2023

Home Health
For the Years Ended December 31,
2022

2021

Amount
(in Thousands)

% of Segment
Net Service
Revenues

Amount
(in Thousands)

% of Segment
Net Service
Revenues

Amount
(in Thousands)

% of Segment
Net Service
Revenues

  $

41,078  
12,613  
3,087  

72.3   %   $
22.2    
5.5    

31,505  
8,698  
2,638  

73.5   %   $
20.3    
6.2    

20,700      
4,457      
1,235      

78.4   %
16.9    
4.7    

  $

56,778  

100.0   %   $

42,841  

100.0   %   $

26,392      

100.0   %

Medicare
Managed care organizations
Other
Total hospice segment net service 
revenues

Medicare
Managed care organizations
Other
Total home health segment net service 
revenues

F-29

 
 
 
 
   
 
 
   
 
 
   
 
   
 
   
 
 
 
 
   
 
 
 
   
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
   
   
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
Table of Contents

The Company derives a significant amount of its revenue from its operations in Illinois, New Mexico and New York. The percentages of segment 

revenue for each of these significant states for 2023, 2022 and 2021 were as follows:

2023

Amount
(in Thousands)

  $

411,081  
92,469  
115,986  
175,182  

Personal Care
For the Years Ended December 31,
2022

Amount
(in Thousands)

% of
Segment
Net
Service
Revenues

% of
Segment
Net
Service
Revenues

2021

% of
Segment
Net
Service
Revenues

Amount
(in Thousands)

51.7   %   $
11.6    
14.6    
22.1    

360,778  
86,592  
105,315  
153,822  

51.1   %   $
12.3    
14.9    
21.7    

328,619      
99,732      
97,784      
159,719      

47.9   %
14.5    
14.3    
23.3    

  $

794,718  

100.0   %   $

706,507  

100.0   %   $

685,854      

100.0   %

Illinois
New York
New Mexico
All other states
Total personal care segment net service 
revenues

Hospice

For the Years Ended December 31,

Ohio
New Mexico
Illinois
All other states
Total hospice segment net service 
revenues

2023

2022

2021

Amount
(in Thousands)

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

  $

74,871  
30,782  
47,247  
54,255  

36.1   %   $
14.9    
22.8    
26.2    

70,503      
30,722      
47,181      
53,366      

35.0   %  $
15.2    
23.4    
26.4    

61,415      
36,063      
—      
54,775      

40.3   %
23.7    
—    
36.0    

  $

207,155  

100.0   %   $

201,772      

100.0   %  $

152,253      

100.0   %

With the acquisition of JourneyCare in 2022, the Company expanded its hospice services to patients in the state of Illinois.

Home Health

For the Years Ended December 31,

New Mexico
Illinois
Tennessee
Total home health segment net service 
revenues

2023

2022

2021

Amount
(in Thousands)

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

Amount
(in Thousands)  

% of Segment
Net Service
Revenues

  $

32,949  
12,851  
10,978  

58.0   %   $
22.6    
19.4    

34,111      
8,730      
—      

79.6   %  $
20.4    
—    

24,735      
1,657      
—      

93.7   %
6.3    
—    

  $

56,778  

100.0   %   $

42,841      

100.0   %  $

26,392      

100.0   %

With the acquisition of Tennessee Quality Care in 2023, the Company expanded its home health services to patients in the state of Tennessee.

A substantial portion of the Company’s revenue and accounts receivable is derived from services performed for state and local governmental 
agencies. We derive a significant amount of our net service revenues in Illinois, which represented 44.5%, 43.8% and 38.2% of our net service revenues for 
the years ended December 31, 2023, 2022 and 2021, respectively. The Illinois Department on Aging, the largest payor program for the Company’s Illinois 
personal care operations, accounted for 20.9%, 20.7% and 21.4% of the Company’s net service revenues for 2023, 2022 and 2021, respectively.

The related receivables due from the Illinois Department on Aging represented 25.8% and 18.0% of the Company’s net accounts receivable at 

December 31, 2023 and 2022, respectively.

F-30

 
 
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
   
 
 
   
 
 
   
 
   
 
   
 
 
 
 
   
 
 
   
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
 
   
 
 
   
 
 
   
 
   
 
   
 
 
 
 
   
 
 
   
 
 
   
   
   
   
   
   
   
   
   
   
   
Table of Contents

In 2019, New York initiated a new RFO process to competitively procure CDPAP fiscal intermediaries. The Company was not selected in the initial 

RFO process. We submitted a formal protest in response to the selection process, which was filed and accepted in March 2021. The New York fiscal year 
2023 state budget, passed in April 2022, amended the Fiscal Intermediary RFO process to authorize all fiscal intermediaries that submitted an RFO 
application and served at least 200 clients in New York City or 50 clients in other counties between January 1, 2020 and March 31, 2020 to contract with 
the New York State Department of Health and continue to operate in all counties contained in their application, if the fiscal intermediary submitted an 
attestation and supporting information to the New York State Department of Health no later than November 29, 2022. The Company submitted an 
attestation on November 22, 2022, which allowed the Company to continue its CDPAP fiscal intermediary operations. However, the Company decided at 
that time to suspend materially all of its new fee-for-service patient admissions in the CDPAP through County Social Service Departments. On June 6, 
2023, the New York State Department of Health notified the Company that it had received a contract award. Under this contract, the Company is providing 
services to all current payors and has resumed new fee-for-service patient admissions through County Social Service Departments in the CDPAP. The 
CDPAP continues to be targeted for changes by New York governmental authorities, however. For example, the governor’s most recent update on the state 
budget contained proposals that could adversely affect the Company’s ability to participate in the CDPAP. 

The Company recognized approximately $40.7 million from the program for the year ended December 31, 2023.

14. Government Actions to Mitigate COVID-19’s Impact

 The acute phase of the COVID-19 pandemic has faded, but the future course of COVID-19 remains uncertain. We will continue to closely monitor 

the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers.

In recognition of the significant threat to the liquidity of financial markets posed by the COVID-19 pandemic, the Federal Reserve and Congress 

took dramatic actions to provide liquidity to businesses and the banking system in the United States, including relief for healthcare providers in the CARES 
Act, which was expanded by the Paycheck Protection Program and Health Care Enhancement (“PPPHCE”) Act, and the Consolidated Appropriations Act 
(“CAA”), as well as the ARPA.

ARPA

The ARPA provides for $350 billion in relief funding for eligible state, local, territorial, and Tribal governments to mitigate the fiscal effects of the 

COVID-19 public health emergency. Additionally, the law provides for a 10-percentage point increase in federal matching funds for Medicaid home and 
community-based services (“HCBS”) from April 1, 2021, through March 31, 2022, provided the state satisfied certain conditions. States are permitted to 
use the state funds equivalent to the additional federal funds through March 31, 2025. States must use the monies attributable to this matching fund increase 
to supplement, not supplant, their level of state spending for the implementation of activities enhanced under the Medicaid HCBS in effect as of April 1, 
2021. 

HCBS spending plans for the additional matching funds vary by state, but common initiatives in which the Company is participating include those 
aimed at strengthening the provider workforce (e.g., efforts to recruit, retain, and train direct service providers). The Company is required to properly and 
fully document the use of such funds in reports to the state in which the funds originated. Funds may be subject to recoupment if not expended or if they 
are expended on non-approved uses.

The Company received state funding provided by the ARPA in an aggregate amount of $3.7 million and $23.4 million for the years ended 
December 31, 2023 and 2022, respectively. The Company recorded revenue of $0.3 million and $1.9 million and related cost of service revenues of $0.1 
million and $1.5 million for certain states that met the revenue recognition criteria for the years ended December 31, 2023 and 2022, respectively. The 
Company deferred the remaining $3.4 million and $21.5 million for the years ended December 31, 2023 and 2022, respectively, which was received from 
states with specific spending plans and reporting requirements. The Company utilized $10.5 million and $8.6 million of these funds during the years ended 
December 31, 2023 and 2022, respectively, primarily for caregivers and adding support to recruiting and retention efforts. The deferred portion of ARPA 
funding was $5.8 million and $12.9 million as of December 31, 2023 and 2022, respectively, which is included within Government stimulus advances on 
the Company’s Consolidated Balance Sheets.

F-31

 
 
 
Table of Contents

Provider Relief Funds

In addition, the CARES Act authorized funding to be distributed through the Provider Relief Fund to eligible providers, including public entities 
and Medicare- and/or Medicaid-enrolled providers. In November 2020, the Company received grants in an aggregate principal amount of $13.7 million 
from the Provider Relief Fund. The Company utilized $12.3 million remaining of these funds during the year ended December 31, 2021 for healthcare 
related expenses, including retention payments, attributable to COVID-19 that were unreimbursed by other sources. The Company documented the use of 
such funds in 2021 in reports to the U.S. Department of Health and Human Services (“HHS”), as required, and submitted the reports to HHS prior to the 
deadline of March 31, 2022. During the year ended December 31, 2023, we submitted an unmodified audit report to HHS for 2022 in accordance with 
Generally Accepted Government Auditing Standards, as required for commercial organizations that received and expended total awards of $750,000 or 
more.

Medicare sequester

The CARES Act and related laws temporarily lifted the Medicare sequester which would have otherwise reduced payments to Medicare providers 

by 2%, as required by the Budget Control Act of 2011, from May 1, 2020, through March 31, 2022. The sequestration payment adjustment was phased 
back in with a 1% reduction beginning April 1, 2022, and returned to 2% on July 1, 2022. These sequestration cuts have been extended through April 2032.

The ARPA increases the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the Pay-As-You-Go 

Act of 2010 (“PAYGO Act”). As a result, an additional Medicare payment reduction of up to 4% was required to take effect in January 2022. However, 
Congress delayed implementation of this payment reduction until 2025. 

In the hospice segment, Medicare sequester relief resulted in an increase in net service revenues of $0.0 million and $1.4 million for the years 

ended December 31, 2023 and 2022, respectively. In the home health segment, Medicare sequester relief resulted in an increase in net service revenues of 
$0.0 million and $0.3 million for the years ended December 31, 2023 and 2022, respectively.

Payroll tax deferral

The CARES Act also provides for certain federal income and other tax changes, including the deferral of the employer portion of Social Security 
payroll taxes through December 31, 2021. The payroll tax deferral requires that the deferred payroll taxes be paid over two years, with half of the eligible 
deferred amount required to be paid by December 31, 2021 and the other half by December 31, 2022. The Company received a cash benefit of 
approximately $7.1 million related to the deferral of employer payroll taxes for 2020 under the CARES Act, for the period April 2, 2020 through June 30, 
2020. Effective July 1, 2020, the Company began paying its deferred portion of employer Social Security payroll taxes and repaid $4.1 million and $3.0 
million as of December 31, 2022 and 2021 respectively. 

F-32

 
 
 
 
 
 
Name of Subsidiary

A Plus Health Care, Inc.
Addus HealthCare, Inc.
Addus HealthCare (Delaware), Inc.
Addus HealthCare (Idaho), Inc.
Addus HealthCare (South Carolina), Inc.
Addus Home Office, LLC
Addus Hospice of Illinois, LLC

Addus Nurse Care, Inc.
Alamo Area Home Hospice, LP
Alliance Home Health Care, LLC
Ambercare Corporation
Ambercare Home Health Care Corporation
Ambercare Hospice, Inc.
Apple Home Healthcare, LTD
Armada Hospice of New Mexico, LLC
Armada Hospice of Santa Fe, LLC
Armada Skilled Home Care of New Mexico, LLC
Coastal Nursecare of Florida, Inc.
County Homemakers Inc.
Cura Partners, LLC
Hospice Partners of America, LLC
Hospice Partners of America Holding, LLC

Hospice Partners of Texas, LLC
House Calls of New Mexico, LLC
HPA Idaho, LLC
HPA Medical Management, LLC

H&PC of America, LLC
Miracle City Hospice, LLC
New Capital Partners II-HS, Inc.
Options Service, Inc.
PHC Acquisition Corporation
PRAC Holdings, Inc.
Priority Home Health Care, Inc.
Professional Reliable Nursing Service, Inc.
Queen City Hospice, LLC

Serenity Palliative Care and Hospice, LLC
SLHC, Inc.
South Shore Home Health Service, Inc.
Summit Home Health, LLC
Tennessee Valley Home Care, LLC
TR&B, LLC
Tri County Home Health and Hospice, LLC

SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1

State of
Incorporation

Montana
Illinois
Delaware
Delaware
Delaware
Delaware
Delaware

Delaware
Texas
New Mexico
New Mexico
New Mexico
New Mexico
Illinois
Delaware
Delaware
Delaware
Florida
Pennsylvania
Tennessee
Delaware
Delaware

Delaware
New Mexico
Idaho
Delaware

Delaware
Delaware
Delaware
Colorado
California
Delaware
Ohio
California
Delaware

Delaware
Arizona
New York
Illinois
Tennessee
Texas
Tennessee

Doing Business As Name

A-Plus HealthCare
Addus HomeCare; Arcadia Home Care & Staffing
Addus HomeCare Delaware
Addus HomeCare
Addus HomeCare; Arcadia Home Care & Staffing
N/A
JourneyCare - Barrington; JourneyCare - Deerfield; JourneyCare - 
Crystal Lake
Lifestyle Options
Alamo Hospice
Ambercare Home Health; Ambercare
N/A
Ambercare Home Health; Ambercare Personal Care Services
Ambercare
JourneyCare Home Health - Chicago
Armada Hospice of New Mexico, LLC
Armada Hospice of Santa Fe, LLC
Ambercare Home Health
Addus HomeCare
Arcadia Home Care & Staffing
Addus HomeCare
Hospice Partners of America
Alamo Hospice of Conroe; Alamo Hospice of Waco; Hospice of 
Virginia
Hospice Partners of Texas
House Calls of New Mexico
Harrison’s Hope; Harrison’s Hope Twin Falls
Alamo Supportive Care; Serenity Supportive Care; JourneyCare 
Palliative Care, Hospice of Virginia Supportive Care
H&PC of America
Miracle City Hospice
New Capital Partners II-HS
Ambercare Personal Care Services
Addus HomeCare
Arcadia Home Care & Staffing
Addus HomeCare
Arcadia Home Care & Staffing
Queen City Hospice; Day City Hospice; Capital City Hospice, Queen 
City Hospice East
Serenity Hospice
Sunlife Home Care
Addus HomeCare
JourneyCare Home Health
Tennessee Quality Care-Home Health
TR&B
Tennessee Quality Care-Hospice

Pursuant to Item 601(b)(21)(ii) of Regulation S-K, certain subsidiaries have been omitted because, when considered in the aggregate, they do not constitute a significant 
subsidiary.

 
 
 
 
 
 
 
  
  
  
  
  
  
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-267253) and on Form S-8 (Nos. 333-272871, 
333-219946, 333-190433, and 333-164413) of Addus HomeCare Corporation of our report dated February 27, 2024 relating to the financial statements and 
the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

Exhibit 23.1

/s/ PricewaterhouseCoopers LLP

Dallas, Texas
February 27, 2024 

 
CERTIFICATION

Exhibit 31.1

I, R. Dirk Allison, Chief Executive Officer and Chairman of the Board of Addus HomeCare Corporation certify that:

1.

2.

3.

4.

I have reviewed this annual report on Form 10-K of Addus HomeCare Corporation (the “Registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the 
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this 
report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the 
financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in 
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the Registrant and have:

(a)

(b)

(c)

(d)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to 
ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those 
entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our 
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for 
external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the 
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most 
recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely 
to materially affect, the Registrant’s internal control over financial reporting; and

5.

The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to 
the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are 
reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal 
control over financial reporting.

Date: February 27, 2024

       /s/    R. Dirk Allison                
R. Dirk Allison
Chief Executive Officer and Chairman of the Board

 
 
 
Exhibit 31.2

I, Brian Poff, Chief Financial Officer of Addus HomeCare Corporation, certify that:

CERTIFICATION

1.

2.

3.

4.

I have reviewed this annual report on Form 10-K of Addus HomeCare Corporation (the “Registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the 
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this 
report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the 
financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in 
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the Registrant and have:

(a)

(b)

(c)

(d)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to 
ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those 
entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our 
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for 
external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the 
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most 
recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely 
to materially affect, the Registrant’s internal control over financial reporting; and

5.

The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to 
the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are 
reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal 
control over financial reporting.

Date: February 27, 2024

                             /s/    Brian Poff

Brian Poff
Chief Financial Officer

 
 
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
(AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Addus HomeCare Corporation (the 
“Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, R. Dirk Allison, Chief Executive Officer and 
Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 
2002, that:

(1)

(2)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the 
Company.

Date: February 27, 2024

BY:

       /s/    R. Dirk Allison                
R. Dirk Allison
Chief Executive Officer and Chairman of the Board

 
 
 
 
 
 
 
 
 
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
(AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Addus HomeCare Corporation (the 

“Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Poff, Chief Financial Officer of the 
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

(2)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the 
Company.

Date: February 27, 2024

BY:

                             /s/    Brian Poff    

Brian Poff
Chief Financial Officer

 
 
 
 
 
 
 
 
ADDUS HOMECARE CORPORATION
Compensation Recoupment Policy

Exhibit 97.1

1. Purpose. The purpose of this Compensation Recoupment Policy of the Company (as amended from time to time, the “Policy”), 
dated as of November 24, 2023 (the “Adoption Date”) is to describe the circumstances in which current and former Executive Officers will 
be  required  to  repay  or  return  Erroneously  Awarded  Compensation  to  members  of  the  Company  Group.  The  Company  has  adopted  this 
Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D 
of  the  Exchange  Act,  Exchange  Act  Rule  10D-1  promulgated  thereunder,  and  the  rules  and  requirements  of  Nasdaq  (including  Nasdaq 
Listing Rule 5608) (such legal requirements, and rules and requirements of Nasdaq, collectively, the “SEC/Nasdaq Clawback Rules”). Each 
Executive  Officer  shall  be  required  to  sign  and  return  to  the  Company  an  acknowledgment  to  this  Policy  in  the  form  attached  hereto  as 
Exhibit A pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy. 

2. Administration.  This  Policy  shall  be  administered  by  the  Committee.  The  Committee  is  authorized  to  interpret  and  construe 
this  Policy  and  to  make  all  determinations  necessary,  appropriate,  or  advisable  for  the  administration  of  this  Policy,  and  any  such 
determinations made by the Committee shall be in the Committee’s sole discretion, and shall be final and binding on all affected individuals. 
Subject to applicable legal requirements and the rules and requirements of Nasdaq, the Committee may delegate any or all of its powers and 
duties  under  the  Policy  to  authorized  officers  of  the  Company,  subject  to  such  limitations  on  such  delegated  powers  and  duties  as  the
Committee may impose, if any. Except as otherwise required by applicable legal requirements or the rules and requirements of the Nasdaq, 
any  determinations  of  the  Committee  hereunder  need  not  be  uniform  with  respect  to  one  or  more  Executive  Officers  (whether  current  or 
former).

3. Definitions. For purposes of this Policy, the following capitalized terms shall have the meanings set forth below: 

(a) “Accounting Restatement” shall mean an accounting restatement due to the material noncompliance of the Company with 
any financial reporting requirement under the securities laws, including any required accounting restatement (i) to correct 
an error in previously issued financial statements that is material to the previously issued financial statements (a “Big R” 
restatement), or (ii) that would result in a material misstatement if the error were corrected in the current period or left 
uncorrected in the current period (a “little r” restatement). For the avoidance of doubt, a restatement resulting solely from 
the retrospective application of a change in generally accepted accounting principles is not an Accounting Restatement.

(b)

(c)

“Board” shall mean the Board of Directors of the Company. 

“Clawback  Eligible  Incentive  Compensation”  shall  mean  all  Incentive-Based  Compensation  Received  by  any 

current or former Executive Officer on or after the Nasdaq Effective Date, provided that: 

(i) such Incentive-Based Compensation is Received after such individual began serving as an Executive Officer;

(ii) such individual served as an Executive Officer at any time during the performance period for such Incentive-

Based Compensation; 

 
 
 
(iii)such  Incentive-Based  Compensation  is  Received  while  the  Company  has  a  class  of  securities  listed  on 

Nasdaq; and

(iv)such Incentive-Based Compensation is Received during the applicable Clawback Period.

(d)

“Clawback Period” shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the 
Company immediately preceding the Restatement Date and any transition period (that results from a change in the Company’s fiscal 
year) of less than nine months within or immediately following those three completed fiscal years.

(e)

(f)

(g)

(h)

“Committee” shall mean the Compensation Committee of the Board. 

“Common Stock” shall mean the common stock, par value $0.001 per share, of the Company.

“Company” shall mean Addus Homecare Corporation, a Delaware corporation. 

“Company Group” shall mean the Company, together with each of its direct and indirect subsidiaries. 

(i)

“Erroneously  Awarded  Compensation”  shall  mean,  with  respect  to  any  current  or  former  Executive  Officer  in 
connection with any Accounting Restatement, the amount of Clawback Eligible Incentive Compensation Received by such current 
or former Executive Officer that exceeds the amount of Clawback Eligible Incentive Compensation that otherwise would have been 
Received by such current or former Executive Officer had such Clawback Eligible Incentive Compensation been determined based 
on the restated amounts as reflected in connection with such Accounting Restatement, computed without regard to any taxes paid.

(j)

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

(k)

“Executive Officer” shall mean any officer as defined in Rule 10D-1(d) (or any successor provision thereof) under 

the Exchange Act.

(l)

“Financial  Reporting  Measures”  shall  mean  measures  that  are  determined  and  presented  in  accordance  with  the 
accounting principles used in preparing the Company’s financial statements, and any other measures that are derived wholly or in 
part from such measures. For purposes of this Policy, stock price and total shareholder return (and any measures that are derived 
wholly or in part from stock price or total shareholder return) shall be considered Financial Reporting Measures. For the avoidance 
of doubt, a Financial Reporting Measure need not be presented within the Company’s financial statements or included in a filing 
with the SEC.

(m)

“Incentive-Based Compensation” shall mean any compensation that is granted, earned or vested based wholly or in 

part upon the attainment of a Financial Reporting Measure.

(n)

(o)

(p)

“Nasdaq” shall mean the Nasdaq Stock Market.

“Nasdaq Effective Date” shall mean October 2, 2023.

“Received” shall mean when Incentive-Based Compensation is received, and Incentive-Based Compensation shall 

be deemed received in the Company’s fiscal period during 

 
 
which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if payment or grant 
of the Incentive-Based Compensation occurs after the end of that period. 

(q)

“Restatement  Date”  shall  mean  the  earlier  to  occur  of  (i)  the  date  the  Board,  a  committee  of  the  Board  or  the 
officers  of  the  Company  authorized  to  take  such  action  if  Board  action  is  not  required,  concludes,  or  reasonably  should  have 
concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally 
authorized body directs the Company to prepare an Accounting Restatement.

(r)

“SEC” shall mean the U.S. Securities and Exchange Commission. 

4. Recoupment of Erroneously Awarded Compensation. 

(a)

If the Company is required to prepare an Accounting Restatement, (i) the Committee shall determine the amount of 
any Erroneously Awarded Compensation for each applicable current or former Executive Officer (whether or not such individual is 
serving as an Executive Officer at such time) (the “Applicable Executives”) in connection with such Accounting Restatement, and 
(ii)  the  Company  will  reasonably  promptly  require  the  recoupment  of  such  Erroneously  Awarded  Compensation  from  any  such 
Applicable  Executive,  and  any  such  Applicable  Executive  shall  surrender  such  Erroneously  Awarded  Compensation  to  the 
Company, at such time(s), and via such method(s), as determined by the Committee in accordance with the terms of this Policy. In 
such event, any such Applicable Executive shall enter into any recoupment or similar agreement as may be reasonably requested by 
the  Committee  in  connection  with  the  Company’s  recoupment  of  Erroneously  Awarded  Compensation  from  such  Applicable 
Executive pursuant to the terms of this Policy.

(b)

For  Incentive-Based  Compensation  based  on  (or  derived  from)  stock  price  or  total  shareholder  return  where  the 
amount  of  Erroneously  Awarded  Compensation  is  not  subject  to  mathematical  recalculation  directly  from  the  information  in  the 
applicable Accounting Restatement, (i) such amount shall be determined by the Committee based on a reasonable estimate of the 
effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation 
was Received, and (ii) the Company will maintain documentation of the determination of that reasonable estimate and provide such 
documentation to Nasdaq.

(c)

The  Committee  shall  determine,  in  its  sole  discretion,  the  method(s)  for  recouping  any  Erroneously  Awarded 

Compensation from any Applicable Executive, which may include one or more of the following:

(i) requiring one or more cash payments to the Company Group from such Applicable Executive, including, but 
not  limited  to,  the  repayment  of  cash  Incentive-Based  Compensation  previously  paid  by  the  Company  Group  to  such 
Applicable Executive;

(ii) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition 
of any equity-based awards previously made by the Company to such Applicable Executive and/or otherwise requiring the 
delivery to the Company of shares of Common Stock held by such Applicable Executive; 

 
 
(iii)withholding, reducing or eliminating future cash compensation (including cash incentive payments), future 
equity  awards  and/or  other  benefits  or  amounts  otherwise  to  be  paid  or  awarded  by  the  Company  Group  to  such 
Applicable Executive;

(iv)offsetting amounts against compensation or other amounts otherwise payable by the Company Group to such 

Applicable Executive;

(v) cancelling,  adjusting  or  offsetting  against  some  or  all  outstanding  vested  or  unvested  equity  awards  of  the 

Company held by such Applicable Executive; and/or 

(vi)taking  any  other  remedial  and  recovery  actions  with  respect  to  such  Applicable  Executive  permitted  by 

applicable legal requirements and the rules and regulations of Nasdaq, as determined by the Committee.

(d)  Notwithstanding anything herein to the contrary, the Company shall not be required to recover Erroneously Awarded 
Compensation  from  any  Applicable  Executive  pursuant  to  the  terms  of  this  Policy  if  (1)  the  Committee  determines  that  such 
recovery would be impracticable, and (2) any of the following conditions is met:

(i) the  direct  expenses  paid  to  a  third  party  to  assist  in  enforcing  the  Policy  would  exceed  the  amount  to  be 
recovered, provided that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded 
Compensation  based  on  expense  of  enforcement  pursuant  to  this  clause  (i),  the  Company  has  (x)  made  a  reasonable 
attempt to recover such Erroneously Awarded Compensation, (y) documented such reasonable attempt(s) to recover, and 
(z) provided such documentation to Nasdaq;

(ii) recovery would violate home country law where that law was adopted before November 28, 2022, provided 
that,  before  determining  that  it  would  be  impracticable  to  recover  any  amount  of  Erroneously  Awarded  Compensation 
based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to 
Nasdaq, that recovery would result in such a violation, has provided copy of the opinion is provided to Nasdaq; or

(iii)recovery  would  likely  cause  an  otherwise  tax-qualified  retirement  plan,  under  which  benefits  are  broadly 
available  to  employees  of  the  Company  Group,  to  fail  to  meet  the  requirements  of  26  U.S.C.  401(a)(13)  or  26  U.S.C. 
411(a) and regulations thereunder.

5. No Indemnification. The Company Group shall not (x) indemnify any current or former Executive Officer against (i) the loss of 
any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating 
to the Company Group’s enforcement of its rights under this Policy, or (y) pay or reimburse any current or former Executive Officers for 
insurance premiums to recover losses incurred under this Policy. 

6. Supersedure.  This  Policy  will  supersede  any  provisions  in  (x)  any  agreement,  plan  or  other  arrangement  applicable  to  any 
member of the Company Group, and (y) any organizational documents of any entity that is part of Company Group that, in any such case, (a) 
exempt  any  Incentive-Based  Compensation  from  the  application  of  this  Policy,  (b)  waive  or  otherwise  prohibit  or  restrict  the  Company 
Group’s right to recover any Erroneously Awarded Compensation, including, without limitation, in connection with exercising any right of 
setoff as provided herein, and/or (c) require or provide for indemnification to the extent that such indemnification is prohibited under Section 
5 above.

 
 
7. Amendment; Termination; Interpretation. The Board may amend or terminate this Policy at any time, subject to compliance 
with all applicable legal requirements and the rules and requirements of Nasdaq. It is intended that this Policy be interpreted in a manner that 
is consistent with the SEC/Nasdaq Clawback Rules.

8. Other Recoupment Rights; No Additional Payments. 

(a)

Any  right  of  recoupment  under  this  Policy  is  in  addition  to,  and  not  in  lieu  of,  any  other  remedies  or  rights  of 
recoupment that may be available to the Company Group pursuant to (i) the terms of any recoupment provisions in any employment 
agreement, incentive or equity compensation plan or award or other agreement, (ii) any other legal requirements, including, but not 
limited to, Section 304 of Sarbanes-Oxley Act of 2002 (subject to Section 8(b) of this Policy below), and (iii) any other legal rights 
or remedies available to the Company.

(b)

Notwithstanding anything herein to the contrary, to the extent that the Committee determines that any Erroneously 
Awarded  Compensation  includes  any  amounts  that  have  been  actually  reimbursed  to  the  Company  Group  from  any  Applicable 
Executive pursuant to Section 304 of the Sarbanes-Oxley Act (any such amounts that have been reimbursed to the Company Group, 
the “Applicable  SOX  Recoupment  Amount”),  in  order  to  prevent  duplicative  recovery,  the  amount  of  any  Erroneously  Awarded 
Compensation to be recovered from any such Applicable Executive shall be reduced by the Applicable SOX Recoupment Amount.

(c)

To  the  extent  so  determined  by  the  Committee,  the  Company  shall  be  entitled  to  recover  from  any  Applicable 
Executive all fees and expenses incurred by the Company Group in connection with enforcing its rights under this Policy against 
any Applicable Executive.

9. Successors.  This  Policy  shall  be  binding  and  enforceable  against  all  current  and  former  Executive  Officers  and  their 

beneficiaries, heirs, executors, administrators or other legal representatives. 

 
 
Exhibit A

Form of Acknowledgment 

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Addus 
Homecare  Corporation  Compensation  Recoupment  Policy  (the  “Policy”).  Capitalized  terms  used  but  not  otherwise  defined  in  this 
acknowledgment shall have the meanings ascribed to such terms in the Policy. 

By signing this acknowledgment, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject 
to  the  Policy  and  that  the  Policy  will  apply  both  during  and  after  the  undersigned’s  employment  with  the  Company  Group.  Further,  by 
signing  below,  the  undersigned  agrees  to  abide  by  the  terms  of  the  Policy,  including,  without  limitation,  by  returning  any  Erroneously 
Awarded Compensation to the Company Group to the extent required by the Policy. 

______________________________
Signature

______________________________

Print Name

______________________________
Date